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Abstract 
Outer membrane proteins (OMPs) mediate the survival and pathogenicity of 
Gram negative bacteria. The biogenesis of these proteins, however, presents 
problems as they must be transported to, inserted and folded correctly in the outer 
membrane in the absence of ATP. This problem is resolved by the β-barrel 
assembly machinery (BAM) complex: a ~203 kDa complex of five proteins 
(BamA-E) that enables the membrane insertion and folding of substrate OMPs 
on a physiological timescale. Despite available crystal structures, the mechanism 
of this vital protein complex remains poorly understood.  
In this thesis I use a variety of structural and biochemical tools to probe the nature 
of BAM-assisted OMP folding, particularly the role of BamA dynamics. Successful 
purification of the intact BAM complex in the detergent DDM allowed the first cryo-
electron microscopy structure of the complex to be obtained, at a resolution of 
4.9 Å. This reveals the intact BAM complex with BamA in a laterally-open 
conformation in which the first (β1) and last (β16) strands of the barrel are no 
longer hydrogen bonded.  
In addition, biochemical assays provide the first in vitro evidence of the functional 
importance of BamA lateral gating in OMP folding. These assays demonstrate 
that in a reconstituted system utilising the BAM complex, inhibiting the lateral 
gating of BamA by incorporating new disulphide bonds diminishes the ability of 
BAM to assist substrate folding. This is shown with two different OMP substrates, 
tOmpA (the β-barrel domain of OmpA) and OmpT. In synthetic lipids, however, 
the presence of prefolded BamA is sufficient to aid substrate folding and inhibition 
of lateral gating by disulphide bonding in this case does not diminish the catalytic 
effect. The results indicate that BamA likely adopts different roles depending on 
substrate and lipid.  
Furthermore, this thesis discusses preliminary experiments towards determining 
the significance of the β-signal: a conserved sequence found towards the C-
terminus of OMPs hypothesised to be important for recognition by BamA. The 
results show that while some mutations may slow the protein’s intrinsic folding 
into the membrane they do not affect the apparent BamA-catalysed folding rate. 
However, other single amino-acid substitutions appear to incur a large energetic 
penalty, rendering the protein incapable of adopting its stable β-barrel structure.  
Combined, the data allow us to begin dissecting the mechanism of BAM-assisted 
v 
folding of OMPs, particularly the role of BamA in passive membrane 
destabilization or active lateral opening. 
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Gram-negative bacteria are important pathogens in the modern world1-3, the 
increasing incidence of antibiotic resistance means there is a strong pressure to 
develop novel antibiotic candidates2-5. The outer membrane (OM) of Gram-
negative bacteria represents their principal line of defence5-9, but may also 
present an antibacterial target6,7,10. Outer membrane proteins (OMPs) are vital in 
Gram-negative bacteria, forming a core component of the OM and performing a 
wide variety of roles7,11-19. 
Over the last 15 years our understanding of OMPs and OMP biogenesis has 
dramatically increased. Moving from the most simplistic notion of the two 
membranes of Gram-negative bacteria15,20,21 we now have detailed knowledge of 
the protein players in every aspect. However, many aspects of OMP biogenesis, 
their journey to the OM, assembly and folding remain unclear. While the proteins 
vital in this pathway are generally known, their mechanisms are yet to be 
elucidated. 
The β-barrel assembly machine (BAM) is vital and highly conserved across 
Gram-negative bacteria21-23. Its absence is lethal and its depletion causes severe 
defects in OMP folding and assembly21,24,25. The central component BamA was 
identified as a member of the Omp85 superfamily, of which a homologue is 
present in all Gram-negative bacteria, mitochondria and chloroplasts26-29. Despite 
knowing that BAM is crucial for the correct assembly of OMPs, the mechanism 
by which it does this, and by which OMPs arrive to the OM is not clear14,19,21,30-35.  
Moving from the bacteria, to OMP sequences, I will summarise what is known in 
these fields, and how it has been studied, before moving to the fundamental 
question: how does BAM, particularly BamA, catalyse the folding of OMPs? 
 
1.1 Gram-negative bacteria 
Bacteria can be classified on the basis of their Gram staining20,36. The simple 
staining method identifies Gram-positive bacteria, which possess a thick 
peptidoglycan cell wall, as stained with crystal violet dye, and remain purple 
following washing. In Gram-negative bacteria the thin peptidoglycan layer allows 
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extensive washing to remove the crystal violet and cells can subsequently be 
stained with a red dye, typically safranin or fuchsin20,36.  
Gram-negative bacteria are characterised by possessing both an inner and an 
outer membrane (IM and OM), with a thick periplasmic space (100- 210Å)37,38 
containing a layer of peptidoglycan (Figure 1-1), with this structure revealed by 
electron microscopy (EM) in 196939. The combination of these elements makes 
the bacteria difficult to target, resistant to the influx of both hydrophilic and 
hydrophobic molecules. The OM is connected to the peptidoglycan by Braun’s 
lipoprotein or Lpp40, the most abundant lipoprotein in enteric bacteria. Lpp is 
capable of lengthening and controls the dimensions of the periplasm41. 
Gram-positive bacteria are protected by thicker layers of peptidoglycan, 30-100 
nanometres thick, as opposed to the few nanometres characteristic of Gram-
negative bacteria (Figure 1-1)13.  Peptidoglycan is made up of repeating units of 
the disaccharide N-acetyl glucoamine-N-acetyl muramic acid42. The 
peptidoglycan is rigid in Gram-positive bacteria and determinant of cell shape42. 
In addition, in Gram-positive bacteria, anionic polymers, known as teichoic acids 
thread through the peptidoglycan, accounting for ~60% of the mass of the cell 
wall13,43. In the absence of an OM, surface-expressed proteins in Gram-positive 
bacteria are tethered into the cell wall.  
Partly due to their protective outer layers and intractability as a target, Gram-
negative bacteria represent the causative agents of many human bacterial 
diseases. They are key contributors to nosocomial infections and show 
widespread development of antibiotic resistance1-7,44. The WHO 2017 priority list 
on bacteria for which antibiotics are urgently needed highlighted many Gram-
negative bacteria, with all of the “critical” priority, including Enterobacteriaceae, 








Priority 1: Critical  
Acinetobacter baumannii Carbapenem-resistant 
Pseudomonas aeruginosa Carbapenem-resistant 
Enterobacteriaceae Carbapenem-resistant, 3rd generation 
cephalosporin-resistant 
Priority 2: High  
Enterococcus faecium Vancomycin-resistant 
Staphylococcus aureus Methicillin-resistant 
Vancomycin-intermediate 
Helicobacter pylori Clarithromycin-resistant 
Campylobacter Fluoroquinolone-resistant 
Salmonella spp. Fluoroquinolone-resistant 
Neisseria gonorrhoeae 3rd generation cephalosporin-resistant 
fluoroquinolone-resistant 
Priority 3: Medium  
Streptococcus pneumoniae Penicillin-non-susceptible 
Haemophilus influenza Ampicillin-resistant 
Shigella spp. Fluoroquinolone-resistant 
Table 1-1: WHO Priority Pathogens List for development of new antibiotics. 
The list shows pathogenic bacteria for which research and development of antibiotics is 
required, their priority, as well as their current antibiotic resistance. Gram-negative 
bacteria are highlighted in grey. Enterobacteriaceae include: Klebsiella pneumonia, 
Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp., Providencia spp, and 
Morganella spp. Figure reproduced from WHO 201745. 
 
Many current antibiotics target elements of the cell envelope of Gram-negative 
bacteria. β-lactam antibiotics, including pencillin and cephalosporin, target 
production of peptidoglycan6,44. These have been the primary antibiotic of choice 
for many years4, but many Gram-negative bacteria now possess extended-
spectrum β-lactamases, enzymatic against multiple β-lactam antibiotics44. Other 
elements that constitute the bacteria’s first layer of defence, the proteins and 
lipids of the outer membrane, also represent excellent targets as they are 
essential, conserved and surface exposed10,46-49. Therefore, improving our 
understanding of the mechanisms behind the biogenesis of the cell envelope may 
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improve the ability to specifically target cell envelope formation, and thus create 
new antibiotics. The work carried out in this thesis was conducted on E.coli OM 
biogenesis. The focus in this introduction, therefore, will principally be on the 
proteins and mechanisms of this species, but in general these apply to other 
Gram-negative bacteria.  
 
Figure 1-1: Gram- negative and -positive cell walls. Schematic comparing the 
cell walls of (a) Gram-positive bacteria, which possess a thick layer of peptidoglycan, 
and (b) Gram-negative bacteria which have a thin layer of peptidoglycan and an Outer 
Membrane. Figure reproduced from Tripathi et al., (2012)50. 
 
1.2 The outer membrane 
The outer membrane (OM) of Gram-negative bacteria represents their first, and 
critical layer of defence5-9,51-53. A crowded asymmetric bilayer, the OM possesses 
an outer leaflet of lipopolysaccharide (LPS) and an inner one of phospholipids54, 
numerous lipoproteins and transmembrane proteins13,19,55-57. All of these 
components must be transported to, and assembled in, the OM following 
synthesis in the cytoplasm. Despite initial evidence showing areas of fusion 
between the IM and OM, known as Bayer bridges58 which would facilitate the flux 
of protein and lipid between the membranes, it now appears this is unlikely and 
all of these components have evolved their own protein-based pathways for 
transport across the periplasm15,21,31,35,51,59-64. The transport mechanisms and 
ultimate assembly of these components are fascinating as while ATP can assist 
initial transport across the IM, the periplasm is devoid of nucleotide65. Therefore, 
an intricate energetically-favourable pathway, powered only by protein 
conformations and affinities, has evolved to facilitate OM assembly in every case. 
As they constitute vital elements of the OM, the nature and transport of OM lipids, 
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LPS and lipoproteins will be briefly discussed, before further emphasis on the 
pathway of interest for the work presented in this thesis: OMP biogenesis. In most 
cases the pathway and proteins responsible have gradually been 
elucidated31,34,52,61, but the OMP pathway has perhaps proved the most 
intractable, with the mechanisms still largely unclear. OMPs constitute vital, 
conserved, defensive elements for Gram-negative bacteria and therefore their 
biogenesis is an important area to study, especially given the urgent need to 
develop new antibiotics in today’s world2,3,5,7,8,45. 
 
1.3 Outer membrane lipids and lipid transport 
Whereas most bacteria exhibit high diversity in the makeup of their lipid bilayer, 
E.coli is unusual in possessing only three phospholipids with an abundance 
higher than 1%(ref. 56). Both inner and outer membranes of E.coli are composed 
primarily of phosphatidylethanolamine (PE), phosphatidylglycerol (PG) and 
cardiolipin (CL) (Figure 1-2)54. These three lipids are all synthesised from simple 
building blocks, via the Kennedy pathway and transported across the periplasm66. 
The outer membrane is enriched in phosphatidylethanolamine, comprising ~90% 
by weight, as opposed to 70% in the inner membrane67.  
While either CL68 and PE69 are dispensible for E.coli cell viability, mutants lacking 
both are not viable70. The lack of requirement is perhaps most surprising for PE 
which makes up a large proportion (70-80%) of total glycerophospholipid in E.coli 
cells70. Depletion of PE in the OM can be compensated by increased proportion 
of the other, anionic lipids (such as CL) and divalent cations, such as Mg2+ and 
Ca2+ (ref. 56,69,70). This implies that the role of the membrane lipids is primarily 
structural, with reduced dependence on the specific type of lipid. In addition, the 
outer membrane is enriched in saturated fatty acids, of which palmitic acid (16:0) 
is the major contributor, making up approximately 30% (ref. 54).  As will be 
discussed further (Section 1.8) a large number of studies on the folding of OMPs 
have been carried out in synthetic bilayers, usually composed principally of 




Figure 1-2: Schematic of lipids. A) Cardiolipin; B) phosphatidylglycerol; C) 
phosphatidylethanolamine and D) phosphatidylcholine. A, B, and C are the lipids 
commonly found in the OM while D (phosphatidylcholine) is commonly used in folding 
assays71,72. Shown is the dihexadecanoyl (16:0) form of PG, PE and PC, eg. DPPC, and 
the 16:1 form of cardiolipin. Chain lengths used in folding assays commonly vary from 
10-16 carbons71,72. 
 
Intriguingly the exact mechanism for lipid transport to the OM is not yet clear48,61. 
Vital components have been identified, such as MsbA which flips lipid A (for LPS) 
and phospholipids across the inner membrane and Mla (maintenance of lipid 
asymmetry) proteins53,73. The Mla proteins were identified as functioning to move 
phospholipids away from the outer membrane, via retrograde transport to the 
inner membrane53. MlaA is an OM lipoprotein53 which maintains the asymmetry 
between the inner and outer leaflets by cooperation with the porin OmpC, 
removing phospholipids that migrate into the outer leaflet (Figure 1-3)74. The 
asymmetry of the OM is critical to strong barrier function in Gram-negative 
cells9,53,75. In growth or stress conditions, phospholipids appear in the outer 
leaflet, and disrupt the LPS, leading to leaky patches. Proteins MlaF, E, D, B and 
C also function to return phospholipids from the OM to the IM. Recent evidence 
suggests these form a complex76 and interaction with related MCE proteins 
allows transport of phospholipids across the periplasm (Figure 1-3)61. Whether 




Figure 1-3: Model for the Mla lipid transport system. Schematic of the pathway 
by which lipids may be transported between the outer membrane (OM) and inner 
membrane (IM) with phospholipids (PL) and lipopolysaccharide (LPS) shown. Shown are 
the Mla proteins MlaF, E, D and B forming a complex in the IM, while MlaC is a soluble 
shuttle protein to the OmpC-MlaA complex in the OM. Figure reproduced from 




Lipopolysaccharide (LPS) is a key constituent of the outer membrane in most 
species of Gram-negative bacteria. The LPS layer, stabilized by divalent cations, 
contributes to making the OM impermeable, particularly to hydrophobic 
molecules, which often include antibiotics9,77. Defects in the biosynthesis of LPS, 
for species that require it, leads to increased permeability of the OM and 
increased susceptibility to hydrophobic molecules77,78. The LPS of the outer 
membrane in E.coli has six fatty acyl chains, attached to a glucosamine 
dissacharide79; these are mostly 14:0 acyl chains (Figure 1-4). LPS presents 
another challenge for E.coli: how is this molecule assembled and presented on 
the outer surface of cells?  
LptD was the first element identified of the LPS transport (Lpt) system (Figure 
1-4)25,55. The gene was named imp for increased membrane permeability, a 
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common phenotype in its deletion25,55,80. The Imp protein was identified as an 
essential OM β-barrel and, despite evidence for Omp85 being important for lipid 
insertion81, quickly became the candidate for an LPS transporter82. The imp4213 
allele was identified as increasing membrane permeability83. However these 
defects were partially corrected with mutations in only bamB83. As yet, the exact 
reason why BamB mutations may correct an LptD deficiency is unclear. Depletion 
of LptD and deletion strains in N.meningitidis where LPS is not required, helped 
to elucidate its role82. Deletion of imp in N.meningitidis causes production of less 
than 10% of wild-type levels of LPS, which never seem to reach the OM62,82.  
LptD is a 26 stranded β-barrel; the LptD/E complex displays unusual plug-and-
barrel architecture84 with LptE almost entirely inserted inside the β-barrel of LptD, 
and its protruding N-terminal forming the typical Lpt fold85,86. The Lpt complex 
requires coordination of the cell, as LptD is assembled by BAM while LptE is 
assembled by the Lol pathway62,75,87,88. There appears, however an internal 
checkpoint as without both components correctly folded, LptD will not adopt the 
correct structure to bind LptA and accept the LPS molecule75,89. LptD forms a 
crenelated β-barrel, with incomplete closure of its β1 and β26 strands and it is 
hypothesised that a putative lateral opening allows the translocation of LPS90. 
This would maintain the saccharide portion within the hydrophilic lumen, and lipid 





Figure 1-4: Lipopolysaccharide (LPS) transport pathway. Schematic of the 
transport of LPS from the inner leaflet of the cytoplasmic membrane to the outer leaflet 
of the OM, with all the relevant proteins. LPS is made up of lipid A, an O-antigen and a 
core oligosaccharide (inset). Lipid A is also known as endotoxin and is a key initiator of 
immune response92. The O-antigen repeats are synthesised in the cytoplasm and flipped 
across the inner membrane by an ABC (ATP-binding cassette) transporter93. On the 
periplasmic side these are polymerized and ligated to the lipid A core93. The lipid A core, 
synthesised on the inner leaflet of the IM, is flipped across the inner membrane by MsbA, 
an inner membrane protein of the ABC superfamily94. The Lpt (lipopolysaccharide 
transport) system is composed of seven essential proteins, in two subassemblies51,95-97. 
LPS is extracted from the IM by LptB2FG, an IM ABC transporter98, transferred to LptC99, 
in one round of ATP hydrolysis before it is delivered on to LptA in a second round of ATP 
hydrolysis. LptA forms a periplasmic bridge, oligomerising in the presence of LPS and 
connecting the IM and OM51,60,100,101. Once reaching the OM, LptA delivers LPS to LptD 
and LptE, which form an insertase in the OM84. Figure reproduced from Okuda et al., 
(2016)52. 
 
1.5 Protein transport to the OM 
The initial transport pathway for lipoproteins and OMPs, as with the biogenesis 
of all proteins, begins the same (Figure 1-5). Proteins are synthesised on the 
ribosome, with an N-terminal signal sequence marking those to be secreted 
outside the cytoplasm34. For proteins destined for the inner membrane, the 
hydrophobic signal sequence is bound by the Signal Recognition protein (SRP) 
and these are co-translationally targeted to the Sec machinery to enable 
immediate integration into the IM following folding102. Periplasmic and OM 
proteins must be post-translationally transported to the SecYEG machinery, to be 
moved across the IM (Figure 1-5)103. However, the substrate recognition for this 
step has been rendered less clear by recent research104,105. The original 
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hypothesis was of substrate recognition by Trigger Factor, handover to SecB, 
then to SecA106,107. It now appears substrates are not exclusively intercepted by 
the periplasmic chaperones trigger factor (TF)108 or SecB109, but may be 
recognised by either the chaperones (TF and SecB), by SecA104 or directly by 
SecY105,110. While it is unlikely that direct recognition by the SecYEG machinery 
is the preferred process for the pathway, mutants lacking SecB are viable111,112. 
SecA is the motor protein, an ATPase providing the energy source to thread the 
protein through the SecYEG translocon (Figure 1-6)113. SecYE and the motor 
protein SecA constitute the minimal translocase114. SecY forms the channel, with 
10 transmembrane α-helices forming a hinge on one side and a lateral gate on 
the other115. This lateral opening allows IM proteins to be released into the 
membrane.  
 
Figure 1-5: Schematic of protein biogenesis. Depicted are the pathways for Inner 
Membrane Proteins (IMPs), Outer Membrane Proteins (OMPs) and lipoproteins. All 
begin by synthesis in the cytoplasm and targeting to the Sec translocon. Figure 
reproduced from Hagan et al. (2011)34. 
 
There are several competing hypotheses as to the motion by which SecA drives 
protein through the SecYEG channel116. Currently favoured is the model of biased 
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Brownian motion117 as depicted (Figure 1-6). This is a probabilistic model as it 
relies on free diffusion of polypeptide, whereas other models are processive or 
mixed116. Processive models typically require a significant conformational change 
in SecA on binding ATP, with a ‘power stroke’ that pushes substrate through 
SecYEG118. It is assumed SecA dimerization or oligomerisation is necessary to 
achieve this119. Mixed processive and probabilistic models allow for the diffusion 
as in the Brownian ratchet model shown, but suggest that the two helix finger of 
SecA pushes substrate through the channel120,121. This assumes a significant 




Figure 1-6: Model of SecYEG translocation by probabilistic Brownian 
ratchet mechanism. SecYEG (red, lateral gate in light red), is bound to SecA (blue, 
channel in light blue and 2-helix-finger in cyan) with substrate (green, signal sequence 
as turquoise rectangle) intercalated. In this model, the N-terminal signal sequence is a 
trigger to partially displace the plug and open the SecYEG channel, which is further 
opened by mature polypeptide and SecA123. There is free diffusion of the polypeptide 
through the channel until bulky amino acids (green circle), which cannot move freely 
through the channel, contact the two helix finger of SecA, located on the cytosolic side 
of the channel117 (ii). ATP then binds SecA (iii), causing a conformational change of SecA 
propagated to SecYEG and fully opening the channel 117 (iv). Substrate diffuses 
through(iv), and ATP will hydrolyse to ADP, returning the channel to a partially open 
state117 (v). Backsliding is prevented as bulky amino acids, once moved to the periplasm 
cannot diffuse back or trigger nucleotide exchange to open the channel (vi)117. Image 
reproduced from Allen et al., (2016)117. 
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1.5.1 Lipoprotein transport 
Lipoproteins are synthesised as precursors with a signal peptide in the cytoplasm 
and translocated across the IM87. The signal peptides of lipoproteins possess a 
consensus lipobox sequence at the C-terminal region Leu- Leu-(Ala/Ser)-
(Gly/Ala)-Cys124. This cysteine is modified by formation of a linkage between Cys 
and diacylglycerol in the IM by the enzyme Lgt125. The signal peptide can then be 
cleaved by LspA126, and the free -amino group acylated by enzyme Lnt127, 
following which the Cys becomes the N-terminal residue of the mature lipoprotein.  
The amino acid following the N-terminal Cys determines the membrane 
specificity128,129. This is known as the “+2” rule128,129, with typically an aspartate 
determining localisation in the inner membrane130. 
Lipoproteins that are destined for transport to the OM must first be recognised by 
the LolCDE complex in the IM (Figure 1-5)131. It is likely that an aspartate at 
position +2 interferes with this recognition, creating a Lol-avoidance system132-
134. The LolCDE complex belongs to the ABC superfamily; LolC/E bind the 
lipoprotein in an ATP independent manner, and binding of ATP to LolD initiates 
a conformational change, decreasing affinity for the lipoprotein. ATP hydrolysis 
is required for handover to the periplasmic chaperone LolA135, which is then able 
to form a water-soluble complex encapsulating the lipoprotein136. LolA traverses 
the periplasm and delivers the lipoprotein to LolB located in the OM137, LolB 
possesses greater affinity for lipoproteins thus no energy is required in this 
step138. LolA and LolB both possess interior hydrophobic cavities important for 
transfer of lipoproteins63 with likely similar cavities occurring in LolC and LolE. 
Until recently it was assumed that lipoprotein biogenesis ended with LolB, with all 
known lipoproteins in E.coli  facing the periplasm19. However more recently it 
appears this is not likely, and in addition to protein-buried (LptE75) or membrane-
buried (CsgA139, Wza140), some lipoproteins continue their biogenesis to become 
surface located141,142. This has been shown for BamC143, as will be discussed in 
detail later (Section 1.7.2.2), and also Lpp141, Pal144 and YaiW145. While the 
majority of the pathway for lipoprotein transport is well characterised87,142, this 




1.6 OMPs and their biogenesis pathways 
1.6.1 Outer Membrane Proteins 
Integral membrane proteins can adopt one of two characteristic structures: α-
helical assemblies or β-barrels146,147. While α-helical membrane proteins are 
ubiquitous throughout eukaryotic and prokaryotic life, β-barrels are only found in 
the outer membranes of Gram-negative bacteria, mitochondria and 
chloroplasts146,147, supporting the hypothesis of endosymbiotic origin of the latter 
two26-29. With the exception of Wza and MlaA, in the outer membrane of Gram-
negative bacteria all proteins adopt a β-barrel structure29,148. As early as 2000 it 
was possible to define some of the construction rules essential to the OMP 
barrels149. These proteins possess an even number of β-strands150 between 8-
26, forming an antiparallel β-barrel149 with N- and C-termini both in the periplasm. 
The β-strand tilt is around 45º, and the shear number, characterising residues of 
offset at closure of the β-barrel, is always positive and around n+2 for n strands149. 
The proteins display periplasmic turns and long external loops149 and exhibit 
greater variability in the loops, and more conservation at transmembrane strands, 
with inward-pointing residues the most highly conserved18. Most importantly, 
most β-barrels have an internal hydrophilic surface, but a lipid-exposed exterior 
and consequently have a hydrophobic surrounding ribbon, approximately 27 Å 




Figure 1-7: Hydrophobic girdle of OMPs. The structure of OmpX [PDB 1QJ8](152) 
is shown with yellow sticks depicting the residues of the aliphatic ribbon and aromatic 
girdle, with sidechains pointing into the membrane. The approximate position of the 
membrane is marked. Figure adapted from Shulz et al., (2000)(149). 
 
OMPs are abundant in Gram-negative bacteria, constituting 2-3% of the 
genome151 and making up ~50% of the mass of the OM18. Only two OMPs are 
known to be essential in E.coli, LptD and BamA14. Structurally important OMPs 
such as OmpA occur at ~100,000 copies/cell18. OMPs are hugely diverse, being 
8-26 β-strands in size, taking monomeric, dimeric or trimeric forms18 and fulfilling 
a huge variety of functions as enzymes151, defensive layers18, making up 
secretion apparatus15, flagella and pili16,17. They can be loosely grouped by their 
function into six families, and one example of each in E.coli is shown (Figure 1-8): 
1) structural proteins, such as OmpA, 2) defensins, such as OmpX, 3) porins, 
such as OmpF, 4) active transporters such as FhuA, 5) passive transporters such 





Figure 1-8: Gallery of OMPs. Shown is a representative example OMP from E.coli 
for each family of protein, showing the diversity of structures. 1) The transmembrane 
domain of OmpA [PDB 1BXW]153, a structural protein  2) OmpX [1QJ8]152, a defensin. 3) 
OmpF [3POX]154, a homotrimer and porin. 4) FhuA [1BY3]155, a siderophore transporter. 
5) FadL [1T16]156, a transporter, and 6) OmpLA [1QD6]157, a phospholipase and dimer. 
Structures were analysed in Pymol158 and are not shown to scale. 
 
 
The long journey of OMPs from the ribosome to the OM in Gram-negative 
bacteria is only accomplished by the concerted action of many different proteins 
(Figure 1-5)14,19,159,160. Following translocation through the Sec machinery, the N-
terminal signal is cleaved by Signal Peptidase I159. Periplasmic chaperones allow 
unfolded OMPs to navigate the periplasm and reach the outer membrane, and 
the BAM complex without misfolding, aggregation or unfolded protein stress 
response. The BAM complex fulfils the final step of OMP assembly into the OM. 
There are numerous questions surrounding this pathway, of which the essential 




1.6.2 Chaperones involved in OMP folding 
There are multiple periplasmic chaperones160: Spy, Skp, DegP, SurA, FkpA, 
PpiA, and PpiD of which the latter four have peptidyl-prolyl isomerase (PPIase) 
activity19. Three are important in the correct transport of OMPs: SurA, Skp and 
DegP (Figure 1-5 and Figure 1-9). Despite initial hypotheses that Skp and SurA 
may act sequentially19,161 they appear to operate in partially redundant, 
overlapping pathways162. There is strong evidence against these acting 
sequentially as, unlike BamA, SurA is not able to release a Skp-bound OMP163, 
making it likely that both chaperones deliver OMPs to the BAM complex. Skp and 
DegP are hypothesised to function in the same pathway, as deletion of either of 
these is tolerated in E.coli but lethal when combined with mutation of SurA164. In 
addition SurA is thought to be the principal pathway for folding OMPs in the 
periplasm162. Fascinatingly, data from single-molecule force spectroscopy 
experiments on FhuA demonstrated the different roles of Skp and SurA165. In 
these experiments, while Skp was able to prevent misfolding of FhuA, it increased 
the proportion of unfolded protein, while SurA was able to facilitate folding and 
increase the fraction of correctly folded protein, outlining the different roles these 
chaperones may play in OMP biogenesis. 
 
Figure 1-9: Structures of three major periplasmic chaperones. Crystal 
structure of SurA [PDB 1MY]166 with missing residues modelled in. The domains are 
coloured individually: N-terminal domain (blue), P1 (green), P2 (yellow), C-terminal 
domain (red). b) Crystal structure of Skp [PDB 1U2M]167 shown as a trimer, with each 
monomer chain coloured separately. Missing residues in chain B and C were modelled 
in from chain A. c) DegP [PDB 2ZLE]168 12-mer from a cryo-EM reconstruction with a 
folded 16-strand porin (yellow) in the centre. Structures are not shown to scale relative 




SurA is a conserved periplasmic chaperone, vital to the assembly of OMPs169,170. 
SurA possesses four domains: two parvulin-like peptide prolyl isomerase 
domains (P1 and P2) and N- and C-termini domains (Figure 1-9a)166. The PPIase 
activity is only found in P1, however, PPIase activity appears unnecessary for 
OMP chaperoning171,172.  
SurA is likely to be the principal chaperone responsible for delivery of OMPs 
across the periplasm, as its depletion causes severe reduction in density of the 
OM and slower kinetics of folding of LamB while a skp/degP double deletion has 
a less severe effect162. Additionally, chemical cross-linking between SurA and 
BamA was shown in vivo, with the lipoprotein BamB also able to pull-down SurA 
and BamA whereas other chaperones were not observed162. In addition, SurA 
has been shown to preferentially bind a distinct aromatic repeating sequence of 
peptide (Ar-X-Ar)173. This is highly similar to the “β-signal” of OMPs, with a typical 
GxxΦxΦ motif at the C-terminus, where ϕ represents hydrophobic residues174,175. 
Therefore, while Skp/DegP are clearly important in OMP folding, and their 
deletion causes defects164,176 SurA likely operates a principal pathway in OMP 
folding and assembly. 
 
1.6.2.2 Skp 
The seventeen-kilodalton protein (Skp) was first identified by its ability to bind 
unfolded OmpF by affinity chromatography177. Skp has broad substrate 
specificity, binding over 30 different proteins178 and binds OMP substrates with 
low-nanomolar affinity179. The skp gene is immediately downstream of BamA24 
and regulated by the σE regulon. 
Skp has a jellyfish-like architecture with three extended, flexible arms, held 
together by coordination of a 9 stranded β-barrel domain (Figure 1-9b)167. The 
tips of the protein are rich in positively charged residues, while the interior 
contains hydrophobic patches167. OMPs form interactions with Skp with 
nanomolar affinity, as measured by tryptophan fluorescence179 and FRET 
experiments180. The interaction with OMPs is principally by charged residues, as 
above pH 11, or below pH 5, Skp and OMPs are unable to bind179. Consistent 
with this, increasing NaCl concentration from 0 to 1 molar caused a decrease in 
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affinity of Skp for OmpA of approximately four-fold179. Nuclear magnetic 
resonance (NMR) data demonstrate that Skp-OMPs form multiple weak, transient 
interactions, consistent with these mainly being electrostatic effects and with Skp 
providing a holding cage for unfolded OMP substrates181. Interestingly, Skp binds 
BamA with higher affinity than other OMPs (0.3 nM Kd for BamA as opposed to 
12- 50 nM for other OMPs measured)179, this may reflect necessary tighter 
binding in the handover of substrate OMPs. 
It has been demonstrated that Skp may bind unfolded OMPs and forms a 3:1 
complex, aiding identification of functional Skp as a trimer182. Studies have been 
carried out with OmpA and for this it has been demonstrated that the presence of 
Skp or LPS slows OMP folding into preformed lipid bilayers, but both together 
accelerates folding179. LPS binding sites were identified on the Skp monomer167 
and it was assumed that the three together form a complex183, particularly as the 
presence of LPS renders a Skp-OMP complex more accessible to tryptophan 
quenching. However, NMR studies demonstrated LPS likely carries out a non-
specific denaturing effect on Skp184, thus explaining the apparent accelerated 
folding. While tryptophan fluorescence data indicate a 1:1 stoichiometry of Skp 
trimer to OMP substrate for OMPs of all sizes183, later kinetic and native ESI-MS 
data demonstrated that a higher ratio of Skp: OMP may be necessary to 
sequester larger substrates163. The cavity within Skp could likely only 
accommodate a 25 kDa folded protein167, while many OMP substrates will exceed 
this apparent size limit. Additionally molecular dynamics simulations demonstrate 
how Skp may coordinate to bind and enclose larger unfolded OMPs, creating a 
strong resemblance to eukaryotic chaperone prefoldin163.  Dynamics of the helical 
tentacles of Skp oligomers increase the cavity size for binding larger OMPs163.   
 
1.6.2.3 DegP 
The DegP monomer has three domains: a protease domain and two C-terminal 
PDZ domains for substrate binding160. DegP possesses protease and chaperone 
activities185, and while originally thought to switch in a temperature-dependent 
manner, it now appears that its natural, hexamer state blocks exposure of 
protease sites186 (Figure 1-9c). Deletion of degP alone shows a temperature-
sensitive phenotype, while E.coli containing mutations of both degP and surA are 
only able to grow below 23ºC (164). Double mutants of degP and surA show a 
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synthetic phenotype, with reduction of envelope protein levels, but no 
considerable cell morphological changes, unlike that seen for skp/surA 
mutants164. DegP fulfils a crucial role as a protease164,176. In the presence of DegP 
with full protease function, the skp/surA double mutant is bacteriostatic, but when 
DegP is mutated to have no protease function this is bactericidal164. This is likely 
due to the toxic, high accumulation of unfolded OMPs in the absence of DegP 
protease function, as seen in degP deletion strains164. 
 
1.7 The BAM complex 
The BAM complex in E.coli is a five protein complex, composed of BamA and 
four associated lipoproteins (BamB-E). While BamA and BamD are the only 
essential components of the complex21,25,187,188, the depletion of the associated 
lipoproteins decreases the BAM complex catalytic activity189 and may lead to 
impairment of OMP folding or membrane impermeability21,25,176,187,190. BamB, 
BamC and BamD are all expressed on the same σE regulon, a regulon also 
important for response to cell stress187. 
 
1.7.1 BamA 
1.7.1.1 Discovery and Evolution of BamA 
BamA is part of the Omp85 protein family22. The protein family was first identified 
as a D15 surface antigen, as a target of antibodies for patients infected with 
H.influenza191. However, the first thorough identification of the protein family 
came from cyanobacteria, as these bacteria contain a structural homolog of the 
chloroplastic protein, Toc75, in the outer membrane22. Identified in the 
cyanobacteria family Synechocystis and referred to as SynToc75, the sequence 
of this protein was used to search databases, and revealed that a member of this 
protein family was present in all Gram-negative bacteria genomes known at the 
time22. An Omp85 homologue has since been identified in all bacteria with an OM 
for which genomes are available26. A clear relationship is evident between 
Omp85 proteins, even those with low sequence homology, as all possess similar 
size, a proven or predicted outer membrane localization, a cleavable N-terminal 
signal sequence and a predicted β-strand secondary structure22. In addition, the 
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compared proteins showed areas of high sequence identity, and a highly 
conserved C-terminal motif22. 
The difficulty in deleting the Omp85 gene, in Synechocystis, Haeomophilus 
ducreyi and E.coli demonstrated that the protein is essential22,25,192. The 
conserved Omp85 family at this point had unknown function, but was a strong 
candidate as part of the OMP insertion machinery, for which no components were 
yet identified21. Studies using a depletion strain for Omp85 in N.meningitidis 
provided further evidence that Omp85 protein expression is essential for growth 
and viability21. It was anticipated that if Omp85 is involved in OMP insertion, then 
its depletion would decrease levels of OMPs detected. Intriguingly, while OMP 
expression levels in N.meningitidis did not appear to be significantly affected in 
the Omp85-depletion strain, PorA and B accumulated as monomers, rather than 
the correctly folded trimers21,193. The proteins also showed increased sensitivity 
to trypsin and extractability from the membrane21. Therefore, the proteins were 
not correctly folded into the OM. Later studies, using an Omp85-depletion strain 
in E.coli showed impaired growth, and similarly caused a decrease in the amount 
of folded OmpA and LamB and an increase in the unfolded OmpA and LamB 
detected over time25. In addition, immunofluorescence using antibodies directed 
at different OMPs demonstrated weaker labelling in the absence of Omp85, while 
protein expression remained constant, implying less OM localisation21. As 
opposed to the wild-type homogenous coverage of labelling, Omp85-deficient 
cells were irregularly labelled, with labelling absent at the cell division septa21. 
These studies, combined with the high homology to Toc75 in chloroplasts, 
provided strong evidence that the Omp85 protein family is involved in correct 
assembly and folding of OMPs.   
 
1.7.1.2 Structure of BamA 
E.coli BamA is comprised of a C-terminal β-barrel in the OM and five N-terminal 
polypeptide transport associated (POTRA) domains. Due to its intractability as a 
membrane protein, the structure of BamA was not solved until 2013194, two years 
after the associated lipoproteins195. However, models of its structure were 
possible from general understanding of β-barrels and the rules that define them149 
and the structure of the loosely related FhaC196. 
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Structures of the BamA β-barrel from Haemophilus ducreyi (Hd) and Neisseria 
gonorrhoeae (Ng) were solved in 2013, with two and five of their five POTRAs 
respectively194. Shortly after the Escherichia coli (Ec) BamA structure was solved 
containing the β-barrel and POTRA5 (Figure 1-10c)11. These structural studies 
confirmed the suspected architecture of the Omp85 family, in addition to fulfilling 
expected properties for an OMP β-barrel, with a 16 stranded β-barrel. Several 
interesting differences between the structures were noted: firstly there was 
considerable dynamics of the POTRA domains, with the POTRA domains of 
NgBamA occluding access to the barrel194, while the HdBamA POTRAs did not, 
and the EcBamA POTRA5 structure appears to adopt a conformation 
intermediate between the two11. Further, while the HdBamA structure (Figure 
1-10a) adopted the anticipated closed β-barrel, with eight H-bonds between the 
first and last β-strands, the NgBamA structure formed only two H-bonds, with the 
C-terminal strand tucked inside the barrel (Figure 1-10b)194. The EcBamA 
structure also showed weakly associating β1 and β16 β-strands (Figure 1-10c). 
 
 
Figure 1-10: Crystal structures of BamA from three Gram-negative species. 
The first (β1) and last (β16) strand of each structure is highlighted in dark blue. a) The 
crystal structure of H. ducreyi BamA (construct contains POTRA4 and POTRA5) 
[4K3C]194 shows a close association between β-strands 1 and 16, forming eight hydrogen 
bonds. b) Conversely N. gonorhoeae BamA [4K3B]194 displays a weak interaction 
between β-strands 1 and 16, forming only 2 hydrogen bonds, and with a disordered C-
terminus of β16 tucked inside the barrel194. c) E.coli BamA (construct contains only 
POTRA5) [4C4V]11 also shows a weak interaction between β-strands 1 and 16, also with 
only 2 hydrogen bonds, and with a disordered C-terminus.  
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Prior to solving the BamA structures, the most closely related structure was that 
of the two-partner secretion protein FhaC. This is an Omp85 family protein, but 
functioning as a toxin translocation pore196 (Figure 1-11b). Comparison of the 
BamA structures, however, reveals several similarities to the crystal structure of 
Omp85 protein TamA, which also has an incompletely closed -barrel197 (Figure 
1-11a). 
For FhaC, substrates are hypothesised to thread through the lumen of the 
barrel196. The extensive contact of the β1 and β16 strands196 (Figure 1-11b) 
renders lateral opening between the strands unlikely. In addition no lateral 
opening propensity was observed by molecular dynamics simulations unlike 




Figure 1-11: Crystal structures of a) TamA and b) FhaC highlighting 
differences in β-barrel closure. Structures are shown with the barrel in wheat, the 
periplasmic domains in brown, β1 in green and β16 in red. a) The structure of TamA 
[PDB 4C00]197 from E.coli demonstrates incomplete closure of β1 and β16 in the β-barrel, 
with an inward kink of β16 (red). b) The structure of FhaC [4QKY]200 from B.pertussis 
shows a more extensive interaction of β1 (green) and β16 (red) β-strands.  
 
 
The structure of the majority of the periplasmic portion of BamA, the POTRA 
domains, was solved in E.coli before solution of the β-barrel structure (Figure 
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1-12a)11,201. The POTRAs structure revealed a dimer formed by a β-strand 
interaction between strand 2 of POTRA3 and the first residues of POTRA5201 
(Figure 1-12b). Although possibly a crystal artefact, it demonstrates a means of 
interaction between polypeptides and POTRA domains of β-augmentation202. In 
addition, the second structure solved for POTRA domains 1-4 showed a similar 
β-augmentation of POTRA3, but with the additional β-strand binding in an 
opposite orientation (Figure 1-12c)203. This supports a role for POTRA domains 
in assisting OMP assembly in a way that is blind to the sequence of the 
polypeptide chain201. 
 
Figure 1-12: Crystal structure of E.coli POTRA domains and β-
augmentation to POTRA3. POTRA domains 1-4 [PDB 2QDF]201, coloured red to 
pink. Despite possessing low sequence similarity all POTRA domains show the same 
structural folds. Each POTRA domain is made up of a three-stranded β-sheet and a pair 
of α-helices. b) β-augmentation of the β-sheet of POTRA3 with a β-strand from the N-
terminus of POTRA5 in a parallel orientation(pink), from Kim et al., (2007)201. c) β-
augmentation of β-sheet of POTRA3 with a β-strand from POTRA5 (residues 345-349) 
in an antiparallel orientation (red). b and c) are adapted from Gatzeva-Topolova et al., 
(2008)203. 
 
Studies deleting each POTRA domain individually demonstrate that these 
variants are all expressed, targeted correctly to the outer membrane and folded, 
as assessed by heat modifiability201. Additionally, any of the first four POTRA 
domains can be deleted and still maintain interactions of BamA with BamD, 
BamC and BamE201. This provided strong evidence that the periplasmic POTRA5 
domain scaffolds the other four proteins.  
The POTRA domains have been shown to be highly dynamic, with a potential 
hinge between POTRA2 and POTRA3204,205. This dynamic nature may be 
mediated by binding to BamB204,205, binding to the membrane206 or 
24 
conformational changes of the BamA barrel31,207-210. Analysis of the structures of 
the BAM complex207-210 demonstrates how the dynamic nature of the POTRA 
domains may be mediated by lipoproteins and the BamA β-barrel and integral to 
the overall conformational change of BAM in substrate interaction. This is 
discussed in detail in Chapter 3 (Section 3.3) with analysis of the cryo-EM 
structure. 
Studies of deletion mutants of POTRA domains in vivo, with and without BamA 
present, show that deletion of the POTRA domains further from the barrel (P1 
and P2) is less damaging than deletion of those closer (P3 and P4)201. Deletion 
of P5 creates a BamA toxic to cells, likely due to mishandling β-barrel 
substrates201. Furthermore, in contrast to previous evidence of the BAM complex 
functioning as an oligomer211, these studies showed it behaving as a monomer. 
Mobility on Blue-Native PAGE was less than 230 kDa and whereas lipoproteins 
were immunoprecipitated by the POTRA domain deletion mutants, BamA was 
not, demonstrating that oligomerisation is not occurring through BamA201. 
 
1.7.2 Lipoproteins of the E.coli BAM complex 
1.7.2.1 BamB 
BamB is a 42 kDa, 8- bladed β-propeller, belonging to the WD40 superfamily195. 
It is found in all α-, β- and γ- proteobacteria195.  It possesses a ring-link structure, 
with closure of the propeller ring controlled by antiparallel pairing of the most N- 
and C-terminal β-strands195 (Figure 1-13).  
The interaction between BamA and BamB was identified as direct, occurring in a 
conserved region of BamB, between residues P171 to P181190. Specifically, 
mutagenesis of L173, L175 or R176 causes defects and reduces the ability of 
BamB to immunoprecitate BamA190. Disrupting the BamA-BamB interaction 
causes a phenotype similar to BamB deletion, suggesting that the interaction of 
BamB with BamA is necessary for BamB function190. Deletion mutants of yfgL 
(BamB) showed increased sensitivity to antibiotics and SDS, demonstrating 
increased OM permeability187. The same mutant showed a 10-fold increase in σE 
activity and reduced OMP profile187. A separate conserved region (V319-H328) 
was also shown to be needed for correct folding of BamB, but not its function190. 
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The OMPs most affected by BamB deletion are larger (18-26 strands), suggesting 
that BamB provides additional surface area to aid folding of larger 
substrates187,212-214. In addition, BamB and SurA deletion mutants are 
indistinguishable215 and the simultaneous deletion of BamB and SurA or BamB 
and DegP is a synthetic lethal combination187 lending more evidence to these 
proteins playing overlapping, redundant roles. This also provides further evidence 
for BamB interacting early in the process of OMP folding.  There exists a theory 
that SurA may deliver OMPs to BamA via BamB215 however this is unlikely as 
mutants of BamB which pull down less BamA pull down equivalently less SurA190. 
Thus, it is more likely that the interaction of BamB-SurA is mediated by BamA190. 
The crystal structure of the full BAM complex confirmed the interaction between 
BamB and BamA POTRA2 and POTRA3 (Figure 1-17)208 and demonstrated that 
the presence of BamB may link to the structural rearrangements of POTRAs in 
BamA dynamics208,210, discussed in Chapter 3 (Section 3.3). Furthermore, recent 
studies displaying OMPs in assembly “precincts”, or concentrated clusters on the 
cell surface have proven that BamB is required for the oligomerisation of BAM 
complexes216. It was determined that the interacting residues of BamB could be 
crosslinked in situ and also that deletion of the BamB gene, while not impacting 
cell growth, caused loss of assembly precincts containing the BAM complex216. 





Figure 1-13: Crystal structure of BamB from E.coli. BamB forms an eight-
bladed β-propeller with four β-strands in each blade, coloured individually and 
numbered 1-8. Image created with Pymol (PDB: 2YH3)195. 
 
1.7.2.2 BamC 
BamC possesses an N-terminal segment with no regular secondary structure, 
~70 amino acids in length and two independently folded helix-grip domains 
(Figure 1-14)195. Despite low sequence identity, the helix-grip domains form 
structurally similar folds with five antiparallel β-sheets and two α-helices195.  The 
unstructured N-terminal domain is the most highly conserved region212, and is 
important for interaction with BamD and BamE (Figure 1-14)217. 
Immunofluorescence demonstrated that segments of BamC are surface exposed 
and while the unstructured N-terminal region is in the periplasm and interacts with 
BamD, the helix-grip domains are likely located on the E.coli surface143. Analysis 
of γ-proteobacteria sequences demonstrate that there are three regions in the 
unstructured N-terminus of BamC which are highly conserved. The first is 
essential for binding BamD (residues 26-42), the second (residues 48-68) 
extends this interaction, while the third (residues 74-102) appears between the 
BamD binding segment and the two structural domains (Figure 1-14)143. As this 
third motif appears highly hydrophobic it is likely that this segment traverses the 
membrane, and has evolved with a sequence capable of doing so143. 
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Crystal structures of the BAM complex confirmed the high flexibility of segments 
of BamC, with reduced electron density observed for the C-terminal domain in 
some cases207 and seen interacting with BamD and POTRA 2 in others208. This 
is evidently in contrast to the suggestion of BamC being surface exposed143, and 
may be due to the conditions imposed by crystallization and the detergent micelle. 
The exact physiological role of BamC is unknown but it may be involved in the 
response to antibiotics215. Deletion mutants of nlpB (BamC) show increased 
sensitivity to the amphipathic antibiotic rifampicin, and are synthetic lethal with 
deletion of SurA187. In addition, other lipoproteins displayed an increased 
protease sensitivity in a BamC deletion strain143. Also, as previously discussed, 
the N-terminal 70 amino acids of BamC bind BamD217, but the pocket of BamD 
observed to bind, between TPR domains 1 and 2 (Figure 1-14, green and pale 
blue), is also that proposed to bind the OMP targeting signal217. This suggests a 
role for BamC in regulating OMP access to BamD190,217,218, but the functional role 
of these domains in OMP biogenesis remains unclear. 
 
 
Figure 1-14: Crystal structure of BamCD subcomplex and (inset) schematic 
of BamC domain organisation. The crystal structure is shown with BamC in cartoon, 
with N-terminal domain in magenta, and the first structured domain in purple. The 
schematic follows the same colouring, with the C-terminal structured domain in grey, and 
residue numbers indicated. BamD is in a surface representation with its TPR domains 
individually coloured. The unstructured N-terminal domain of BamC forms a lasso 





BamD is entirely α-helical, composed of five tetra-tricopeptide repeat (TPR) 
domains195 (Figure 1-15), which are typical for protein-protein interactions219. 
BamD is the only essential lipoprotein of the BAM complex187. 
BamD binds BamA via POTRAs 1, 2 and 5201,208 and provides a platform on which 
BamC and BamE dock, confirmed in structures of the full BAM complex208 (Figure 
1-17). In addition, molecular dynamics simulations demonstrate that removal of 
BamD may significantly increase the dynamics of the POTRA domains208. The 
interaction between BamA and BamD is highly significant, with mutations in this 
interface causing low cell growth or cell death208. 
The first three TPR domains of BamD form a structural scaffold open to protein 
binding (Figure 1-15)195. In the original crystal structure, the C-terminus of the 
next BamD protein was found to bind within this scaffold195, while the BamCD 
crystal structure revealed the unstructured N-terminal 70 amino acids of BamC 
binding in the same region217 (Figure 1-14). However, the substrate groove was 
shown to be of appropriate dimensions for binding the conserved C-terminal six 
amino acids of OMPs195. Peptides containing typical residues conserved in this 
sequence could be docked to TPR1-3195. The role for BamD in substrate 
recognition and assembly is supported by further recent evidence175,220. The 14 
strand of BamA, which contains the conserved OMP β-signal sequence, is 
necessary and sufficient for binding of BamA, as a substrate, to BamD175. In 
addition, trapping an incomplete folding intermediate of LptD showed interactions 
between BamD and LptE, normally located within the LptD barrel220. It is likely, 






Figure 1-15: Crystal structure of BamD. TPR domains (1-5) are highlighted red-
pink. TPRs1-3 are thought to form key binding sites to bind substrate proteins or BamC. 
Image created in Pymol (PDB: 3Q5M)221.  
 
1.7.2.4 BamE 
BamE is the smallest, most recently discovered of the four lipoproteins of BAM176, 
and non-essential, with its deletion causing no growth defects, but increased 
membrane permeability176,222. While a BamE deletion strain shows only slight 
deficiency in folding OMPs176 the combination with a BamC deletion, or BamD 
mutant renders the cell severely defective in OMP biogenesis, while combination 
with BamB is synthetically lethal176. Additionally, the stability of the complex is 
shown to be compromised in its absence176. BamE specifically binds 
phosphatidylglycerol (PG), in a site near its BamD binding site223 and was 
therefore hypothesised to bring the complex to sites of high concentration of PG, 
thus assisting OMP folding182. Structures of the BAM complex, however, 
demonstrate this binding site to remain far from the position of the membrane207. 
In BamE the N-terminal acylation site is followed by a short unstructured linker. 









Figure 1-16: NMR structure of BamE. The BamE ααβββ topology is shown with β-
strands in red and α-helices in cyan. PDB: 2KXX224. 
 
BamE has been shown to exist in both monomer and dimer forms195,223,224. The 
first crystal structure of BamE showed a hexameric protein complex with three 
intercalating dimers and a significant interface between monomers195. Small 
additional interfaces between non-conserved regions of BamE lead to 
hexamerization195. The formation of oligomeric species up to hexamer was 
evidenced by SEC and cross-linking, and extraction of native BamE from natural 
membranes with detergent demonstrated the presence of a higher molecular 
weight complex, suggesting that some oligomer formation occurs naturally195. 
There is evidence for the dimeric BamE being the active form due to its structural 
homology to β-lactamase inhibitor proteins195 which typically operate as a tandem 
fold the size of dimeric BamE225. However, it has been demonstrated that BamE 
in the periplasm is principally monomeric and it may be misfolded localisation in 
the cytoplasm that leads to its dimerisation223. 
 
1.7.3 Structure of the BAM complex  
Despite crystal structures of all the individual components, until 2016 there was 
no structure of the full BAM complex and there were unconfirmed hypotheses of 
how the complex may fit together226,227. This was well-informed, however, by 
several subcomplex structures, including BamCD217, BamAB204,228, BamAD226 
and cross-linking and pull-down studies, demonstrating which regions of each 
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protein are significant for interactions25,190,201,217,223. The first crystal structure of 
the BamACDE complex207 therefore confirmed many of the suspected interfaces 
between proteins but also gave unique insight into the architecture of the 
complex. While the general conformation of the complex was oriented as 
anticipated, the arrangement of POTRAs and lipoproteins was more compact 
than hypothesised, forming a closely-associated ring at the periplasmic side of 
BamA (Figure 1-17). The BamD TPR motifs lie nearly parallel with the membrane 
and with a significant interface with the POTRA domains (buried surface area > 
1100 Å2), forming a large potential interaction surface for substrates207 (Figure 
1-17). 
The first solved crystal structures came with a surprise, however, not in 
arrangement of the subunits, but in the conformation of BamA. This had 
previously been hypothesised as moving between the lateral closed structure 
observed in crystal structures of BamA alone11 and the lateral open structure such 
as observed in Neisseria gonorrhoeae BamA194. The crystal structures confirmed 
this, showing the β-barrel of BamA to adopt one of two profoundly distinct states. 
The first is an “inwardly open” conformation in which the BamA β-barrel is sealed 
on its extracellular face and between the first (β1) and last (β16) β-strands, and 
open to the periplasm (Figure 1-17a). A second conformation has been observed 
(Figure 1-17b) in which the BamA β-barrel has undergone a large conformational 
rearrangement. The barrel becomes distorted by the rotation of the first six β-
strands and displacement of three loops on the extracellular face. This creates 
the “lateral open” conformation, in which the BamA β-barrel is open to the outer 




Figure 1-17: Comparison of crystal structures of the BAM complex. Crystal 
structure of (a) BamABCDE (PDB 5D0O)208 and (b) BamACDE (PDB 5EKQ)207. BamA 
(brown), BamC (green), BamD (blue) and BamE(magenta) are visible in both structures 
in addition to BamB (yellow) in (a). The β1 and β16 strands are depicted in blue, 
highlighting the conformation of the BamA lateral gate in each structure. In addition, 
conformational changes between lateral open and closed structure are visible in the 
POTRA domains and in the extracellular loops at the top of the barrel.  
 
The ‘lateral open’ conformations have only been observed in crystal structures of 
the BAM complex which lack the 42 kDa, β-propeller lipoprotein, BamB207,208, 
while crystal structures of the intact complex contain a lateral-closed BamA 
structure similar to that published of the protein in isolation11,208,209. This leads to 
the hypothesis that changes in the BamA β-barrel conformation may represent a 
gating reaction driven by BamB binding. Our own structural analysis of BAM by 
cryo-electron microscopy has since disproved this theory31,210, generating a 
structure which displays the intact BAM complex with BamA in a lateral open 
conformation in the presence of BamB. This will be discussed in detail in Section 
3.3. 
 
1.8 In vitro studies of OMP folding 
OMPs must fold into the lipids of the outer membrane in the absence of an 
external source of energy.  A huge amount of information has been gleaned from 
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studies of OMP folding using micelles and bilayers in vitro12,33,35,71,72,79,229-246. 
Typically OmpA has been used as the model folding OMP, dating from the 
original studies of Surrey & Jahnig demonstrating the ability to fold OmpA into 
micelles of the detergent β-octylglucoside247 or lipid bilayers composed of 
dimyristoylphosphatidylcholine (DMPC)243.  These studies exploited the heat 
modifiability of OMPs: that they will migrate as distinctive folded and unfolded 
populations on cold SDS-PAGE248,249. Since then studies have advanced apace, 
employing multiple techniques. Far-UV circular dichroism (CD) informs on 
formation of the β-sheet structure, while heat modifiability by SDS-PAGE and 
tryptophan fluorescence inform on the tertiary structure79,250. In addition, 
tryptophan fluorescence quenching can be utilised for single tryptophan variants 
monitoring insertion into a quenching environment, such as brominated lipids237.  
In addition to widespread use of SDS-PAGE, tryptophan fluorescence and CD to 
unravel the structures and mechanisms integral to OMP biogenesis, a plethora 
of further techniques have also been applied246. These include mass 
spectrometry251,252, NMR181,253-255, force spectroscopy165,256,257, FRET258-260 and 
molecular dynamics246. While considerable fundamental understanding, 
summarised here, has been gained through molecular biology and biochemical 
analyses, application of many techniques noted above to the folding of intractable 
outer membrane proteins remains in its infancy. With the fundamental knowledge 
in place however, the field may now increasingly rely on structural and biophysical 
techniques to resolve the finer details of OMP biogenesis. 
Initial kinetic experiments suggested a multi-step model for OMP folding with a 
rapid initial step of hydrophobic collapse, followed by membrane adsorption, and 
with a slower later step of partial folding and insertion of hairpins237,261. This was 
supported by experiments with tryptophan fluorescence quenching of OmpA 
which demonstrated that all four β-hairpins cross the bilayer simultaneously237. 
Studies of folding of OmpA into DLPC bilayers by far-UV CD and gel 
electrophoresis showed similar kinetics, suggesting that secondary and tertiary 
structure are formed concurrently79. This was supported by hydrogen-deuterium 
exchange (HDX) studies demonstrating that when OmpX was folding into 
detergent micelles the rate of hydrogen bond formation between β-strands was 
consistent and simultaneous with tertiary structure formation262. The clustering of 
aromatic residues in the membrane interface of OMPs likely provides a critical 
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force in their assembly and stability263. It is not clear, however, how this data may 
fit with more recent single-molecule force spectroscopy results demonstrating 
that OMPs insert by sequential hairpins256, rendering a single coordinated 
movement to tertiary structure unlikely.   
While parallel pathways of folding have also been suggested for OmpA and other 
OMPs238,264,265, more recently the mechanism of folding and insertion of OmpA 
has been called into question again230. While principally following the same 
pathway as previously deduced79,237, it was shown that an intermediate was 
formed with more β-sheet content than the native state and populations were 
detected of misfolded off-pathway states230. Experiments used the 
transmembrane domain of OmpA (tOmpA) folding into bilayers of different 
thicknesses in studies with CD and SDS-PAGE. It is proposed this goes against 
the previously suggested parallel pathways and supports a “predetermined 
pathway with optional errors”266. It is concluded that the novel structure seen is 
likely due to transient β-strand formation by extracellular loops230. While 
plausible, the loops have also been shown to be amenable to truncation and 
mutagenesis267 and therefore unlikely to be critical for folding. 
Studies of OMP folding in synthetic bilayers widely employ lipids with 
phosphatidylcholine (PC) head groups as these support fast folding71,72. These 
conditions differ from that of the inner leaflet of the OM of E.coli which is 
comprised predominantly of PE and PG54, and ignores the asymmetric nature of 
the bilayer and presence of LPS. While LPS assists the folding of some OMPs in 
vivo it is not necessary for the folding of OmpA247 or OmpT159,189 in vitro. The 
presence of LPS in fact retards the folding of OmpT159, but is required for OmpT 
protease activity268. In addition, while lipid chain length varies in vivo, with the 
inner leaflet of the OM typically composed of phospholipids of 16-18 carbon acyl 
chains54,67, the thickness of synthetic phosphatidylcholine bilayers typically used 
in vitro increases linearly with increasing acyl chain length269. In this respect, 
DMPC (C14) bilayers with a thickness of 23 Å269 are closest to the hydrophobic 
thickness of the OM estimated from average OMP structures (23.7 Å)270. 
However, it is predominantly the 10-12 carbon acyl chain lipids that have been 
most extensively employed in synthetic liposomes used in OMP folding 
studies71,72. These shorter acyl chains favour OMP insertion in vitro compared 
with the inefficient folding in lipids of lengths greater than 12 carbons71,72. 
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A systematic study of the folding of nine different OMPs (OmpX, OmpW, OmpA, 
PagP, OmpT, OmpLA, FadL, BamA and OmpF) in phosphatidylcholine LUVs 
showed several important general considerations previously noted for individual 
OMPs72: 
1) Higher pH values increase folding efficiency, consistent with experiments 
on OmpF244. Experiments were carried out in DLPC LUVs and pH varied 
from 3-10, with an increased fraction folded being observed at pH 8-10. 
As the OMPs have a pI between pH 5 and pH 6 and will have a net 
negative charge at higher pH, this may promote interaction with the 
zwitterionic bilayer. 
2) OMPs fold better in thinner bilayers. Phosphatidylcholine LUVs were used 
with chain length varied from 10-12 carbons:  diC10:0PC (DDPC), diC11:0PC 
(DUPC) and diC12:0PC (DLPC). All OMPs folded fastest in DDPC, in 
accordance with previous data on OmpA79. 
3) OMPs fold better in vesicles of smaller diameter. From comparison of 
folding into SUVs and LUVs of the same lipid type, the increased curvature 
of SUVs promotes folding, as do lipid defects79,229,242. 
4) Effects of temperature were highly variable. In variation between 30º -50ºC 
the folding efficiency of OMPs showed no consistent trend, and properties 
were not correlated with OMP size. This is likely due to different 
aggregation propensities between OMPs at different temperatures. 
While OMPs will spontaneously fold into the short acyl chain model membranes 
widely used (~15 Å acyl chain length for 10-carbon DDPC269), it is likely this would 
not occur at a sufficient rate in the bilayer of a cell comprised of longer lipids71. 
Additionally, the introduction of native-like lipid head groups into the bilayer, such 
as PE and PG, slows OMP folding71. A molar percentage of 20% DDPE in DDPC 
LUVs retarded folding of all OMPs measured (tOmpA, OmpA, OmpX and 
OmpLA) compared with membranes created from DDPC alone71. Although 
apparently paradoxical, this emphasises the role of BamA in relieving this kinetic 
barrier for OMP folding. The presence of BamA in (80:20 mol:mol) DDPC:DDPE 
LUVs increases the kinetics of folding of tOmpA, OmpA, OmpX and OmpLA71. 
Prefolded BamA also increases the rate of folding of OmpA and its 
transmembrane domain (tOmpA) in phosphatidylcholine bilayers (DUPC, DLPC, 
DTPC and DMPC)241,271, and the catalytic rate enhancement of BamA increases 
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with increasing lipid acyl chain length241. Therefore it appears likely that the 
presence of BamA assists in overcoming energetic barriers for OMP folding, and 
specific localisation of BAM in the OM allows folding of OMPs in PG and PE lipid 
types only in that location71, differentiating from the similar periplasmic lipids of 
the IM, and ensuring that OMPs are folded only into the OM. 
One way in which the catalysis afforded by BAM may occur is by lipid defects230. 
OMPs fold faster at regions of lipid non-homogeneity, such as caused by lipids at 
their phase transition temperature230 and BamA’s principal role may be as a 
membrane “disruptase” or causing lipid thinning194,241. This model of BamA 
function will be discussed in full (Section 1.10.2). It has additionally been 
demonstrated that BamA works in a “catalytic”, non-stoichiometric fashion245, 
able to fold a greater concentration of substrate than total concentration of 
prefolded BamA. The rough turnover calculation suggests 1.7 OMPs can be 
folded per BamA, which is equivalent to that measured using the BAM complex 
(BamABCDE)159, suggesting that the additional lipoproteins play no role in 
catalytic capacity or regeneration of activity. However, as will be discussed in 
later chapters, there are conditions in which BamA is insufficient, and it is likely 
that the BamBCDE subunits accelerate activity in more native lipid types210,245. 
 
1.8.1 In vitro studies with the BAM complex 
Our understanding of the BAM complex mechanism is now advancing faster due 
to our ability to monitor substrate OMP folding by the multiprotein complex, or its 
sub-assemblies159,175,189,272-274. Originally, due to difficulties in purification of the 
intact BAM complex, the complex was expressed and purified as two sub-
complexes: BamAB and BamCDE189. The choice of these two subcomplexes was 
due to previous knowledge that BamA binds BamB independently of 
BamCDE188,201. 
Studies of the in vitro activity of the BAM complex, dating from this original 
work189, have largely used the 10- stranded β-barrel OmpT as a 
substrate159,272,274. OmpT is a protease275 and when correctly folded it will cleave 
a substrate possessing sequential charged residues268. The subcomplexes 
BamAB and BamCDE were reconstituted together in E.coli polar lipid 
proteoliposomes and it was demonstrated that OmpT folding and thus activity 
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was significantly increased in the presence of the BAM complex189. Additionally, 
increasing concentration of SurA increased activity, while it was later 
demonstrated that SurA could be functionally replaced by urea159,272. Activity was 
improved when all five protein components of BAM were present, compared with 
either BAM subcomplex alone159,189. Additionally, BamABCDE yielded 
significantly higher activity than BamACDE159. These activities, measured by 
fluorescence, were confirmed as correlating with folding of OMP by migration of 
radiolabelled OmpT on SDS-PAGE159,189.  
The assembly of BamA itself into the lipid bilayer presents somewhat a “chicken 
and egg” problem, as BamA is the catalytic component required for OMP folding 
and BamA itself cannot quickly fold into empty liposomes272. This was solved, 
however, by the demonstration that the lipoproteins BamCDE aid BamA folding 
into E.coli phospholipids but are not able to exert the same effect for OmpA272. 
Subsequently the intact BAM complex was reconstituted following polycistronic 
expression of all five subunits and it was demonstrated that the BAM complex 
displays greater activity when all components are expressed together274, as 
compared by the OmpT assay. This preparation of the BAM complex was 
demonstrated to be functional in folding the autotransporter EspP and its 
passenger domain correctly in proteoliposomes274. It additionally provided the 
first evidence that BAM, reconstituted in protein-supported nanodiscs is 
functional274. 
Most recently, a study of BAM complex catalysis in proteoliposomes composed 
of different lipids demonstrated that the effect of BAM is substrate-, but not lipid-
, specific273. Using the autotransporter EspP as a substrate, the data are striking 
in the invariance of the observed rates and t50s across different membrane 
thicknesses, fluidity and lipid head groups273. This implies that BAM is able to 
overcome the thermodynamic limitations conferred by the different bilayers, and 
catalyse folding to a consistently identical rate. For OmpA, rates are not so 
consistent, with BAM-catalysed OmpA folding faster in short chain lipids than in 
longer chain lipids. However, the range of kinetics observed are small, 
significantly less than for spontaneous OmpA assembly into lipids of varying 
lengths79,241, and a high proportion of folding was observed in all cases273. BAM 
may accelerate folding of different substrates to different extents, but largely it is 
the substrate that influences the catalytic rate, not the lipid.  
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1.9 In vivo studies of BamA 
Lastly, a tool that has been utilised to great effect in unravelling OMP folding 
mechanisms is genetic studies21,24-27,81,83,187,201,220,276,277. Deletion and depletion 
strategies have assisted identification of the roles of all BAM complex subunits 
and chaperones, as discussed in detail, in Sections 1.6.2, 1.7.1 and 1.7.2. For 
BamA studies are necessarily more complicated as the protein is essential for 
cell growth, and therefore BamA cannot be deleted. However, experiments have 
been performed by construction of a strain in which chromosomal BamA is 
deleted, and is replaced with the same gene under control of the araBAD 
promoter25. Using this construct the presence of BamA is regulatable by the 
presence of arabinose. The chromosomal copy of BamA is therefore not 
expressed in the absence of arabinose and cells are only viable if the 
compensating copy from an introduced plasmid is functional. This assay has led 
to great progress in the field, identifying regions or residues of BamA for which 
mutation is lethal25,194,199,201,209,277 and forms the basis for the original evidence 
for BamA lateral gating199, as discussed further below (Section 1.10-4). 
 
 
1.10  Mechanism models of BAM function 
Despite the availability of structures for the BAM complex since 2016207-210  the 
mechanisms of BAM function are still unclear. Several models have been 
proposed212 (Figure 1-18), outlined below, for which the concept and supporting 
evidence is further explained.  
1) Threading (Figure 1-18a): where a substrate OMP utilizes the lumen of the 
BamA barrel for passage through the lipid bilayer before assembling in the 
adjacent membrane.  
2) Membrane destabilization (Figure 1-18b), where the presence of 
BamA/the BAM complex in the lipid bilayer is sufficient to allow OMP 
insertion, possibly via interaction with one or more POTRA domains. 
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3) Oligomerization (Figure 1-18c): by which the BAM complex, or at least 
BamA multimerizes to best interact with the substrate211, and the substrate 
is inserted by the cooperation of the barrels. 
4) Lateral opening (Figure 1-18d) wherein BamA opens via a separation of 
its first (β1) and last (β16) strands and these dynamics allow substrate 
interaction and entry. This is linked to a second theory, that following 
opening of the BamA barrel, substrate OMP β-strands will attach and 
template on BamA, forming a hybrid super-barrel until the substrate OMP 
buds off into the membrane199,212. 
 
 
Figure 1-18: Models of BAM mechanism of action: The models show BamA 
(pink) as representative of the complex, assisting a substrate OMP (yellow) in insertion 
into the lipid bilayer. a) Threading, b) membrane destabilization, c) oligomerization, and 
d) lateral opening. Image reproduced from Kim (2012)212. 
 
1.10.1 BAM catalysis by lumen threading 
The threading model of BAM-assisted OMP folding (Figure 1-18a) is possibly the 
least well supported by current literature. It typically hypothesises the OMP 
substrate moving through the lumen of the barrel and adopting hairpin folds from 
exterior to the cell212. The model appears possible, however, as it is likely that 
adopted by two-partner secretion protein FhaC196,278 (Figure 1-11). In the case of 
FhaC the protein was originally crystallized with the first helix (H1) of the POTRAs 
and loop 6 (L6) of the barrel located inside the barrel pore196. Movement of the 
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dynamic, and essential loop 6 of the barrel allows the pore to widen to allow 
unfolded substrate through, where it may fold outside the membrane196. 
However, this model, when applied to OMPs, may not pay sufficient heed to the 
energy penalty for folding a β-barrel from the exterior of the membrane. 
 
1.10.2 BAM catalysis by membrane destabilization 
The membrane destabilisation model (Figure 1-18b) suggests that the presence 
of BamA/the BAM complex in the lipid bilayer destabilises the lipids in its vicinity 
and thus facilitates the folding of substrates. This must be a BAM-specific effect 
as other OMPs are not shown to catalyse folding241,271, but there is considerable 
evidence supporting this model. Structural studies have shown that the exterior 
rim of the BamA β-barrel has a reduced hydrophobic surface on one side194  
which could produce local distortions in the OM. It has been shown that OMPs 
will fold faster into thinner bilayers, such as those composed of shorter chain 
lipids72,79, but quicker still into bilayers possessing defects such as non-uniform 
phase71,279. Additionally, BamA alone is capable of accelerating OMP folding in 
synthetic lipids in vitro71,245,271 and acts as a better catalyst in thicker bilayers241. 
Lastly, data presented in this thesis demonstrate that lateral opening of BamA β1 
and β16 is unnecessary for it to achieve this catalytic effect (Section 4.2.5241), 
thus the presence of BamA is sufficient to facilitate OMP folding. 
 
1.10.3 BAM catalysis by oligomerization 
There remains a persistent theory that BamA or BAM complexes may oligomerize 
and this would assist OMP assembly211,212,280 (Figure 1-18c). The origins of this 
concept for BamA derive from observation of the protein as a tetrameric species 
by Blue Native PAGE and size exclusion chromatography (SEC)211. Additionally, 
Haemophilus influenza protein HMW1B, also a member of the Omp85 
superfamily, was observed in oligomeric complexes by SEC and negative stain 
EM281,282. However subsequent analysis of the individual BamA protein201 or BAM 
complex207-210 has provided no evidence towards formation of oligomers. It 
remains possible that optimal function of the BAM complex may be in oligomers. 
This is supported by identification of OMPs in concentrated “islands”283 or 
“precincts”216. It has been observed that OMPs will exhibit unexpected clustering 
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behaviour, with BAM included in these clusters, which all gradually migrate 
towards the poles of cells283. Separate work appears to contradict this putative 
movement to the poles of cells but also demonstrates the close localisation of 
multiple copies of BAM, mediated by BamB in so-called BAM “precincts”216. 
However, there is evidence against BAM oligomers being the functional entity. 
Firstly, from early characterisation data which demonstrated that although all 
lipoproteins were capable of associating with BamA, BamA itself was not201. 
Secondly it is demonstrated that oligomers are likely not the functional form of 
Bam, from work on protein-supported nanodiscs. As nanodiscs would only hold 
one copy of BAM complex, demonstration that they are functional in folding the 
autotransporter EspP274 and OmpT (this work, Section 3.6.3) is evidence against 
oligomers of BAM being the obligate functional form. 
 
1.10.4 BAM catalysis by lateral opening 
The long-abiding hypothesis199,212 that the BamA β- barrel opens laterally to 
facilitate OMP folding (Figure 1-18d) was first supported by the observed weak 
interaction of the β1 and β16 β-strands, with only two hydrogen-bonds seen in 
the first crystal structure (Figure 1-10c)11. This is in stark contrast to H.ducreyi 
BamA with eight hydrogen bonds between β1 and β16194 (Figure 1-10a). 
Molecular dynamics simulations of NgBamA and a homology model of EcBamA 
were both predicted to open laterally, with ~9Å separation of β1 and β16 in 
EcBamA in a DMPE bilayer199. However, while thinning of the membrane on the 
side of β1/β16 side of the BamA barrel is observed relative to the other side, in 
all simulations in PC lipids241 and native E.coli lipid206, no lateral opening of BamA 
was observed for long simulation times in native lipid206.  
As discussed (Section 1.7.3), crystal and EM structures of the BAM complex 
subsequently published207-210 demonstrate that the E.coli BamA β-barrel indeed 
visits both lateral open and closed conformations. While ascertaining that the 
lateral open state exists for E.coli BamA, these structures do not inform on 
whether opening is functionally significant or required. The first evidence that 
BamA β-barrel lateral opening was functionally relevant came from in vivo 
experiments199. Utilising a BamA knock-out strain, the two natural cysteines were 
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removed (C690S and C700S) and cysteines were introduced in pairs matching 
up the β1/16 seam (Figure 1-19)199. 
 
Figure 1-19: β1 and 16 double cysteine pairs lock the E.coli BamA β-barrel 
closed. a) Crystal structure of E.coli BamA [4C4V]11 with β1 and β16 shown in dark 
blue. b) Image of the pairs engineered to form disulphide cross-links, reproduced from 
Noinaj, 2014199.  Yellow circles indicate disulphides that would point into the lumen of the 
barrel domain; green circles, disulphides that would point into the membrane.  
 
These studies showed that BamA with disulphide linked β1 and β16 strands, such 
that the β-barrel was trapped closed, could not replace wild-type BamA in vivo 
causing a lethal phenotype199. However, these mutants were rescuable, and the 
bacteria viable when grown in the presence of the reducing agent TCEP199. 
Despite these in vivo results, the effect of lateral gating had not, until recently, 
been directly assessed in any in vitro or purified systems. Lethality in in vivo 
experiments, while a measure of functional importance, could have arisen by 
several means. Concurrent to work discussed in this thesis, another group 
tackled this question, with complementary results. The Sousa group in 2017231 
utilised disulphide pairs along the putative lateral opening of BamA and upon 
prefolding the protein in 80:20 mol/mol DDPC:DDPE liposomes, demonstrated 
disulphide-linked BamA was still capable of folding substrate OmpX at wild-type 
rates. This parallels results shown in Results Section 4.2.5 where the implications 
will be fully discussed, but demonstrates that BamA alone facilitates OMP folding, 
at least by a membrane disruptase effect. While lethal in vivo, at least for small 
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substrates and short-chain synthetic lipids, lateral gating appears unnecessary 
for OMP folding in vitro231. 
 
1.11  OMP recognition by the BAM complex 
In addition to the mechanism of how OMP folding is catalysed by the BAM 
complex, how OMPs are recognised by BAM remains unknown, and one of the 
key questions within the field. As OMPs display high conservation, at both 
structural and residue level it has long been hypothesised there is a ‘signal 
sequence’ to direct OMPs to BAM encoded within the sequence, known as the 
β-signal.  
This is typically the C-terminal membrane-spanning fragment, or β-strand, as it 
has been found this is essential for membrane localisation for many OMPs284. 
This so called β-signal is particularly conserved, and involves a pattern of 
alternating hydrophobic residues, and a highly conserved terminal Phe285. Lipid 
bilayer experiments show that the 12 terminal amino acids of an OMP, forming 
this ‘β signal’ are capable of mimicking a substrate OMP’s abilities to induce 
channel-opening in BAM211. The experiments confirmed importance of the 
terminal Phe, but also displayed significant species specificity, as PorA from 
N.meningitidis was unable to cause channel opening with E.coli BamA211. While 
the C-terminal end of PorA appears to conform to the C-terminal OMP signature 
sequence, the lack of channel opening was attributed to the charged residue at 
the penultimate position of Neisserial OMPs211. Subsequent bioinformatics 
analysis suggests that the incompatibility between the two is more likely due to a 
histidine three residues from the C-terminus286.  
Studies on BamA are yet more complicated, as while the sequence of β-strand 
16 sequence mirrors the consensus β-signal71, it is a segment on strand 14 that 
is capable of stalling BAM function175, suggesting that the β-signal of BamA 
resides in β14. In addition, deletion of the C-terminal Phe of two small OMPs was 
shown not to affect their intrinsic folding rate, but to slow BamA-catalysed 
folding71. 
The concept of the β-signal anticipates specific recognition of a β-strand of 
substrate OMPs by a β-strand of the Omp85 protein. This overlaps with the 
hypothesis of lateral gating199,212, as this would be most effectively managed in 
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cases where lateral opening provides accessibility to the C-terminal strand of 
BamA, with a sequence mirroring the consensus β-signal71. Significantly the 
mitochondrial Omp85-channel, Sam50, homologous to BamA, has been more 
fully validated as functioning with a lateral gating and β-signal recognition 
mechanism287. A series of cross-linking experiments demonstrated that Sam50 
opens between β1- β16 and that the β-signal of the substrate protein is 
specifically recognised by Sam50 β1287. The precursor protein inserts in this 
vicinity, and the mature protein is then released into the membrane287. This 
experimental evidence, on a closely related system, strongly suggests that lateral 
opening is the correct model for Omp85 proteins, but whether the mechanism is 
conserved for different Omp85 protein complexes across mitochondria, 
chloroplast and Gram-negative bacteria, or for different substrates, remains to be 
seen.  
 
1.12  Aims of this thesis: 
This introduction has highlighted current knowledge about the OM of Gram-
negative bacteria, OMP biogenesis and the BAM complex, from studies in vitro 
and in vivo. There remain a large number of unanswered questions about a 
pathway that is critical for bacterial survival. This project has taken a biochemical 
approach to understanding components of the pathway in vitro, to elucidate the 
roles and importance of BAM in OMP folding.  
Briefly, Chapter 3 describes the optimization of purification and reconstitution of 
the BAM complex, which was then used for structural studies. A key assay used 
to examine BAM complex activity (the OmpT enzymatic assay) was optimised 
and explored and BAM was reconstituted into different membrane mimetics, to 
examine the effect of the lipid environment on activity. 
Chapter 4 begins the examination of the role of lateral gating: looking at BamA-
catalysed tOmpA folding. In addition, results in this chapter explore the nature of 
recognition by BamA, with experiments on the role of substrate β-signal. 
Chapter 5 presents results utilising the optimised purification and reconstitution 
described in Chapter 3, to examine multiple variants of the BAM complex. Their 
differential activity in folding the substrates tOmpA and OmpT can inform our 
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understanding of the BAM complex, the role of BamA dynamics and particularly 
of lateral gating.  
The discussion then combines the findings presented into a new model for BAM 
function, points the way to future experiments needed to refine this model and 
reviews the importance of understanding this vital pathway.  
The principal question guiding throughout the research was: How does BamA/the 
BAM complex recognise and catalyse OMP folding in the outer membrane?
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Acetic acid, glacial Fisher Scientific, Loughborough, UK 
Acrylamide 30 % (w/v) Severn Biotech, Kidderminster, UK 
Agar Melford Laboratories, Suffolk, UK 
Agarose Melford Laboratories, Suffolk, UK 
L-(+)-Arabinose Sigma Life Sciences, MO, USA 
Aldrithiol (4,4’-dypyridyl-disulphide, 4-DPS) Sigma Life Sciences, MO, USA 
Ammonium persulphate (APS) Sigma Life Sciences, MO, USA 
Ampicillin sodium salt Formedium, Norfolk, UK 
B  
Bactotryptone Fisher Scientific, Loughborough, UK 
Benzamidine hydrochloride Sigma Life Sciences, MO, USA 
Bromophenol blue Sigma Life Sciences, MO, USA 
C  
Carbenicillin disodium Formedium, Norfolk, UK 
Chloramphenicol Sigma Life Sciences, MO, USA 
Chloroform Fisher Scientific, Loughborough, UK 
Copper Sulfate (CuSO4) Sigma Life Sciences, MO, USA 
Calcium chloride (CaCl2) Sigma Life Sciences, MO, USA 
D  
Dithiothreitol (DTT) Formedium, Norfolk, UK 
Diamide Sigma Life Sciences, MO, USA 
n-dodecyl β-D-maltoside (DDM) Anatrace, OH, USA 
E  
Ethidium bromide (EtBr) Sigma Life Sciences, MO, USA 
Ethanol Sigma Life Sciences, MO, USA 
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific, Loughborough, UK 
G  
Guanidine hydrochloride Sigma Life Sciences, MO, USA 
Glycerol Fisher Scientific, Loughborough, UK 
H  




Imidizole Sigma Life Sciences, MO, USA 
Instant Blue Coomassie Blue Stain Expedeon, CA, USA 
Iodine Sigma Life Sciences, MO, USA 
Isopropanol Fisher Scientific, Loughborough, UK 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
Formedium, Norfolk, UK 
M  
Methanol Fisher Scientific, Loughborough, UK 
MOPS Sigma Life Sciences, MO, USA 
N  
Nickel sepharose GE Healthcare, Buckinghamshire, UK 
Nickel nitrilotriacetic acid (Ni-NTA) GE Healthcare, Buckinghamshire, UK 
P  
Phenylmethanesufonyl fluoride (PMSF) Sigma Life Sciences, MO, USA 
Potassium chloride (KCl) Fisher Scientific, Loughborough, UK 
Potassium phosphate monobasic Sigma Life Sciences, MO, USA 
Potassium phosphate dibasic Sigma Life Sciences, MO, USA 
S  
Sodium azide (NaN3) Sigma Life Sciences, MO, USA 
Sodium chloride (NaCl) Fisher Scientific, Loughborough, UK 
Sodium hydroxide (NaOH) Fisher Scientific, Loughborough, UK 
Sodium dodecyl sulphate (SDS) Sigma Life Sciences, MO, USA 
Super Optimal Catabolite (SOC) New England Biolabs, MA, USA 
T  
Triton X-100 Sigma Life Sciences, MO, USA 
Tris Fisher Scientific, Loughborough, UK 
Tetramethylethylenediamine (TEMED) Sigma Life Sciences, MO, USA 
Tris(2-carboxyethyl)phosphine (TCEP) Sigma Life Sciences, MO, USA 
U  
Urea MP biomedicals, Loughborough , UK 
 
Fisher Scientific, Loughborough, UK 





2.1.2 E.coli Bacterial Strains 
E.coli DHα (NEB) 
E.coli BL21(DE3) (Agilent) 
E.coli BL21(DE3)pLysS (Agilent) 
E.coli JCM166 (BamA depletion strain): MC4100 ara r/- Δ(λatt-ιom) : : bιa PBADyaeT 
araC ΔyaeT  provided by Thomas Silhavy, Princeton  
HBD150 (for expression trial of Bam complex): MC4100 ompT::spc ΔaraBAD 
leuD::kan provided by Harris Bernstein, NIH 
2.1.3 Origin of Plasmids 
BamA and OmpA N-terminal β-barrel domain (1-171) lacking signal sequence (E. 
coli) in pET11a vectors were both obtained from Karen Fleming, John Hopkins 
Univ. 
His-tag(HT)-Skp clone in pET28b plasmid was obtained from Sebastian Hiller, 
University of Basel. 
Bam complex : Full-length genes, with signal sequences of BamA,B,C,D and E. 
8xHistag at C-terminus of BamE in a pTrc99a vector was a gift from Harris 
Bernstein, NIH.  
HT-BamA: N-terminal HT, with signal sequence in pZS21 vector was obtained 
from Thomas Silhavy, Princeton University. 
SurA: Mature SurA sequence (SurA A21-N428) with N-terminal HT in pET28b 
vector was obtained from Daniel Kahne, Harvard Univ. 
SecB-HT in pRSFDuet-1 vector was a gift from Ian Collinson, University of Bristol. 




















790  * 
BamA (22-810) 
C690S/C700S/I430C/K808C 
pET11a 88 140165  
 











pET11a 88 140040  
 
 
790  * 
HT-OmpT pET11a 35 79760 311 5.9  
FLAG-OmpT pET11a 35 79760 305 5.1 * 
HT-OmpT(G306P) pET11a 35 79760 311 5.9 * 
HT-OmpT(G306A) pET11a 35 79760 311 5.9 * 
tOmpA (1-171) pET11a 18 46870 172 5.7 Fleming 
tOmpA (1-171)-RHK pET11a 18.9 45380 172 6.2  
tOmpA (1-171) (G166A) pET11a 18.9 46870 172 5.7 * 
SurA (H6-SurA) pET28b 45.5 29450  412 6.2 Kahne 
HT-SurA ΔP2 pET28b 35.5 18450 320 6.8  
HT-SurA N-Ct pET28b 23.9 12950 211 8.0  
SecB-HT pRSFduet 18.1 12950 161 4.8 Collinson 
HT-Skp 
pET28b 17. 1490  162 9.7 Hiller 
HT-MSP1D1 
pET28a 24.8 21430 212 5.9 Sligar 
MSP1D1 
pET28a 22.0 18450 190 5.7  
BamABCDE-HT (pJH114) pTrc99a 200 292025 1813 5.0 Bernstein 
BamABCDE-HT 
C690S/C700S 
pTrc99a 200 292025 1813 5.0 * 
BamABCDE-HT 
C690S/C700S/I430C/K808C 
pTrc99a 200 292025 1813 5.0 * 
BamABCDE-HT 
C690S/C700S/E435C/S665 








pTrc99a 200 291650 1813 5.0 * 
HT-BamA pZS21 89.4 140040 798 5.0 Silhavy 






pZS21 89.4 140040 798 5.0 * 
HT-BamA 
C690S/C700S/I430C/K808C 








pZS21 89.3 140040 798 5.0 * 
Table 2-1: Table of proteins used in this study. Details of plasmid and source. 
* denotes constructs made in this study, while constructs not in bold were purified 
by others. For all of the HT-BamA constructs, these were used solely in an in vivo 
assay and not as expression constructs for any of the work discussed in this 
thesis. 
 
2.1.5 Primers for mutagenesis 
All mutants were prepared using the Q5 Site-Directed Mutagenesis (NEB) kit 
used according to the manufacturer’s instructions. All mutants of BamA (in 
pET11a, pTrc99a or pZS21) were originally mutated to create the Cys-free 
(C690S/C700S) pseudo-wild-type, followed by single rounds of mutagenesis for 
introduction of each cysteine.  The primers used are detailed below for BamA in 
pET11a (Table 2-2), BAM complex in pTrc99a (Table 2-3), HT-BamA in 























35 23 56°C 




35 40 63°C 
66 °C 
Reverse CTACCGGTGTTGCGCTCT 18 61 66°C 




33 48 63°C 
66 °C 
Reverse AAGCTACCGGTGTTGCGC 18 61 67°C 
G431C      
Forward CTTTGGTATTtgcTACGGTACTGAAAG 27 41 58°C 
61 °C 
Reverse TTGAAGCTACCGGTGTTG 18 50 60°C 




29 38 55°C 58 °C 
Reverse TGGAACTGTTCTGCCTTG 18 50 59°C  
K808C      
Forward TAACATCGGTtgcACCTGGTAAGATC 26 46 57°C 
60 °C 
Reverse AACTGGAACTGTTCTGCC 18 50 59°C 
T809C      
Forward CATCGGTAAAtgcTGGTAAGATCCG 25 48 55°C 
58 °C 
Reverse TTAAACTGGAACTGTTCTGC 20 40 58°C 
Table 2-2: Primers used for Q5 site-directed mutagenesis of BamA in 











Forward TATTGGTTACtgcACTGAAAGTGGC 25 44 57°C 
58 °C 
Reverse CCAAAGTTGAAGCTACCG 18 50 61°C 
E435C      
Forward TTACGGTACTtgcAGTGGCGTGAG 24 54 60°C 
59 °C 





Forward TTACGGTACTtgcAGTGGCGTGAG 24 54 62°C 
62 °C 
Reverse CCGCAACCAAAGTTGAAG 18 50 61°C 
S665C  
Forward  TGGCTTCCAGtgcAATACCATTGG 24 50 65°C 
68 °C 





27 44 60°C 
61 °C 
Reverse TGTTCTGCCTTGTCTCCA 18 50 63°C 
K808C  
Forward TAACATCGGTtgcACCTGGTAAGTG 25 48 57°C 60 °C 





28 39 57°C 
58 °C 
Reverse TGGAACTGTTCTGCCTTG 18 50 62°C 
Table 2-3: Primers used for mutagenesis of BamA in the BAM complex 
using pTrc99a. The base-pairs encoding the region of amino acid substitution are in 
lower case. Where the new primer is not specified, the corresponding BamA in pET11a 












Forward GTTCCAGTTTtgcATCGGTAAAACCTG 27 44 60°C 
61 
°C 
Reverse TGTTCTGCCTTGTCTCCA 18 50 63°C 
G807C  
Forward GTTTAACATCtgcAAAACCTGGTAAGTG 28 39 57°C 
58 °C 
Reverse TGGAACTGTTCTGCCTTG 18 50 62°C 
K808C  
Forward TAACATCGGTtgcACCTGGTAAGTG 25 48 59°C 
60 °C 
Reverse AACTGGAACTGTTCTGCC 18 50 62°C 
T809C      
Forward CATCGGTAAAtgcTGGTAAGTGTTC 25 44 55°C 
56 °C 
Reverse TTAAACTGGAACTGTTCTG 19 37 56°C 
Table 2-4: Primers used for mutagenesis of HT-BamA using pZS21, for in 
vivo studies. The base-pairs encoding the region of amino acid substitution are in 
lower case. Where the new primer is not specified, the corresponding BamA in pET11a 




Mutation Oligo Sequence 
Len
gth 












29 59 67°C 
68°C 
Reverse ATGCCGTTGTCCGGACGA 18 61 69°C 
OmpT-G306P      
Forward CACTACTGCTccgCTTAAGTACAC 24 50 55°C 
56°C 
Reverse ATGAAGTTATAGTTTTCTATACC 23 26 56°C 
OmpT-G306A 
     
Forward CACTACTGCTgcgCTTAAGTACAC 24 50 57°C 
57°C 
Reverse ATGAAGTTATAGTTTTCTATACC 23 26 56°C 
Table 2-5: Primers used for mutagenesis of other proteins. The base-pairs 




2.2 Molecular Biology 
2.2.1 Preparation of competent cells 
Cells of the desired strain were streaked onto an LB agar plate with no antibiotics 
and incubated overnight at 37 ºC. A single colony was selected and used to 
inoculate 10 mL autoclaved LB and incubated overnight at 37 ºC with shaking at 
200 rpm. 5 mL was used to inoculate 100 mL autoclaved LB which was grown 
(37 ºC, 200 rpm) until the optical density (OD) at 600 nm was 0.40 – 0.45. Cells 
were harvested by centrifugation (4000 rpm (4000 g), 10 min, 4 °C) in a pre-
chilled Beckman JS-5.3 rotor.  The pellet was gently resuspended in 10 mL of 
filter-sterilised, pre-chilled 100 mM CaCl2.  After incubation on ice for 10 minutes 
the cells were centrifuged as described previously and the supernatant removed.  
The pellet was resuspended gently in 2 mL of pre-chilled 100 mM CaCl2 30% 
(w/v) glycerol.  Cells were aliquoted (100 μl) into 1.5 mL Eppendorf tubes pre-
cooled on dry ice and stored at -80 °C. 
2.2.2 Transformation 
For transformation of plasmid stocks 50 μL of the appropriate commercial (for 
BAM complex) or laboratory-prepared competent cells were thawed on ice, then 
transferred to a round-bottom 14 mL transformation tube. 1-2 μL of plasmid DNA 
(100-200 ng/μL) was added and the cells incubated on ice for 30 minutes. 
Subsequently the cells were heat-shocked at 42 ºC for 45 seconds and returned 
to ice for 5 minutes. All 50 μL was plated directly onto LB agar containing relevant 
antibiotics (100 μg/mL carbenicillin or 50 μg/mL kanamycin). 
2.2.3 Site-directed mutagenesis 
Mutagenesis was carried out to create a number of different plasmid variants. 
Mutagenesis primers (Table 2-2-Table 2-5) were designed utilising 
NEBaseChangerTM, the online NEB primer design software and primers 
manufactured by Eurofins Genomics.  
All mutagenesis was carried out utilising Q5 Site-Directed Mutagenesis Kit and 





 Reagent 25 μL RXN FINAL CONC. 
Q5 Hot Start High-Fidelity 2X Master Mix  12.5 μL 1 x 
10 μM Forward Primer 1.25 μL 0.5 μM 
10 μM Reverse Primer 1.25 μL 0.5 μM 
Template DNA (1–25 ng per μL) 1 μL 1-25 ng 
Nuclease-free water 9.0 μL 
 
 
Using a Bio-RAD PCR machine the following PCR thermocycling conditions were 
then carried out:   
STEP TEMP TIME 
Initial Denaturation 98 °C 30 seconds 
25 Cycles 98 °C 10 seconds 
50–72 °C* 10–30 seconds 
72 °C 20–30 seconds per kb 
Final Extension 72 °C 2 minutes 
Hold 4–10 °C   
*Ta, primer annealing temperature (Table 2-2-Table 2-5) is utilised here. 
 
The PCR product was then visualised by agarose gel electrophoresis (see 2.2.4) 
and, if successful, the sample was subjected to Kinase Ligase and DpnI (KLD) 
treatment to circularize the plasmid and remove template DNA. Reagents were 
mixed as follows: 
 Reagent  VOLUME FINAL CONC. 
PCR Product 1 μL   
2X KLD Reaction Buffer 5 μL 1 × 
10X KLD Enzyme Mix 1 μL 1 × 
Nuclease-free Water 3 μL   
 
The KLD reaction was mixed thoroughly by pipetting and incubated for a 




For these transformations, NEB 5α competent E.coli cells were thawed on ice. 5 
μL of the KLD mix was added and tapped to mix. Following incubation on ice for 
30 minutes, cells were heat-shocked at 42 ºC for 45 seconds and returned to ice 
for 5 minutes. 950 μL of room temperature SOC (Super Optimal Catabolite) was 
added and incubated for 60 minutes (37 ºC, 200 rpm). Cells were mixed by 
tapping the tube and 50 – 300 μL spread onto LB agar plate containing relevant 
antibiotics (100 μg/mL carbenicillin or 50 μg/mL kanamycin). In some cases it 
was necessary to either dilute cells or briefly centrifuge and resuspend in lower 
volume to obtain an appropriate number of single colonies. 
 
2.2.4 Agarose gel electrophoresis 
Agarose gels were prepared by adding 1.5% (w/v) agarose to 150 mL TAE buffer 
and heating in a microwave until the agarose was dissolved. TAE buffer was 
prepared as a 50x stock containing 121 g Tris, 28.55 mL glacial acetic acid, 50 
mL 0.5 M EDTA in 500 mL (pH 8.0). The agarose solution was left to cool to ~50 
ºC before addition of 10 mg/mL EtBr at 10 μL per 100 mL.  Gels were poured into 
a 12 x 15 cm gel tray containing a lane comb and allowed to set. DNA samples 
were mixed 5:1 with gel loading buffer. Gel loading buffer was made up as a 6x 
stock with 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 40% (w/v) 
sucrose in H2O. Samples containing 1 kb and 100 bp DNA ladders were included 
for comparison. Gels were electrophoresed in 1x TAE buffer at 100 volts for 
approximately 1 hour. Gels were imaged using a UV transilluminator (Syngene). 
2.2.5 Preparation of Plasmids 
For small scale DNA preparation, 10 mL of LB with appropriate antibiotics was 
inoculated with a single colony and incubated overnight (37 ºC, 200 rpm). A cell 
pellet was obtained by centrifugation (4000 rpm, 10 minutes) and the QIAprep 
Spin Miniprep Kit (QIAGEN, UK) or Wizard Plus SV Minprep Kit (Promega, UK) 
was used as per manufacturer’s instructions. DNA concentrations were obtained 
using a Nanodrop 2000 (Thermo Fisher Scientific, UK). 
2.2.6 Sequencing 
DNA sequencing was carried out by Beckman Coulter Genomics or Genewiz. 
The standard T7 promotor forward and reverse primers were used for sequencing 
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all pET vectors. For other vectors, or where these did not provide sufficient 
coverage, primers were designed to sequence the regions of interest. 
2.2.7 Growth media 
E.coli cells were grown in lysogeny broth (LB) (Miller) medium (VWR) at a 
concentration of 25 g/L. Medium was autoclaved for 20 minutes at 120 ºC and 
supplemented with antibiotics when cooled to room temperature. Antibiotics were 
made up as 1000x stock as follows: carbenicillin (100 mg/mL in sterile H2O), 
kanamycin (50 mg/mL in sterile H2O), chloramphenicol (25 mg/mL in 100% 
ethanol). These were filter sterilised prior to addition to LB. 
For solid agar plates 25 g/L of LB and 15 g/L of agar were autoclaved for 20 
minutes at 120 ºC. On cooling to ~50 ºC antibiotics were added to working 
concentration and 20-25 mL poured into sterile Petri dishes. 
For expression of the BAM complex using pZS21, 2xTY medium was used, 
prepared as follows: 
- 16 g Bacto-tryptone (Fisher Scientific) 
- 10 g Yeast extract (Fisher Scientific) 
- 5 g NaCl (Fisher Scientific) 
This was made up to 1 L with dH2O and autoclaved as described above. For 
expression medium, antibiotics were added immediately prior to inoculation. 
 
2.3 Protein Expression 
2.3.1 Expression of BamA, tOmpA and OmpT 
All OMPs were expressed as described288.  Briefly, the relevant plasmid was 
transformed into E.coli BL21[DE3] cells using the appropriate selectable marker. 
Single colonies were then used to inoculate starter cultures in 5-10 mL LB, which 
were grown overnight (37 ºC, 200 rpm) with 100 µg/mL carbenicillin. The cultures 
were diluted 1 in 100 into 500 mL fresh LB medium containing 100 µg/mL 
carbenicillin at 37 °C with shaking (200 rpm).  Expression was induced with a final 
concentration of 1 mM Isopropyl β-D-1-thiogalactopyranoside  (IPTG in dH2O) 
when the culture reached an OD600 of 0.5-0.6, and cells were then harvested after 
4h by centrifugation (5000 g, 15 min, 4 °C) and stored at -20 °C. Cells were 
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resuspended in 20 mL 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 2 mM benzamidine (from 100x stock of 
both in ethanol), and lysed by sonication (6 x 1 min bursts with 1 min cooling on 
ice between each sonication). The insoluble fraction was collected by 
centrifugation (25000 g, 30 min, 4 °C), resuspended in 20 mL 50 mM Tris-HCl, 
pH 8.0, 2% (v/v) Triton-X-100 and incubated for 1 h at room temperature, with 
gentle agitation. The insoluble fraction was again pelleted (25000 g, 30 min, 4 °C) 
and the inclusion bodies washed twice by resuspension (50 mM Tris-HCl, pH 
8.0), incubated for 1 h at room temperature with gentle agitation, followed by 
centrifugation (25000 g, 30 min, 4 °C). The inclusion bodies were solubilised in 
25 mM Tris-HCl, 6 M Gdn-HCl, pH 8.0 and centrifuged (20,000 g, 20 min, 4 ºC). 
The supernatant was filtered (0.2 μM PVDF syringe filter, Sartorius, UK) and 
purified first by nickel affinity and then gel filtration or just the latter for OMPs 
without a His-tag (HT). For HT-OmpT, the supernatant was applied to a pre-
equilibrated 5 mL HisTrap column (GE Healthcare). The column was washed with 
25 mM Tris-HCl, 6 M Gdn-HCl, pH 8.0 with 20 mM imidazole, and protein eluted 
with buffer containing 500 mM imidazole. Fractions containing protein were then 
pooled and concentrated. Pooled protein (or non-purified supernatant, for those 
without a HT) were applied to a Superdex 75 HiLoad 26/60 column (GE 
Healthcare, UK) (tOmpA and OmpT), or a Sephacryl S200 26/60 (GE Healthcare) 
(BamA), equilibrated with 25 mM Tris-HCl, 6 M Gdn-HCl, pH 8.0. Peak fractions 
were concentrated to ~500 μM using Vivaspin 20  concentrators (Sartorius, UK) 
(5 kDa MWCO for tOmpA, 10 kDa for OmpT and 30 kDa for BamA), snap-frozen 
in liquid nitrogen, and stored at -80 °C. OMPs were typically buffer exchanged 
into 8 M urea, 50 mM glycine pH 9.5 or 8M urea, 20 mM Tris, 150 mM NaCl using 
Zeba spin desalting columns (Thermo Scientific, UK) prior to use.  
 
2.3.2 Determination of protein concentration 
Protein concentration was determined spectrophotometrically for all OMPs using 
their absorbance at 280 nm, in urea immediately prior to use.  Theoretical molar 
extinction coefficients at 280 nm, calculated using the ExPASy Protparam 




2.3.3 Expression of His-tagged (HT)-Skp and HT-SurA 
HT-Skp (expressed and purified by B. Schiffrin) and HT-SurA were purified using 
a protocol adapted from Burmann et al181. The pET28b plasmid, containing the 
Skp/SurA gene with an N-terminal 6xHis-tag and thrombin cleavage site, was 
transformed into E.coli BL21[DE3]pLysS cells. Single colonies were used to 
inoculate a starter culture. Following inoculation with 10 mL of starter culture (LB, 
supplemented with 50 μg/mL kanamycin and 25 µg/mL chloramphenicol), cells 
were grown in 2x 1L LB medium containing kanamycin and chloramphenicol at 
37 °C with shaking (200 rpm) until the culture reached an OD600 of ~0.6. The 
temperature was then lowered to 20 °C and expression induced with 0.4 mM 
IPTG. Following overnight expression (~18 h) cells were harvested by 
centrifugation, resuspended in 25 mM Tris-HCl, pH 7.2, 150 mM NaCl, 20 mM 
imidazole, containing a cocktail of EDTA-free protease inhibitors (Roche), and 
lysed using a cell disrupter (Constant Cell Disruption Systems, UK). Following 
centrifugation to remove cell debris (20 min, 4 °C, 39000 g), the lysate was 
applied to a 5 mL HisTrap column (GE Healthcare) and washed with 25 mM Tris-
HCl, pH 7.2, 150 mM NaCl, 20 mM imidazole. The protein was denatured on-
column with 25 mM Tris-HCl, 6 M GuHCl, pH 7.2, and eluted with a 0-500 mM 
imidazole gradient over 50 mL in 25 mM Tris-HCl, 6 M GuHCl, pH 7.2. Fractions 
containing pure protein were pooled and the protein refolded by dialysis against 
25 mM Tris-HCl, pH 7.2, 150 mM NaCl. Refolded His-tagged Skp was 
concentrated to ~50 µM (trimer) using Vivaspin 20 (5 kDa MWCO) concentrators 
(Sartorius, UK), aliquoted, snap-frozen in liquid nitrogen and stored at -80 °C. 
Skp has a very low molar extinction coefficient at 280 nm (1490 M-1 cm-1) as its 
sequence contains no tryptophan residues, and only one tyrosine residue. Skp 
concentrations were determined using a Pierce bicinchoninic acid (BCA) assay 
(ThermoFisher), according to the manufacturer’s instructions (2.3.9). Refolded 
His-tagged SurA was further dialysed into 50 mM Glycine NaOH pH 9.5 and 
concentrated to ~200 µM using Vivaspin 20 (10 kDa MWCO) concentrators 
(Sartorius, UK). 
SurA variants SurA-ΔP2 and SurA N-Ct were generated by Julia Humes 
(University of Leeds) using HT-SurA in a pET28b plasmid. These were generated 
by removal of the P2 domain (residues 282-389) yielding ΔP2, and subsequent 
additional deletion of the P1 domain (residues 172-281), generating the N-Ct 
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variant. These were carried out by Q5-site-directed mutagenesis. The proteins 
were purified as for wild-type, and their properties are given in Table 2-1. 
 
2.3.4 Expression of HT-SecB 
E.coli BL21(DE3) cells were transformed with pRFSDuet-1 containing His-tagged 
SecB. Single colonies were used to inoculate 100 mL starter cultures (LB with 50 
μg/mL kanamycin). After overnight growth (37 °C, 200 rpm) starter cultures were 
diluted 1/100 into 1 L TY broth containing 50 μg/mL kanamycin. Cells were grown 
(37 °C, 200 rpm)  to OD600 of 0.6 and expression induced with 1 mM IPTG for 3 
hours before cells were harvested by centrifugation. 
The cells were resuspended and homogenized in 10 mL/L 20 mM Tris, 50 mM 
KCl, pH7.5, lysed with a cell disruptor (Constant Cell Disruption Systems, UK), 
then centrifuged (39000 g, 20 min, 4 ºC). The supernatant was filtered and 
applied to a 5 mL Histrap column pre-equilibrated with 20 mM Tris, 50 mM KCl, 
pH 7.5. The column was washed with 20 mM Tris, 50 mM KCl, 50 mM imidazole, 
pH 7.5, the protein was eluted with 20 mM Tris, 50 mM KCl, 330 mM imidazole 
pH 7.5. Protein was dialysed overnight against 20 mM Tris, 50 mM KCl at 4 ºC to 
remove imidazole, concentrated and further purified on a HiTrap Q HP column 
with a gradient of 50- 1000 mM KCl in 10 column volumes over a 20 mL bed 
volume. 
 
2.3.5 Expression and purification of BamABCDE wild-type and variants in 
n-dodecyl-β-D-maltoside (DDM) 
The complete BamABCDE complex was expressed and purified using a protocol 
adapted from Roman-Hernandez et al274. E.coli BL21(DE3) cells were 
transformed with plasmid pJH114 (see Table 2-1) containing all five Bam genes 
(BamABCDE-HT) and grown overnight (37 °C, 200 rpm) in LB containing 100 
μg/mL carbenicillin. Cells were diluted 1:100 into fresh TY broth with the same 
antibiotic selection and grown (37 °C, 200 rpm) to an OD600 of 0.5-0.6 before 
addition of 0.4 mM IPTG to induce expression. Following 1.5 h expression, cells 
were harvested with a Beckman JLA-8.1000 rotor (4000 rpm, 15 min, 4 ºC). The 
cell pellet was resuspended and homogenised in 10 mL/L 20 mM Tris-HCl pH 8, 
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lysed with a cell disruptor (Constant Cell Disruption Systems, UK), then 
centrifuged (6000g, 10 min, 4 ºC). The supernatant was ultracentrifuged with a 
50.2Ti rotor (244280 g, 45000 rpm, 30 min, 4 °C) to pellet membranes. Pelleted 
membranes were incubated with 10 mL/L cold 50 mM Tris-HCl pH 8, 150 mM 
NaCl, 1% (w/v) DDM at 4 ºC for 2 h and the ultracentrifugation repeated to remove 
insoluble material. Supernatants were then incubated overnight at 4 °C with 2 
mL/L Ni-NTA agarose on a tube roller. Ni-NTA beads were washed with one 
column volume of TBS, 0.05% (w/v)  DDM, 50 mM imidazole and BamABCDE 
was eluted using two column volumes of TBS, 0.05%(w/v)  DDM, 500 mM 
imidazole.  
The protein was concentrated to ~10 mg/mL, using a Vivaspin concentrator and 
further purified by gel filtration chromatography using an Analytical Superdex200, 
10/300 GL column, equilibrated with TBS + 0.05 % (w/v)  DDM running at 0.5 
mL/min. 0.5 mL fractions were collected and those containing complete 
BamABCDE complexes were identified by SDS-PAGE, pooled and concentrated. 
Protein concentration was determined using the Pierce BCA Protein Assay 
according to the manufacturer’s instructions (Section 2.3.9). The purified 
BamABCDE complex was concentrated to 10-15 mg/mL, flash frozen in liquid N2, 
and stored at -80 ºC. 
BamABCDE complexes containing BamA variants were prepared using Q5 Site-
Directed Mutagenesis (NEB) kit following the manufacturer’s instructions to 
create the Cys-free C690S/C700S pseudo-wild-type, followed by single rounds of 
mutagenesis for each subsequent mutation, see Table 2-3 for primer details.  
2.3.6 Expression and purification of BamABCDE in Triton X-100 
Purification of BamABCDE was also initially performed in Triton X-100, as 
described in Roman-Hernandez et al274. In this protocol LB rather than TY broth 
was used for growth. In addition, during protein purification using Ni-NTA agarose 
resin in batch mode, the resin was washed with TBS+ 0.03% (w/v) DDM and the 
complex eluted in TBS+ 0.5% (w/v) Triton X-100. Gel filtration was carried out as 
above, however after this step, protein was concentrated to only ~1 mg/mL as 
yields of less than 1 mg per litre of culture grow were obtained. 
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2.3.7 BAM complex expression trials 
Small-scale expression trials were carried out to optimize protein expression. 
Briefly, plasmid pJH114 was transformed into E.coli BL21(DE3) cells or the 
specific cell line HBD150 (MC4100 ompT::spc ΔaraBAD leuD::kan). Single 
colonies were used to inoculate starter cultures of 10 mL LB with 100 μg/mL 
carbenicillin and overnight cultures were diluted 1:50 in 100 mL of fresh LB or TY 
broth, containing 100 μg/mL carbenicillin. Cells were grown (37 °C, 200 rpm) to 
an OD600 of 0.5-0.6 before addition of 0.4 mM or 1 mM IPTG to induce expression. 
1 mL cell samples were taken pre-induction and at various later time points, cells 
were diluted to the same cell density, boiled with loading buffer and analysed by 
SDS-PAGE(2.6.1). 
2.3.8 Expression and purification of MSP1D1 
Membrane Scaffold Proteins were prepared by Dr Anton Calabrese (University 
of Leeds) for use in nanodiscs. Briefly, E.coli BL21 (DE3) cells were transformed 
with pET28a containing His-tagged MSP1D1. Single colonies were used to 
inoculate 100 mL starter cultures (LB with 50 μg/mL Kanamycin). After overnight 
growth (37 °C, 200 rpm) starter cultures were diluted 1/100 into 1 L LB containing 
50 μg/mL Kanamycin. Cells were grown (37 °C, 200 rpm)  to OD600 of 0.6 and 
expression induced with 1 mM IPTG for 3 hours before cells were harvested by 
centrifugation. 
The cells were resuspended in 15 mL/L 20 mM phosphate buffer pH 7.4 
containing 1 mM PMSF. Following resuspension, 5 mg of deoxyribonuclease I 
was added and Triton X-100 was added to a final concentration of 1% (v/v). The 
cells were homogenised and lysed by sonication (6 x 1 min bursts with 1 min 
cooling on ice between each sonication). The lysate was centrifuged (30000 g, 
10 min, 4 ºC). The supernatant was applied to a 5 mL Histrap column pre-
equilibrated with 20 mM phosphate buffer, pH 7.4. The column was washed with 
~100 mL each of Buffer 1 (40 mM Tris-HCl, 0.3 M NaCl, 1 % (v/v) Triton X-100, 
pH 8), Buffer 2 (40 mM Tris-HCl, 0.3 M NaCl, 50 mM sodium cholate, 20 mM 
imidazole, pH 8), Buffer 3 (40 mM Tris-HCl, 0.3 M NaCl, 50 mM imidazole, pH 8) 
before elution with 25 mL 40 mM Tris-HCl, 0.3 M NaCl, 0.4 M imidazole. The 
sample was dialysed against 20 mM Tris-HCl, 0.1 M NaCl, 0.5 mM EDTA pH 7.4 
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overnight at 4º. Protein was concentrated, filtered and snap-frozen in liquid N2 for 
storage at -80 º. 
In some cases the HT was cleaved from MSP1D1 (for example for use with BAM 
where BamE also posseses a His-tag). For this the purified protein was dialysed 
against 20 mM Tris-HCl, 100 mM NaCl pH 8 overnight at 4 ºC. His6-TEV was 
added to the protein at 1:50-1:100 (w/w) concentration and incubated at 4 ºC 
overnight. This was then applied to a 5 mL HisTrap column pre-equilibrated with 
40 mM Tris-HCl, 0.3 M NaCl, pH 8 and recirculated over the column several 
times. The cleaved His6 tag and His6-TEV binds the column and the flow-through 
contains cleaved MSP1D1, which was concentrated, filtered and snap-frozen in 
liquid N2 for storage at -80 º. 
 
2.3.9 Determination of BAM protein concentration by Pierce BCA Protein 
Assay 
The protein concentrations of purified BAM complex, proteoliposomes created by 
dialysis (Section 2.10.2), SMALPs and nanodiscs were measured using the 
Pierce BCA Protein Assay (ThermoFisher). Briefly, using the 2 mg/ml Albumin 
(BSA) provided, a series of 10 standards from 0 μg/mL – 2000 μg/mL BSA were 
prepared in the buffer of choice. This included TBS (50 mM Tris, 150 mM NaCl 
pH 8), TBS+ 0.05 % DDM, 50 mM glycine-NaOH pH 9.5, or TBS + 10% glycerol 
to match the sample to be measured. The sample was diluted in the same buffer 
to be within the 25 – 2000 μg/mL range. Using a clear-bottom 96-well plate, 25 
μL of each standard and sample (usually in triplicate) was added to 200 μL of 
working reagent. The plate was covered, incubated at 37 ºC for 30 minutes and 
absorbance at 562 nm was measured on the Clariostar. The average blank-
corrected measurement for the standards provides a standard curve when plotted 






2.4 Mass Spectrometry (MS) 
All mass spectrometry experiments detailed in this thesis were carried out by Dr 
Anton Calabrese (University of Leeds). 
2.4.1 Non-covalent (MS) 
Non-covalent MS was carried out on the BAM complex purified in TBS + 0.05 % 
(w/v) Triton X-100 for verification of intact mass. The purified BAM complex was 
buffer exchanged into 200 mM ammonium acetate, 0.02% (v/v) Triton X-100 pH 
6.9 using Zeba spin desalting columns (Thermo Scientific, UK) immediately 
before MS analysis. Nanoelectrospray ionization–MS spectra were acquired 
using a Synapt HDMS hybrid quadrupole–travelling wave–time-of-flight mass 
spectrometer (Waters Corporation, UK) using in-house prepared platinum/gold-
coated borosilicate capillaries. Typical instrument parameters included the 
following: capillary voltage 1.2–1.6 kV, cone voltage 120 V, trap collision voltage 
60 V, transfer collision voltage 10 V, trap DC bias 20V and backing pressure 7 
mBar. Data were processed using MassLynx v4.1, (Waters Corporation, UK) and 
UniDec290. 
 
2.4.2 Denaturing MS for molecular mass determination 
Denaturing mass spectrometry was carried out on wild-type BAM complex 
(Section 3.2.2) in TBS + 0.05% (w/v) DDM. Purified BAM complex was 
precipitated by chloroform–methanol to minimize detergent contamination. For 
this a sample of protein (50 μL, 10 μM) was taken, and methanol (150 μL) and 
chloroform (50 μL) were added. The solution was mixed by vortexing, water (100 
μL) was then added and the solution was mixed again before centrifuging (10,000 
g, 2 min). The upper aqueous phase was removed (leaving the white protein 
pellet and the lower organic phase) and methanol (150 μL) was then added. The 
solution was mixed by vortexing, centrifuged (10,000 g, 2 min) and the 
supernatant removed. The precipitated protein was air dried in a laminar flow 
hood. The dried protein pellet was resuspended in formic acid (4 μL) and 18 MΩ 
H2O (Purite) was then added (46 μL) for subsequent MS analyses. Proteins were 
analysed intact using online desalting liquid chromatography–MS on a 
nanoAcquity LC system interfaced to a Xevo G2-S mass spectrometer (Waters 
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Ltd., Wilmslow, Manchester, UK). The sample (2 μL) was loaded onto a 
MassPREP protein desalting column (Waters Ltd, Wilmslow, Manchester, UK), 
which was washed with 2% (v/v) solvent B in solvent A (solvent A was 0.1% (v/v) 
formic acid in water, solvent B was 0.1% (v/v) formic acid in acetonitrile) for 5 
minutes at 40 μL/min. After valve switching, the bound proteins were eluted using 
a fast gradient of 2-40% (v/v) solvent B in A over 1 minute at 0.5 μL/min. The 
column was subsequently washed with 95% (v/v) solvent B in A for 6 minutes 
and re-equilibrated with 5% (v/v) solvent B in solvent A for the next injection. The 
column eluent was infused into a Xevo G2-S mass spectrometer (Waters Ltd, 
Wilmslow, Manchester, UK). Data were processed using MassLynx v4.1, (Waters 
Corporation, UK) and UniDec290. 
2.5 Electron microscopy 
All electron microscopy in this thesis, discussed in Section 3.3 was carried out by 
Dr Matthew Iadanza. Analyses of structures was carried out by Dr Matthew 
Iadanza with assistance from Dr Bob Schiffrin (both University of Leeds). 
Purified BAM complex in TBS with 0.05% (w/v) n-dodecyl β-D-maltopyranoside 
(DDM) at a concentration of 13 mg/mL was diluted 1:2 in the same buffer. A 4 μL 
aliquot of solution was applied to a quantifoil r3.5/1 EM grid (Quantifoil Micro 
Tools), allowed to incubate at room temperature and 95% humidity for 30 s, then 
manually blotted with a Whatman filter paper. A second 4 μL aliquot of BAM 
solution was added and the grid blotted and vitrified by plunging into liquid ethane 
using a Leica EM GP plunge freezer (Leica Microsystems). 
The grids were imaged on a Titan Krios electron microscope (FEI Corporation) 
operating at 300 kV. Seven thousand and five hundred micrographs with a 
nominal defocus range of 1.5–3.5 μM were recorded with a Gatan K2 Summit 
energy-filtered direct detector (Gatan, Inc.) as 20 frame movies with a total 
electron dose of ~40e/Å2. The sampling rate was 1.04 Å per pixel.  
2.5.1 Image processing 
Individual micrograph frames were combined into stacks using IMOD291 and drift 
corrected using Motioncorr292. Individual particles were windowed manually using 
EMAN2293 and automatically using Relion294. The raw particle set (472,857 
particles) was culled through repeated cycles of two- and three-dimensional 
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classification using Relion295. The vast majority of these discarded particles were 
incorrectly picked by the automatic particle picking algorithms required to deal 
with a data set consisting of ~7,200 individual micrographs. These ‘junk particles’ 
represented carbon, ice contamination and a small amount of aggregated protein 
material. A total of ~120,000 particles were identified as BAM and after further 
classification, a total of 95,878 particles were used for structural analysis. 
Following alignment and three-dimensional reconstruction, the final structure was 
generated after performing per-particle motion correction on individual 
micrograph frames296 and post-processed using Relion. Frames 4–14 of the 
original micrographs were used for the final reconstruction, for a total dose of 20 
e/ Å2. The local resolution of the final map was calculated using resmap297 and it 
was then filtered by local resolution using LocalFilt. The final resolution was 
determined by ‘gold standard’ Fourier shell correlation of two independent half 
maps. 
 
2.5.2 Atomic model fitting 
An initial model of the BAM–ABCDE complex was constructed by manually fitting 
BAM subunits from previously published crystal structures to the EM density 
using UCSF Chimera298. BamA was constructed from 5D0Q208 and 5D0O208. 
BamC and BamD were taken from 5D0Q208, BamE from 5D0O208 and BamB 
constructed from 3Q7O299 and 2YH3195. Selenomethionines in each model were 
replaced with methionine. The initial model was then refined by flexible fitting to 
the EM density using MDFF300 and Monte Carlo simulations with RosettaEM301.  
2.5.3 Analysis of angles between BamA POTRA domains  
To calculate angles between E. coli BamA POTRA domains in all available 
structures, an arbitrary point within the loop on either side of each POTRA domain 
was identified. These same points in all X-ray and EM structures were the Cα 
atoms of F24, T93, A175, Y266, N345 and R421. The angles between each pair 
of POTRA domains were then calculated by placing three of these points on a 
plane. For example, the angle between POTRA 2 and POTRA 3 was calculated 
as the in-plane angle for T93-A175-Y266, the three spheres shown in the figure 
(Figure 3-10). This is 120º for the EM structure.   
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2.6 Gel electrophoresis 
2.6.1 SDS gel electrophoresis 
Electrophoresis was typically carried out with Tris-Tricine buffered SDS-PAGE 
gels (Table 2-6) made the day before use, using a 2x loading buffer (50 mM Tris-
HCl pH 6.8, 2 % (w/v) SDS, 0.1 % (w/v) bromophenol blue, 10 % (v/v) glycerol).  
 
Table 2-6: Volumes of reagents for Tris-Tricine buffered SDS-PAGE gels. 
The volumes indicated are sufficient to cast two 8 cm by 10 cm mini-gels using a 1.5 mm 
spacer. 
 
For these gels, TEMED was added last immediately prior to pipetting of first the 
resolving, then stacking gels in the casting apparatus. The stacking gel was 
poured carefully on top of the resolving gel. After addition of loading buffer, the 
samples were boiled briefly before 20 μL was loaded on the gel. Precision Plus 
Protein™ Dual Xtra Standards (Bio-Rad, UK) were loaded into one lane to aid 
size determination and identification of protein bands. Gels were electrophoresed 
with the inner reservoir of the gel tank containing cathode buffer (100 mM Tris, 
100 mM tricine, 0.1% (w/v) SDS, pH 8.25) and the outer reservoir containing 
anode buffer (200 mM Tris-HCl, pH 8.8). Electrophoresis was typically carried out 
with a constant current of 30 mA, or 70 mA through the stacking and resolving 
gels, respectively. 
Following electrophoresis gels were stained with Instant Blue stain (Expedeon, 
UK)  and imaged using the Syngene gel documentation system (Syngene, UK). 
When appropriate (folding into DMPC liposomes, tOmpA assay), bandshift 
assays were repeated three times and quantified. The folding yield was quantified 




30% (w/v) acrylamide:0.8% (w/v) 
bis-acrylamide 
7.5 0.83 
3 M Tris, 0.3% (w/v) SDS 
(pH 8.45) 
5.0 1.55 
H2O 0.44 3.72 
Glycerol 2.0 - 











 Equation 2-1 
 
2.6.2 Semi-native PAGE and “low SDS” 
Analysis of the differential migration of heat-treated (unfolded) and non-heat-
treated (folded) OMPs in order to quantify folding yield can normally be carried 
out on any gel electrophoresis system. For BamA semi-native PAGE is 
necessary. For this, “low SDS” conditions were used: the Tris resolving gel buffer 
contained no SDS and loading buffer (2x) was 50 mM Tris-HCl pH 6.8, 0.1 % 
(w/v) SDS, 0.1 % (w/v) bromophenol blue, 10 % (v/v) glycerol. After allowing 
sufficient time for protein folding boiled samples were heated to 100 C for a 
minimum of 30 minutes with loading buffer, while “unboiled” samples were added 
to sample loading buffer and immediately loaded on the gel. For the semi-native 
PAGE electrophoresis the gels were run using a constant current of 10 mA 
overnight at 4 °C.  
 
2.6.3 Redox gels  
In order to determine the redox status of BamA variants in different conditions, a 
number of different gel types were surveyed to resolve BamA with and without 
intramolecular cross-links. These include precast 4-20%(w/v) polyacrylamide 
gradient Mini-PROTEAN gels (BioRad), used with Tris-Glycine running buffer, 
precast 4-20%(w/v) polyacrylamide gradient Midi gels (Novex) with Novex Tris-
Glycine buffer  or 5% Tris-Tricine gels run with MOPS buffer. The latter were 
found to yield the high resolution between oxidized and reduced variants. 
Electrophoresis of all gels was carried out at 4 °C. Analysis by Tris-Tricine gels 
is detailed below (Table 2-7), other gels were used according to the 
manufacturers instructions.  
To visualize the proteins, folding reactions were performed using 2 µM BamA, 
1600:1 LPR (lipid: protein ratio), 0.24 M urea in 50mM glycine-NaOH pH 9.5. 
Folding reactions were allowed to proceed in the correct conditions (2 hours at 
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25 °C for DUPC lipids, overnight at 30 °C for DMPC). Reducing/oxidizing agents 
were then added to the correct final concentrations (25 mM tris(2-
carboxyethyl)phosphine (TCEP), 1 mM Copper(II) Sulphate (CuSO4), 25 mM 
dithiothreitol (DTT) or 100 µM diamide) and allowed to incubate for a minimum of 
30 minutes at the required folding temperature. Half of each sample was mixed 
with 6x or 2x loading buffer containing 0.1 % or 0.6% SDS and boiled for 30 
minutes, while the rest was mixed with loading buffer immediately prior to gel 
loading. 
Where it was desired to visualise the redox state of BamA in the BAM complex, 
in either TBS + 0.05% DDM, or proteoliposomes these were diluted to a 
concentration of 1-2 µM with or without redox agents. Proteins were incubated 
with redox agents for an hour, 15 μL sample added to 5 μL 6x loading buffer 
containing 0.6 % SDS and boiled for 30 minutes. A variety of redox agents were 
used. Typically these were DTT (at 25 mM final concentration), diamide (at 100 
μM final concentration) or CuSO4 (at 1 mM final concentration). Additionally 
diamide, CuSO4, iodine and aldrithiol (4,4’-dypyridyl-disulphide or 4-DPS) were 
assessed at concentrations 1 (4 μM), 2 (10 μM) 3 (40 μM), 4 (100 μM), 5 (1 mM), 
6 (10 mM). Any alterations to conditions are noted in the main text. 
For Tris-Glycine gels the resolving gel must be poured, allowed to set and then 
stacking gel added. For redox states of BamA, 15 μL was loaded for each sample 
and the gels were electrophoresed with MOPS buffer for 3 hours at 30 mA at 4 
ºC. 
Table 2-7: Volumes of reagents for 5% Tris-Glycine buffered SDS-PAGE 
gels. The volumes indicated are sufficient to cast two 8 cm by 10 cm mini-gels using a 
1.5 mm spacer. 
 
Reagent Resolving gel  
Volume to add 
(mL) 
Stacking gel 
Volume to add 
(mL) 
30% (w/v) Acrylamide:0.8% (w/v) 
bis-acrylamide 
2.5 0.83 
H2O 8.4 3.4 
1.5 M Tris.HCl pH 8.8 3.8 - 
1 M Tris.HCl  pH 6.8 - 0.63 
10% (w/v) SDS 0.15 0.05 
10% (w/v) ammonium persulphate 0.15 0.05 
TEMED 0.006 0.005 
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2.6.3.1 BAM complex reduce-then-oxidize experiment 
An additional experiment was carried out to determine whether the BAM complex 
variants could be oxidized. Protein for each variant (Lateral-lock1, Lateral-lock2 
and Lid-lock) was diluted in TBS + 0.05% (w/v) DDM to 4 μM, with addition of 
DTT to 50 mM and incubated for 1 hour at room temperature. Nickel beads were 
prepared by washing with ddH20, TBS+DDM, TBS+DDM + 50 mM imidazole and 
again with TBS + DDM. These were mixed 1:1 with sample (total volume 80 μL) 
and incubated at 4 °C for 30 minutes with gentle agitation. The nickel beads were 
centrifuged and washed 4x with TBS + DDM, resuspended in 40 μL TBS +DDM 
+ 200 μM diamide and incubated 45 minutes at room temperature. Samples were 
taken pre- and post- DTT treatment, of the first wash and of the final nickel beads. 
This was mixed with SDS loading buffer, boiled for 15 minutes and analysed by 
redox gel, 5% (w/v) acrylamide SDS-PAGE. 
 
2.6.4 Native PAGE 
Native PAGE was carried out to assess the intact state of the BAM complex in 
detergent, proteoliposomes, nanodiscs and SMALPs. Precast Invitrogen 
NativePAGE 4-16 % Bis-Tris gels were used according to the manufacturer’s 
instructions. Approximately 10 μg of sample was mixed with 4x sample buffer and 
10 μL loaded as well as 5 μL Native Mark Standard (LifeTechnologies). 
Electrophoresis was carried out at 150 V for 120 minutes at room temperature. 
Quick Coomassie staining was carried out of Native PAGE. The gels were placed 
in 100 mL of fixing solution (40% methanol, 10% acetic acid), microwaved for 45 
seconds and shaken for 15 minutes. The process was repeated with 100 mL of 
destain (8% acetic acid) and shaken until bands are visible, after which the gel 




2.7 Preparation of LUV liposomes 
The lipids 1,2-diundecanoyl-sn-glycero-3-phosphatidylcholine (DUPC hereafter), 
1,2-didecanoyl-sn-glycero-3-phosphoethanolamine (DDPE hereafter) and 1,2-
dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC hereafter) (all purchased 
from Avanti Polar Lipids, AL, USA) were used in the course of this work, (see 
2.17 for table of all lipids). Lipids were dissolved in 80:20 (v/v) HLPC grade 
chloroform:methanol in glass test tubes. Solvent was then removed by drying 
under a gentle stream of N2, followed by further drying in a desiccator under high 
vacuum for > 3 h. Where mixed DUPC:DDPE (80:20 molar ratio) liposomes were 
required, the appropriate volumes of 25 mg/mL DUPC and 15 mg/mL DDPE lipids 
were mixed in their lipid solvated phase, prior to drying.  
The resulting thin lipid film was resuspended in buffer (50 mM glycine, pH 9.5) to 
give a 40 mM lipid suspension, vortexed briefly and left to stand at room 
temperature for 30 min, before vortexing again. The large multilamellar vesicles  
that formed were disrupted by five freeze-thaw cycles. 100 nm Large Unilamellar 
Vesicles (LUVs) were prepared by extruding the lipid mixtures eleven times 
through a 0.1 μM polycarbonate membrane (Nucleopore, Whatman, Clifton, NJ) 
using a mini-extruder (Avanti, Alabaster, AL, USA) as described previously72. 
Where DMPC lipids were used, extrusion was carried out at 37 °C to maintain 
these lipids above the phase transition temperature, and in the liquid phase. All 
LUVs were stored at 4 ºC immediately following extrusion and used within a week. 
 
 
2.8 Protein Analysis 
2.8.1 Fluorescence Emission Spectra  
Fluorescence emission spectra were measured using a Photon Technology 
International Fluorimeter (Ford, West Sussex, UK).  BamA samples contained 0.8 
μM BamA protein, 1.28 mM DUPC (molar LPR 1600:1), and 0.24 M urea in 50 
mM glycine buffer, pH 9.5 for folded samples, or 0.8 μM BamA protein in 8 M 
urea, 50 mM glycine buffer, pH 9.5 for unfolded samples. Samples were folded 
by incubation at 25 °C for two hours prior to measurement. Each spectrum was 
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recorded from 280 nm to 400 nm in 1 nm increments, using an excitation 
wavelength of 280 nm.  
Fluorescence emission spectra were additionally measured for tOmpA and 
OmpT variants, in studies of β-signal mutants. Here 0.4 µM protein was used, 
1.28 mM DUPC (molar LPR 3200:1), and 2 M urea in 50 mM glycine buffer, pH 
9.5 for folded samples, or 0.4 μM protein in 8 M urea, 50 mM glycine buffer, pH 
9.5 for unfolded samples. Samples were folded by incubation at 25 °C overnight 
prior to measurement. 
It is possible to use tryptophan fluorescence to study the folding state of a protein 
in LUVs, provided that certain conditions are followed250. An appropriate “blank” 
sample, containing no protein was subtracted from measurements to remove 
contributions due to light scattering by liposomes from the final spectra. 
 
2.8.2  Circular Dichroism (CD) 
Far-UV CD spectra were acquired on a Chirascan plus circular dichroism 
spectrometer (Applied PhotoPhysics) with a bandwidth of 2.5 nm, step size of 1 
nm and a pathlength of 0.1 mm.  Samples contained 0.8 μM BamA, 1.28 mM 
DUPC, and 0.24 M urea in 50 mM glycine buffer, pH 9.5 for folded samples, or 
0.8 μM BamA protein in 8 M urea 50 mM glycine buffer, pH 9.5 for unfolded 
samples. Samples were incubated at 25 °C for two hours prior to measurement.  
CD spectra were additionally measured for tOmpA and OmpT variants, in studies 
of β-signal mutants. For these 5 µM tOmpA/OmpT protein was used, 4 mM DUPC 
(molar LPR 800:1), and 2 M urea in 50 mM glycine buffer, pH 9.5 for folded 
samples, or 5 μM protein in 8 M urea, 50 mM glycine buffer, pH 9.5 for unfolded 
samples. Samples were folded by incubation at 25 °C overnight prior to 
measurement. The instrumentation was identical to as specified for BamA but a 
bandwith of 3.5 nm was used. In addition a temperature ramp was attempted for 
OmpT samples folded in DUPC. This was measured from 20- 90 ºC with a 1 ºC 
step and 120 seconds settling time for each reading. 
The appropriate blank, of liposomes, or urea in glycine buffer was subtracted for 
each sample. The measured ellipticity in each wavelength was then converted to 




[θ]MRE = (MRW x θλ) / (10 x d x c) (Equation 2-2) 
Equation 2-2: Calculating Mean Residue Ellipticity. Where [θ]MRE is the MRE, θλ 
is the measured ellipticity at a particular wavelength, d is the pathlength in cm, and c is 
the concentration in g/mL and MRW is Mean Residue Weight. MRW given by: MRW = 
M / (N-1) where M is the molecular mass of the protein in Daltons and N is the number 
of amino acids it contains.  
 
2.9  Kinetics of OMP folding determined by intrinsic tryptophan 
fluorescence 
The kinetics of OMP folding was monitored by tryptophan fluorescence using a 
Photon Technology International Fluorimeter (Ford, West Sussex, UK).  These 
experiments used a truncated form of OmpA, possessing only the 
transmembrane domain (residues 1-171, 18875 Da, tOmpA), as substrate and 
the chaperone protein Skp. Aliquots of both tOmpA and Skp were kindly provided 
by Bob Schiffrin, having been previously prepared and purified as detailed288, see 
Methods 2.3.1 and 2.3.3.  
Samples were made to a final concentration of 0.4 μM tOmpA, 1.28 mM lipid 
(molar LPR 3200:1 substrate), and 0.24 M urea in 50 mM glycine buffer, pH 9.5. 
Samples containing Skp had a two-fold molar excess of Skp trimer over tOmpA 
substrate, while BamA protein variants were used at a concentration of 0.8 μM of 
each BamA protein.  
Unless otherwise indicated, samples were made up in the absence of tOmpA, 
and BamA (if included) was allowed to fold, for 2 hours at 25 °C. Denatured 
tOmpA in 8 M urea, 50 mM glycine buffer pH 9.5 was then added immediately 
prior to measurement. In experiments containing Skp, Skp was pre-incubated 
with tOmpA for 5 minutes as a 6x stock and the subreaction was then titrated into 
the reaction containing pre-folded BamA immediately prior to measurement.  
Where oxidizing or reducing agents were used these were diluted to 10x working 
concentration in 50 mM glycine pH 9.5 buffer. For experiments with DUPC or 
DUPC:DDPE LUVs these were added prior to BamA folding, and at the following 
final concentrations in the reaction mixture: reducing agents Dithiothreitol (DTT 2 
mM), 2-Mercaptoethanol (BME 20 μM), oxidizing agents Copper (II) Sulphate 
(CuSO4 100 μM), diamide (1 mM).  
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A timebased acquisition was used, with excitation wavelength of 280 nm, 
emission wavelength of 335 nm, slit widths 0.4 nm, 1 point/second and maximum 
duration 7200 seconds (2 hours). Four replicates were measured simultaneously. 
Results were analysed using Igor graphing programme (Wavemetrics) and fitted 
globally to either a single (Equation 2-3) or double (Equation 2-4) exponential 
function such that the transients share the same rate constant(s).  
 𝒚 = (𝑨𝟏 ∗ 𝒆
−𝒌𝟏𝒕) + 𝒄  Equation 2-3 
 
𝒚 = (𝑨𝟏 ∗ 𝒆
−𝒌𝟏𝒕) + (𝑨𝟐 ∗ 𝒆
−𝒌𝟐𝒕) + 𝒄  Equation 2-4 
For experiments using DMPC lipids a similar approach was used as described 
above with the exceptions that BamA pre-folding reactions and measurements 
were carried out at 30 °C, and reactions were monitored for a maximum duration 
of 90,000 seconds (25 hours). Cuvettes and samples were incubated for a 
minimum of 20 minutes at 30 °C before measurement. In addition, where used, 
redox reagents were added to final concentrations of 25 mM DTT, 10 mM TCEP 
or 1 mM CuSO4. These were added following BamA folding, for a minimum of 30 
minutes with incubation at 30 °C before addition of tOmpA and measurement of 
folding by tryptophan fluorescence as described above. Due to difficulties with 
consistent fitting of exponential curves, the results were also analysed by 
extracting a t50 or time to reach 50 % of total fluorescence change. Each transient 
was independently analysed with a horizontal line fit to the final 10% of data 
containing the maximum fluorescence. A minimum of three repeats, in different 
liposome batches was carried out for each experiment, creating a total of 12 
transients for an average t50. Errors were calculated as the standard error of the 
mean. Error in fold change of t50 values for tOmpA-RHK experiments (Section 
4.3) were calculated as follows: 










    Equation 2-5 
 
In Equation 2-5 𝛿R is the error in fold change, |R| is the fold change value, X and 





2.10  Reconstitution of BAM complex into proteoliposomes 
Three methods were used to reconstitute purified BAM complex into 
proteoliposomes. All utilise E.coli polar lipid extract solubilised at 25 mg/mL in 
80:20 chloroform: methanol. In the first method (‘dilution’), proteoliposomes were 
made by the method of dilution and ultracentrifugation following the method 
described by Roman-Hernandez et al.274.  
2.10.1 BAM proteoliposomes by dilution 
Briefly, E.coli polar lipid extract phospholipids (Avanti Polar Lipids) were 
dessicated, resuspended in water at 20 mg/mL, sonicated, and 40 µL of the lipid 
suspension added to 200 µL of purified BamABCDE in TBS containing 0.05 % 
(w/v) DDM at 20 µM. This sample was incubated on ice for 5 minutes, then diluted 
with 4 mL of 20 mM Tris-HCl pH 8 and incubated for a further 30 minutes. 
Proteoliposomes were pelleted using a Beckman TLA 110 (50,000 rpm, 4 ºC, 30 
min) and resuspended in 200 µL 20 mM Tris-HCl pH 8. 
2.10.2  BAM proteoliposomes by dialysis 
Alternatively, BAM complex was reconstituted into proteoliposomes using a 
procedure established for the outer-membrane protein FhuA (‘dialysis’)257. DDM-
solubilized BamABCDE (0.3 mg) was mixed with E. coli polar lipid films 
solubilized in 200 µL of TBS + 0.05 % (w/v) DDM using a 1:0.5 (w/w) ratio of lipid 
to protein. This was placed into a 200 µL 12-14 kDa MWCO dialysis tube (D-tube 
dialyser mini, (Merck Millipore)) and dialysed against detergent-free buffer (20 
mM Tris-HCl pH 8, 150 mM KCl, 0.01 % (w/v) sodium azide (dialysis buffer)) at 
21 °C for 7 days.  
To assess whether reconstitution was successful, the samples were centrifuged 
at 16000 g, the pellet resuspended in dialysis or experimental buffer and a sample 
of the protein-lipid pellet was boiled in SDS-containing loading buffer (50 mM Tris-
HCl pH 6.8, 2 % (w/v) SDS, 0.1 % (w/v) bromophenol blue, 10 % (v/v) glycerol) 
for 10 minutes, whilst another sample was left unboiled. Samples were then 
analyzed by Tris-Tricine SDS-PAGE(Section 2.6.1). This showed that all five 
BAM complex proteins were associated with the liposome pellet, and also that 
BamA was folded, displaying increased electrophoretic mobility (a “bandshift”) on 
boiling. Proteoliposomes created using this procedure resulted in the vast 
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majority of protein incorporated into the liposomes in marked contrast with the 
yields obtained using the dilution method. 
Empty liposomes were made with 220 µL E. coli polar lipids solubilized in TBS + 
0.05 % (w/v) DDM. For BamA-proteoliposomes, BamA in 8 M urea, 50 mM 
glycine-NaOH was folded by ~30-fold dilution into TBS containing 0.05 % (w/v) 
DDM, 3 M urea, and 0.3 mg was then reconstituted by dialysis into 
proteoliposomes as described for the BAM complex above. The folding of BamA 
into E.coli polar lipid liposomes was analyzed by low SDS-PAGE bandshift 
assays (Section 2.6.2) 
2.10.3 BAM proteoliposomes using Biobeads 
The third method utilized involved the generation of proteoliposomes using 
Biobeads to remove detergent, as described previously278,303. Briefly, E.coli polar 
lipid films were re-hydrated with water and sonicated for 10 minutes. The 
resuspended lipids were then diluted to 4 mg/mL in H2O with 0.05% (w/v) DDM. 
The BAM complex, purified in TBS containing 0.05 % (w/v) DDM was diluted to ~ 
1 mg/mL in TBS and 0.05% (w/v) DDM and 200 µL each of lipids and protein were 
mixed together. The suspension was incubated for 30 min at 4C with gentle 
agitation. Meanwhile the Biobeads were prepared by washing twice with 
methanol, twice with ethanol, four times with distilled H2O and twice with buffer: 
(TBS + 0.05% (w/v) DDM). All washes were done by resuspension and pelleting 
for 1 min at 13000 rpm in a bench-top centrifuge. The beads were resuspended 
in TBS containing 0.05 % (w/v) DDM to a final concentration of about 80 mg/mL, 
and 500 L was added to the protein– detergent–phospholipid suspension. After 
2 hours of incubation at 4 C, the Bio-Beads were sedimented by a brief 
centrifugation in an Eppendorf centrifuge and discarded. The overlaying solution 
was then mixed with 40 mg of freshly washed Bio-Beads. After incubation at 4 C 
for 4 h, the Bio-Beads were sedimented and the supernatant was mixed with 60 
mg of fresh Bio-Beads. The mixture was finally incubated overnight at 4 C. After 
sedimentation, the supernatant was collected, the Bio-Bead fraction was washed 
separately with 1 mL of 20 mM Tris pH 8, and the supernatants of both steps 
were pooled. Proteoliposomes were collected by ultracentrifugation with TLA110, 




2.11  Dynamic Light Scattering of BAM complex 
proteoliposomes 
The BAM complex which had been reconstituted into E.coli polar lipid 
proteoliposomes by either dilution and ultracentrifugation or by extensive dialysis, 
was analysed by dynamic light scattering to assess the size distribution of the 
resultant proteoliposomes. Proteoliposome samples were diluted 1/120 (dilution 
method), or 1/60 (dialysis method). 250 µL of the samples were then injected into 
a Wyatt miniDawnTreos® system (equipped with an additional DLS detector) and 
the data analysed using Astra 6® software supplied with the instrument. Filtered 
(0.22 µm) and de-gassed Tris dialysis buffer was used to obtain baselines before 
and after sample injection. Data were plotted using Origin Pro® 8.6. DLS 
measures the fluctuation of scattered light as a function of time. The correlation 
function (Equation 2-6) determines the changes in light intensity over time. 




Equation 2-6: Correlation Function where I is intensity of scattered light, t 
is initial time, and 𝒕 + 𝝉 is elapsed time, and brackets indicate an average 
over all t values. 
The correlation function is based on delay τ, amount the intensity trace shifts from 
the original prior to averaging. For a monodisperse sample, the correlation 
function is given in Equation 2-7: 
 
𝑔2(𝜏) = 𝐵 + 𝐴𝑒(−2Γ𝜏) 
Equation 2-7: B= baseline for correlation function at infinite delay, A is the 
correlation function amplitude at zero delay and Γ is the decay rate. 
 
To find Γ a non-linear least squares algorithm must be fit to correlation function 
data. The diffusion coefficient for the particle can be found with Equation 2-8: 
 
𝐷 =  
Γ
𝑞2







Equation 2-8: n0 is the refractive index of the solvent, λ0 is the vacuum λ 




To determine the hydrodynamic radius of the particle the Stokes-Einstein 







Equation 2-9: Stokes-Einstein Equation for determining the hydrodynamic 
radius (Rh) of a particle using DLS. D = translational diffusion coefficient 
(cm2 s-1), k = Boltzmann’s constant, T= absolute temperature and η = 
viscosity (kg m-1s-1). 
Correlation function data can be fit to a single-exponential decay with Equation 
2-10: 
 
𝑦 = 𝑦0 + 𝐴𝑒
−(𝑥−𝑥0)
𝑡  
Equation 2-10: Single Exponential Decay equation fit to correlation function 
data. A is the amplitude, y0 is the y axis intercept, x0 is the x-axis intercept 
and t is time. 
 
The correlation function assumes that the sample is monodisperse. In addition 
Cumulants and Regularisation analysis can be performed in the Astra software. 
The cumulants analysis will yield z-average (mean) radius and width (standard 
deviation of a solution. The values can be used to obtain a polydispersity index 
(Equation 2-11).  




Equation 2-11: The Polydispersity Index (PDI) is given by the width 
(standard deviation, σ) of the mean particle size (z-average radius, z) 
divided by the z-average radius squared. 
Values giving a Polydispersity Index (PDI) greater than 0.7 are considered highly 
polydisperse, while those with a PDI lower than 0.1 are typically monodisperse. 
Regularisation analysis by the software determines the average hydrodynamic 
radii present. Plots of hydrodynamic radii are shown for each sample, where the 
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y-axis is the differential intensity fraction (log nm-1) against the size of the species 
(nm) where values for the most intense peak (highest differential intensity 
fraction) are noted. 
 
2.12  OmpT activity assays 
For OmpT assays, HT-OmpT (or variant, as described) prepared according to 
Section 2.3.1 was buffer exchanged into 8 M urea, 50 mM Glycine-NaOH pH 9.5 
prior to use. The fluoropeptide, Abz-Ala-Arg-Arg-Ala-Tyr(NO2)-NH2 (ARRAY) was 
ordered from PeptideSynthetics and resuspended in 18 mΩ H2O to a 20x stock 
concentration. The fluorescence emission intensity following excitation at 325 nm 
was monitored at 430 nm with readings every 10 seconds for up to 5 hours using 
a Clariostar plate reader (BMG Labtech GmbH).  
Following initial optimisation, urea concentrations, buffer and temperature were 
kept constant, as it was noted that these may impact results, and the fluorescence 
gain on the Clariostar was set, leading to more consistent total fluorescence. 
Where normalisation was necessary this was done by subtraction of the average 
background signal produced at the zero time point. A degree of variability is still 
seen in the fluorescence counts, however quantification was carried out by fitting 
a line to the final section of data, containing the maximum fluorescence and 
determining t50, for which the fluorescent counts are therefore not relevant. 
Variability was also observed between proteoliposome preparations of the same 
BAM complex protein, with a narrow average distribution of t50s but some 
significant outliers. In cases of outlying t50s, comparisons are only made between 
conditions within the same experiment, and not included in general averaging. 
 
2.12.1 Activity assays of wild-type and mutant BAM complexes 
Following optimisation of proteoliposomes preparation and setup of OmpT assay 
the conditions for the OmpT assay were kept constant. The protein concentration 
of proteoliposomes prepared by extensive dialysis was determined by the Pierce 
BCA Protein Assay (Section 2.3.9) and diluted to a constant 3.5 μM.  BAM 
complex proteoliposomes (0.5 μM) were incubated briefly with 2 mM of the 
fluoropeptide Abz-Ala-Arg-Arg-Ala-Tyr(NO2)-NH2 (Peptide Synthetics). Purified 
81 
 
OmpT denatured in 8 M urea, 50 mM glycine-NaOH at 100 μM was diluted 10-
fold into solutions of 70 μM His6-SurA in folding buffer (50 mM glycine-NaOH pH 
9.5). Where concentrations of OmpT are altered these are diluted from a 
corresponding 10 x buffer stock, to maintain a constant urea concentration in the 
final assay. These SurA-OmpT solutions were mixed and instantly diluted two-
fold into the proteoliposome-containing solutions. The final concentrations of the 
reaction components were 5 μM OmpT, 35 μM SurA, 0.25 μM BAM complex, and 
1 mM fluorogenic peptide, 0.8 M urea, 50 mM glycine-NaOH pH 9.5. Assays were 
then performed on the Clariostar and analysed as described above.  
 
2.12.2 BAM activity assay for dilution versus dialysis proteoliposomes 
Resuspended proteoliposomes formed by dilution, with assumed BAM 
concentration of 10 μM were diluted two-fold into 50 mM glycine-NaOH, pH 9.5 
containing 2 mM of the fluoropeptide Abz-Ala-Arg-Arg-Ala-Tyr(NO2)-NH2 
(Peptide Synthetics). OmpT and SurA were then mixed to form a solution with 
final concentrations of 20 μM OmpT, 140 μM His6-SurA in 50 mM glycine-NaOH 
pH 9.5, 1.75 M urea. This sample (SurA-OmpT ‘subreaction’) was then 
immediately diluted two-fold into proteoliposome-containing solutions to initiate 
the folding reaction. All OmpT folding reactions were carried out in 30 μL final 
reaction volume. 
For proteoliposomes formed by dialysis, proteoliposomes were pelleted by 
centrifugation (16000 g, as above). The pellet was then resuspended in equal 
volume dialysis buffer to assumed 7 μM concentration and diluted to a 
concentration of 5 µM in 50 mM glycine-NaOH, pH 9.5 containing 2 mM of the 
fluoropeptide Abz-Ala-Arg-Arg-Ala-Tyr(NO2)-NH2 (Peptide Synthetics). This was 
then mixed with the same SurA-OmpT subreactions as described above.  
 
2.12.3 OmpT assays with altered components 
OmpT assays were carried out with inhibitors (Section 3.5.3). Where possible 
(JB-95 and L27-11) these were dissolved in glycine buffer at 20x final assay 
concentration. For BamD protein was buffer-exchanged (using a ZebaSpin 
desalting column (Thermo Scientific) into glycine buffer and used in the assay. 
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The potential inhibitor Peptide 2 was dissolved in DMSO, therefore an appropriate 
volume of DMSO was included as a control. 
OmpT assays were also carried out with various chaperones and at altered 
concentrations of SurA (Section 3.5.4). The preparation of SurA (2.3.3), Skp 
(2.3.3) and HT-SecB (2.3.4) is described, as well as the generation of SurA 
variants (ΔP2 and N-Ct) which were purified identically to wild-type SurA. These 
assays were carried out as described above, with chaperones buffer exchanged 
into 50 mM glycine-NaOH pH 9.5 prior to use where necessary. In experiments 
with increased ratio of SurA: OmpT (Section 0, Figure 3-28) for some of the 
samples the reaction was done “in plate” with no preincubation of OmpT-SurA, to 
maximise final SurA concentration. However, later experiments were repeated 
with a more concentrated stock of SurA and show no differences. 
The t50s for altered components are calculated as the half-time to maximum 
fluorescence reached by that trace in 10,000 seconds of experiment, as many do 
not demonstrate substantial fluorescence increase. In order to better quantify the 
results comparing chaperones in the OmpT assay the initial rate was also 
calculated. As some variation is seen in fluorescence counts, traces were first 
normalised to the maximum fluorescence value observed within each individual 
experiment. The slope of each curve over the first 500 seconds was then 
quantified and compared. 
OmpT assays were also carried out with OmpT folded into DUPC LUVs in the 
absence of BAM, in order to test inhibitors (Section 3.5.3) and OmpT variants 
(Section 4.4.3). For the latter, the OmpT variant protein was buffer exchanged 
into 8 M urea, 50 mM glycine-NaOH pH 9.5. Samples were folded by incubation 
at 25 °C overnight with 5 µM protein, 4 mM DUPC (molar LPR 800:1), and 2 M 
urea in 50 mM glycine buffer. 24 μL of folded OmpT sample was then added in 
the OmpT assay plate to 3 μL 10 mg/mL LPS and 3 μL 10 mM fluoropeptide. 
Consistent with requirement for LPS in OmpT enzymatic activity268, following 
folding in synthetic LUVs it was necessary to supplement with LPS to observe 
protease activity. The final concentrations were 4 µM OmpT, 2.4 mM DUPC, 1 
mg/mL LPS, 1 mM fluropeptide, 1.8 M urea in 50 mM glycine buffer. For the 
testing of inhibitors, wild-type OmpT was folded by incubation overnight at 25 ºC 
at 1 μM OmpT, 3.2 mM DUPC (molar LPR 3200:1), 0.3 M urea in 50 mM glycine-
NaOH pH 9.5. 24 μL of folded OmpT sample was then added in the OmpT assay 
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plate to 3 μL 10 mg/mL LPS and 3 μL10 mM fluoropeptide. The final 
concentrations were 0.8 µM OmpT, 2.56 mM DUPC, 1 mg/mL LPS, 1 mM 
fluropeptide, 0.24 M urea in 50 mM glycine-NaOH pH 9.5. For consistency, BAM-
folding of OmpT in the same assay was carried out with 0.8 μM OmpT, 5.6 μM 
SurA, 0.25 μM BAM complex, and 1 mM fluorogenic peptide. 
 
 
2.13  tOmpA folding assay with BAM complex 
An SDS-PAGE-based assay was developed to compare the activity of all BAM 
complex variants in folding the small substrate tOmpA under all reduced and 
oxidized conditions. BAM proteoliposomes formed by dialysis were resuspended 
in TBS (20 mM Tris-HCl pH 8, 150 mM NaCl) and protein concentration verified 
by Pierce BCA Protein Assay (Section 2.3.9). Two subreaction mixtures were 
prepared: the first contained 2 μM BAM complex proteoliposomes, and any 
reducing or oxidizing agents in TBS (20 mM Tris-HCl pH 8, 150 mM NaCl). The 
second comprised purified, denatured tOmpA (8 M urea, TBS at 20 μM) diluted 
5-fold into solutions of 20 μM His6-SurA in TBS folding buffer. These SurA-tOmpA 
solutions were mixed and immediately diluted two-fold into the proteoliposome-
containing solutions. The final reaction mixture therefore contained 2 μM tOmpA, 
10 μM SurA, 1 μM BAM complex proteoliposomes, 0.8 M urea in 20 mM Tris-HCl 
pH 8, 150 mM NaCl. The folding reaction was incubated at 25 ºC. When required, 
reducing/oxidising agents were used at a final concentration of 100 μM diamide, 
or 25 mM DTT, diluted from a 20-fold stock in TBS. These were incubated with 
the BAM subreaction for 1 hour at 25 ºC prior to initiation of the reaction. Samples 
were taken at time-points of 2, 5, 10, 15, 20, 30, 45, 60, 90 and 120 minutes 
whereupon 15 μL of the reaction mixture was quenched by addition to 5 μL of 6x 
loading buffer (50 mM Tris-HCl pH 6.8, 6 % (w/v) SDS, 0.6 % (w/v) bromophenol 
blue, 40 % (v/v) glycerol). The samples were not boiled, and when the reaction 
was complete, 15 µL of each sample was loaded on Tris-Tricine gels and 
electrophoresis carried out at room temperature. The identical assay was carried 
out to analyse folding of tOmpA or HT-OmpT mutants by BAM. The setup was as 
described, with only wild-type BAM proteoliposomes used, and the OMP of 
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interest buffer-exchanged in 8 M urea TBS and diluted to 100 μM. Time points 
are described when they differ from those utilised above. 
The folding yield was quantified using ImageJ302, by analysis of each band within 




 Equation 2-1 
 
The results were analysed using Igor graphing programme (Wavemetrics) and fit 
to a single exponential function (Equation 2-3). A minimum of three replicates 
was carried out for every condition of BAM mutants folding tOmpA and values 
averaged. 
A titration of BAM concentration was also carried out for this assay (Section 5.8) 
using wild-type and Lateral-lock2 BAM proteoliposomes. For this the BAM 
subreactions were set up at 2x the required final concentration in 20 mM Tris-HCl 
pH 8, 150 mM NaCl (+ 50 mM DTT in the case of Lateral-lock2) and incubated at 
25 ºC for 1 hour. As before, the second subreaction of SurA-tOmpA was mixed 
and immediately diluted two-fold into the proteoliposome-containing solutions. 
The final reaction mixtures therefore contained 2 μM tOmpA, 10 μM SurA, 0.8 M 
urea, (25 mM DTT for Lateral-lock2) and BAM concentrations at 0.1, 0.2, 0.3, 0.4, 
0.5, 0.6, 0.7, 0.8, 0.9 and 1 μM in 20 mM Tris-HCl pH 8, 150 mM NaCl. The folding 
reaction was incubated at 25 ºC for one hour before quenching by addition of the 
sample to 6x SDS loading buffer. 
 
 
2.14  Use of Styrene Maleic Acid Lipid Particles (SMALPs) to 
extract the BAM complex 
SMA2000 was a kind gift from Dr Tim Knowles (U. of Birmingham). The protocol 
followed was an adaptation of that published by Lee et al., (2016)304. BAM 
complex expression was carried out as described previously (see Methods 2.3.5) 
until the membranes were pelleted. At this stage the membranes were 
resuspended at 80 mg/mL in TBS buffer, (50 mM Tris, 500 mM NaCl, 1 mM DTT, 
pH 8) and homogenised with a Dounce homogeniser. The SMA2000 anhydrous 
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powder was dissolved to 5% (w/v) in an equal volume of the same buffer. The 
two solutions were mixed together, and solubilised by rotation for three hours at 
room temperature. Solutions were centrifuged to pellet insoluble material (25000 
rpm, 30 min), the supernatant filtered and applied to a 5 mL Ni-NTA column (pre-
washed with buffer), overnight at 4 °C using a peristaltic pump.  The column was 
then washed with 4 column volumes of buffer containing 10 mM imidazole and 
eluted in 1 mL fractions with buffer containing 250 mM imidazole. Fractions were 
analysed by SDS-PAGE and fractions containing the BAM complex were pooled. 
Samples were concentrated to a volume < 1mL using a Generon Vivaspin20 
concentrator (100 kDa MWCO). Purification was attempted by gel filtration using 
the Analytical Superdex S200, however no distinct elution peak was seen and 
fractions were analysed across the 8-14 mL elution volume.  
The protocol was later repeated using a phosphate buffer. For this resuspension 
of the membranes was carried out in 50 mM phosphate pH 8, 500 mM NaCl, 10% 
(v/v) glycerol. The SMA solution was made up in the same buffer. Following 
application of the protein to a Ni-NTA column, the column was washed with 5 
column volumes of buffer containing 20 mM imidazole (Wash1), 4 column 
volumes of buffer containing 100 mM imidazole (Wash2) and eluted in 1 mL 
fractions with buffer containing 500 mM imidazole. Where SEC was not carried 
out, samples were diluted in buffer without imidazole prior to concentration or 
dialysed without it. 
 
2.15  Use of nanodiscs 
The reconstitution of the BAM complex into nanodiscs was also attempted as a 
method to observe a more native-like system. This utilises BAM complex protein, 
as purified previously, MSP1D1 scaffold protein, purified by Dr Anton Calabrese 
and E.coli polar lipid extract, prepared in TBS with sodium cholate. 
2.15.1 Preparation of E.coli polar lipid extract 
The required volume of lipid extract, solubilised at 25 mg/mL was aliquoted into 
a clean, dry test tube, dried under a stream of N2 and dessicated for ~ 5 hr or 
overnight. The lipid was then resuspended in an equivalent volume of 100 mM 
sodium cholate, 20 mM Tris, 150 mM NaCl. The resuspended lipids were 
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vortexed and sonicated (1-2 min each) several times, and run under a stream of 
warm water, ensuring that the lipid film is fully dissolved. The resuspended lipids 
were then aliquoted and stored at - 80 °C. 
2.15.2 Reconstitution of BAM into MSP1D1 nanodiscs 
The components were mixed together in a 1.5 mL Eppendorf tube. The molar 
ratios used for empty nanodiscs were 1:35 MSP1D1:lipid and for BAM containing 
nanodiscs 1:3:60 BAM:MSP1D1:lipid. The final concentrations in empty 
nanodiscs were 36 μM MSP1D1, 1.26 mM lipid, 14 mM sodium cholate in TBS + 
10 % (v/v) glycerol. The final concentrations in BAM-containing nanodiscs were 
6 μM BAM, 18 μM MSP1D1, 360 μM lipid, 14 mM sodium cholate in TBS + 10 % 
(v/v) glycerol. Typical final volume was 500 μL, although several volumes were 
attempted. 
A small amount (~50 μL) of dry Biobeads was then added to the mixture. Prior to 
use, Biobeads were prepared by washing 3 times with methanol, 3 times with 
ddH2O and washed twice with buffer immediately prior to use. The sample was 
incubated with fresh Biobeads 2-3 times, including one overnight incubation. In 
order to remove Biobeads after use, the Eppendorf containing the sample was 
pierced with a needle, and briefly centrifuged within a 15 mL Falcon tube such 
that the sample flowed out and Biobeads remained in the Eppendorf. 
Formation of the Nanodiscs was verified by SDS-PAGE, Blue Native PAGE or 
SEC. For gel filtration chromatography ~400 μL of sample was injected on an 
Analytical Superdex200, 10/300 GL column. This was as with the BAM prep, but 
equilibrated with TBS + 10 % (v/v)  glycerol. In addition to gel filtration with the 
Superdex S200 attached to the standard Akta Prime, it was also attempted with 
the column on an AktaMicro, where the column was run at 0.05 mL/min but 
smaller (100- 1000 μL) fractions could be collected in a plate. 300 μL fractions 
were collected, as analysed in Section 3.6.2, Figure 3-33.  
In addition, BAM-Nanodisc samples were usually mixed with nickel beads and 
eluted in a smaller volume to increase the concentration and purity of the BAM 
samples. In these cases 100 μL pre-washed nickel-sepharose beads was added 
to 900 μL Nanodiscs mixture (estimated protein concentration 6 μM). The beads 
were incubated with sample, washed twice with buffer (TBS+10% glycerol) 
containing 50 mM imidazole and protein eluted with buffer containing 200 mM 
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imidazole. The sample was dialysed against TBS + 10% (v/v) glycerol using a 
200 µL 12-14 kDa MWCO dialysis tube (D-tube dialyser mini, (Merck Millipore) to 
remove excess imidazole and protein concentration verified by the Pierce BCA 
Protein Assay (Section 2.3.9). 
 
2.16 JCM166 assay 
An assay was carried out to test the in vivo lethality of BamA mutations. This 
utilised JCM166 cells and a pZS21 plasmid containing HT-BamA, both kind gifts 
from Professor Tom Silhavy, Princeton. The pZS21 plasmid has a kanamycin 
resistance gene and contains HT-BamA under control of an arabinose-inducible 
pBAD promoter. The JCM166 cells (genotype MC4100 ara r/- Δ(λatt-ιom) : : bιa 
PBADyaeT araC ΔyaeT ) are carbenicillin resistant, and will naturally express wild-
type BamA but this is suppressed in the presence of glucose. Growth in glucose 
conditions is therefore only possible if the BamA on the pZS21 plasmid is 
functional. 
All mutations of interest were introduced into the pZS21 plasmid by Q5 site-
directed mutagenesis (Section 2.1.5, Table 2-4). Plasmids were transformed into 
JCM166 cells, with a pRSFDuet-1 plasmid used as an empty vector control. 
Following outgrowth with LB + 0.2 % (w/v) arabinose, cells were grown on LB 
agar + 100 µg/mL carbenicillin + 50 µg/mL kanamycin + 0.2% (w/v) arabinose 
(LB carb/kan/ara). 
The following day a single colony was used to inoculate 5 mL LB carb/kan/ara 
which was then cultured for ~6 hours at 37 ºC. 500 µl of culture was subsequently 
pelleted at 3000 xg for 3 minutes and the pellet washed three times to remove 
arabinose. The cells were then resuspended to OD600  of 0.1 in PBS. Cells were 
streaked on to LB-agar + 100 µg/mL carbenicillin + 50 µg/mL kanamycin + 0.2% 



































3 Results Chapter 1: The BAM complex 
3.1 Introduction 
Understanding of the BAM complex has advanced considerably in the time of this 
PhD, with multiple recently published crystal structures of the complex, 
enlightening the field as to its intrinsic dynamics207-210. At the beginning of the 
thesis work, there were limited studies on the activity of the BAM complex in vitro, 
with only a few examples showing active BAM in proteoliposomes159,189,272,274. 
Only one study had used intact purified BAM274 and this demonstrated higher 
activity than that purified as two subcomplexes. The time was apt, therefore, for 
structural investigation of the BAM complex and biochemical dissection of its 
function. This chapter will discuss the inception of this aspect of the project and 
optimisation required along the way. 
As will be discussed throughout this thesis, a principal aim of this project was to 
understand the role of lateral gating, and other dynamics in BamA function. One 
of the ways this is examined is by creation of variants in the BAM complex. The 
variants and their impact on BAM activity will be discussed in Chapter 5. 
However, some optimisation of the BAM preparation discussed here was carried 
out on both wild-type BAM (WT) and the first disulphide-lock variant created for 
this study (I430C/K808C). 
Here I also introduce the OmpT enzymatic assay, an indirect assay which allows 
us to assess features of the BAM-chaperone-OMP folding system via changes in 
OmpT’s ability to cleave a fluorogenic substrate peptide268. The assay is widely 
used for studies of BAM complex activity34,189,274 and in this chapter I discuss 
some of the assay optimisation, its applications and also its limitations. 
Other features of the BAM complex were also of interest, such as the membrane 
environment and how this may impact both structure and function. The current 
protocol for studies of BAM involves extraction from the native membrane, 
purification and subsequent structural studies using detergent and reconstitution 
in native-like lipids for activity assays274. By trialling new membrane mimetics, 
such as SMA-lipid particles (SMALPs)305 and protein-supported nanodiscs306, I 
could purify BAM complex in which structural and functional studies could be 
carried out on the same sample. In addition to the reassurance that the structure 
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observed was the functional form, the structure in lipid may differ from that 
previously seen in detergent.  
Some data in this chapter were obtained with the assistance of Dr Matthew 
Iadanza (cryo-EM), Dr Anton Calabrese (Mass Spectrometry) and Dr Bob 
Schiffrin (analysis of structures). In addition, considerable parts of this chapter 
formed the basis for the following publication: Higgins, A.J.*, Iadanza, M.G.*, 
Schiffrin, B., Calabrese, A.N., Brockwell, D.J., Ashcroft, A.E., Radford, S.E., 
Ranson, N.A.. “Lateral opening in the intact B-barrel assembly machinery 
captured by cryo EM”. Nature Communications 7, 12865 (2016). 
 
3.2 Purification of the intact BAM complex 
The full BamABCDE complex (named herein as BAM), expressed 
polycistronically on a single plasmid, was expressed and purified as previously 
described274, see Methods (Section 2.3.6) for details. Briefly, proteins were 
expressed in E.coli BL21 (DE3) cells, the cells were then disrupted and 
ultracentrifuged to pellet cell membranes. Membranes were disrupted using 
DDM, ultracentrifuged again and BAM purified from the soluble fraction by nickel 
affinity chromatography followed by size-exclusion chromatography (SEC), with 
the detergent Triton X-100.    BAM consistently eluted as a triple peak by SEC 
(Figure 3-1a). SDS-PAGE analysis showed that each peak contained all five 
subunits of BAM and hence different elution volumes may reflect different 
conformational states or differing proportions of detergent and/or lipid binding. All 
five protein components were verified by SDS-PAGE and seen in approximately 
equal stoichiometry (Figure 3-1b). A low quantity of protein (<1 mg pure 
protein/litre culture) was obtained from these initial purifications, and while this 
was taken forward and used in activity assays, work was undertaken in parallel 







Figure 3-1: Purification of BAM complex using Triton X-100. Example trace of the 
elution of the BAM complex I430C/K808C variant from size-exclusion chromatography 
(a) using a Superdex200 10/300 column, with TBS (50 mM Tris pH 8, 150 mM NaCl) + 
0.5% (w/v) Triton X-100. (b) Identification of protein by SDS-PAGE. Lines on the elution 
profile (a) indicate the beginning of the 0.5 mL fraction analysed by SDS-PAGE in (b). 
The protocol for purification is given in Methods, Section 2.3.6. It can be noted that the 
complex consistently elutes earlier on the size exclusion chromatogram than is expected 
considering its size relative to calibrants. However this is likely due to presence of the 
detergent micelle and associated lipids. 
 
3.2.1 Optimization of BAM complex expression 
Due to the low yield of the BAM complex obtained in all initial purifications using 
the published protocols274, see Methods 2.3.6, persisting difficulties and loss of 
protein throughout, expression trials were carried out to determine whether 
altering the bacterial growth or protein expression conditions could improve 
protein yield. The triple peak seen in size-exclusion chromatography traces also 
gave question as to consistent protein conformation. Therefore the separate 
peaks were never pooled, contributing to even lower yield.  
Three aspects of the expression were tested. Firstly, the protocol followed274 is 
unusual in that a low IPTG concentration (0.4 mM) and short expression time (1.5 
h) are used following induction of protein expression (Methods 2.3.6 for details). 
Changing these parameters was therefore tested. Expression was also 
attempted in the more nutrient-rich TY broth (Methods, Section 2.3.7), using 
similar induction times to determine whether an increased yield could be 
obtained. A small-scale expression trial was carried out for wild-type (WT) BAM 
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and a disulphide-lock variant (I430C/K808C, XL) and analysed by SDS-PAGE 
(Figure 3-2). 
 
Figure 3-2: SDS-PAGE showing expression trial of BAM wild-type (WT) and 
cross-linked BamAI430C/K808CBCDE variant (XL). Following transformation in E.coli 
BL21 (DE3), overnight cultures were diluted 1:50 in 100 mL of fresh LB or Terrific (TY) 
broth, containing 100 μg/mL carbenicillin. Cells were grown (37 °C, 200 rpm) to an OD600 
of 0.5-0.6 before addition of 0.4 mM IPTG (denoted by 1) or 1 mM IPTG (2) to induce 
expression. Cells in TY broth were all induced with 0.4 mM IPTG. 1 mL cell samples 
were taken pre-induction and at various later time points, cells were diluted to the same 
cell density before analysis by SDS-PAGE. 
 
Due to the low expression level typically seen for such membrane proteins, the 
small scale expression trials were inconclusive (Figure 3-2). Therefore a larger 
scale (9 L) purification of the BAM complex was carried out, incorporating several 
alterations. The preparation was performed 1) utilising BL21(DE3) E.coli cells, 
and LB, 2) with BL21(DE3) cells but in TY broth or 3) utilising the E.coli strain 
HDB150 (MC4100 ompT::spc ΔaraBAD leuD::kan)  which was used in the 
original BamABCDE preparation274 with LB, with 3 L of purification by each 
method (the precise protocols used are detailed in Methods, Section 2.3.7). This 
permitted comparison of three methods (Figure 3-3), for which the size-exclusion 
trace of each is shown. In addition SDS-PAGE analysis of the fractions from 
method 2) growth with TY broth (Figure 3-3d) is shown. From visual inspection of 
the SDS-PAGE and final yield of protein, it was concluded that use of TY broth 
improved yield, while other alterations had little effect. TY broth and 
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transformation in BL21(DE3) cells was used, therefore, in all further preparations 
of the BAM complex.  
 
Figure 3-3: Comparison of alterations to BAM complex purification. Elution 
from size-exclusion chromatography with 3 runs of each, traces from a) utilising 
BL21(DE3) E.coli cells, and LB, b) utilising the E.coli strain HBD150 with LB, or c) with 
BL21(DE3) cells but in TY broth. d) Elution fractions from second elution following growth 
in TY (c-red line) analysed by SDS-PAGE. The 6 samples are 0.5 mL fractions from 9.5-
12.0 mL shown with black marks on (c). The majority of the protein is found in the first 
peak (lanes2-6) which elutes at approximately 10 mL. 
 
The protocol followed for BAM expression, as used in Roman-Hernandez et al., 
274, and discussed above, uses DDM to disrupt cell membranes, but in the nickel 
affinity step the detergent used (necessary to keep the complex in a folded state) 
is switched from DDM to Triton X-100. This step appeared unnecessary, and may 
contribute to decreasing yield throughout the preparation. In addition, while Triton 
X-100 may have been chosen to render the protein more amenable to down-
stream applications, the aromatic ring of Triton X-100 causes absorbance at 280 
nm, commonly used for estimating protein concentration, and may therefore 
strongly contribute to the varied intensity in absorbance traces seen by size-
exclusion in repeat runs. 
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It was decided to attempt a full scale purification of the BAM complex utilising 
DDM as the detergent throughout (see Methods Section 2.3.5). The use of 
detergent DDM improved the behaviour on SEC (Figure 3-4), thus allowing 
pooling of fractions across this peak. Also, as can be seen by the higher 
absorbance values of (Figure 3-4a) compared with (Figure 3-1) more protein is 
obtained. A single peak was routinely observed for SEC of the BAM complex, 
which was verified by SDS-PAGE (Figure 3-4b) to contain all five protein 
components. The final yield of this preparation was 1.8 mg pure BAM per litre 
bacterial growth.  
 
Figure 3-4: Purification of BAM complex using DDM. Shown is an example trace 
for elution from a Superdex S200, 10/300 GL column (a) and SDS-PAGE analysis of the 
central fraction(b). SEC was performed with TBS containing 0.05 % (w/v) DDM (see 
Methods, Section 2.3.5 for a detailed protocol). 
 
3.2.2 Mass spectrometry of the intact BAM complex 
In order to validate the complex as intact, non-covalent ‘native’ ESI mass 
spectrometry and native PAGE were carried out (Methods, Sections 2.4.1 and 
2.6.4) (Figure 3-5). As noted, the complex elutes at a high molecular weight with 
comparison to calibrants (Figure 3-4), likely due to the presence of the detergent 
micelle. Native MS and PAGE (Figure 3-5) aid in confirming that this is not due 
to oligomers, only one copy of the complex is present. All mass spectrometry 
experiments were carried out by Dr Anton Calabrese on my preparation of wild-
type BAM complex in Triton X-100. The spectrum showed a distinct population 
containing all five subunits, distributions corresponding to BamABCDE2 and to 
the subcomplexes BamAB and BamACDE. The charge state distribution 
corresponding to BamABCDE is the predominant species in the spectrum, with 
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an observed mass of 203,456 ± 22 Da, closely matching the predicted mass of 
203,218 Da. The subcomplexes observed (BamAB,BamACDE) are consistent 
with known architecture of the BAM complex188,201,217 and with previous 
reconstitution of the complex from BamAB and BamCDE subcomplexes159,189 
and are likely due to dissociation in the gas phase. The appearance of a 
BamABCDE2 species is also unsurprising, due to uncertainties about BamE 
dimerization195,223,224 and difficulty ascertaining whether one or two copies were 
found in previous preparations of the complex189. Native PAGE of the complex in 
TBS+DDM confirms it is intact and that no oligomerisation is observed. The 
protein consistently migrates at a slightly higher molecular weight than 
anticipated (~200 kDa)274, although not large enough for oligomers, and we 
typically see a slight doublet formation, likely corresponding to altered 
conformations of the proteins or detergent micelle.  
 
Figure 3-5: Intact BAM complex demonstrated by a) mass spectrometry and 
b) native PAGE. a) Charge states from the intact complex, as well as subcomplexes 
formed by gas phase ionization (inset) are indicated. BAM complex, purified in Triton X-
100 was exchanged into 200 mM ammonium acetate, 0.02% (v/v) Triton X-100 pH 6.9. 
Nanoelectrospray ionization-mass spectra were acquired (see Methods Section 2.4.1). 
Figure reproduced from Higgins/Iadanza et al.(2016)210. b) Native PAGE of BAM 
complex preparation in DDM. Precast Invitrogen NativePAGE 4-16 % Bis-Tris gels were 
used according to the manufacturer’s instructions. Approximately 10 μg of sample were 
loaded, as well as Native Mark Standard (LifeTechnologies). Electrophoresis is carried 




To confirm more precisely the mass of each subunit, denaturing ESI mass 
spectrometry was also carried out (Methods, Section 2.4.2) (Figure 3-6). Two 
peaks are typically seen on the chromatogram, one for the membrane-integrated 
and one for the soluble fraction, which following deconvolution can be determined 
to contain all 4 lipoproteins. This confirmed the mass of each subunit as well as 
determining the lipid moiety attached N-terminally to each lipoprotein subunit. 
Two consistent species are observed for each lipoprotein, corresponding to a 
mass increase of ~790 Da (3x C16) or ~813 Da (2x C16 1x C18) however the 
number of double bonds in the acyl chains cannot be determined. 
 
Figure 3-6: Denaturing ESI mass spectrometry of the BAM complex. (a) ESI  
mass  spectrum  of  BamA. (b) ESI mass spectrum of BamB, C, D and E. Deconvoluted 
spectra are displayed in insets in (a) and (b). (c) Theoretical and measured masses.  The 
mass discrepancy  between  the predicted   and   experimentally   measured   values   is   
shown,   along   with the   post-translational modification (PTM) associated with the 
observed mass difference. The number  of  double  bonds  in  the  acyl  chains  of  the  
lipids cannot  be  determined  at this resolution. (d) Chemical structure of the N-terminal 
modified Cys residue. X,Y, and Z denote the position of the PTMs indicated in part (c). 
Figure reproduced from Iadanza et al.(2016)210. 
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3.3 Cryo-electron microscopy of the BAM complex 
Having obtained high yield of a pure preparation of the BAM complex, validated 
as intact, and with no structures of the intact BAM complex published at the time, 
we turned to structural techniques, particularly cryo-EM. Optimization of the 
preparation of wild-type BAM complex protein in DDM allowed my colleague Dr 
Matthew Iadanza to begin studies using cryoEM. Samples were first assessed by 
negative stain EM. Following this, the sample was diluted in TBS buffer (50 mM 
Tris pH 8, 150 mM NaCl), at constant 0.05% (w/v) DDM buffer and applied to a 
quantifoil EM grid. Grids were imaged on a 300 kV Titan Krios electron 
microscope (see Methods 2.5 for details). 7803 micrographs were collected, and 
95787 particles extracted for the final classification. Shown is one example 
micrograph and class averages determined for this dataset (Figure 3-7). 
 
Figure 3-7: Example micrograph (a) and class averages (b) for cryo-EM on 
the BAM complex. Data were collected on a Titan Krios microscope using a Gatan 
K2 Summit energy-filtered direct detector (Gatan, Inc.) at the Electron Bioimaging Centre 
(eBIC, Harwell) by Dr Matthew Iadanza (University of Leeds).  
 
Analysis of the cryo-EM map permitted reconstruction of the structure of the 
complex to 4.9 Å resolution. An initial model assembled from the crystal 
structures of each subunit was fit to the EM map: BamA from 5D0Q208 and 
5D0O208, BamC and BamD from 5D0Q208, BamE from 5D0O208 and BamB from 
98 
 
3Q7O299 and 2YH3195. This was refined by flexible fitting using Molecular 
Dynamics Flexible Fitting (MDFF)300 and Monte Carlo Simulations with 
RosettaEM301. 
Shown front and back, with detergent micelle visible (Figure 3-8a) and without 
(b), there is clear density visible for a single copy each of BamA, B, D and E as 
well as the N-terminal segment of BamC (residues 26- 98). The fitting of the 
model to the cryo-EM density was striking in that it revealed a novel structure 
(Figure 3-8). 
As previously discussed (Introduction 1.7.3) during the course of the previous 
year, a number of crystal structures were published showing the BAM complex, 
in varying degrees of completion and various conformations207-209,226. Those 
structural analyses show that the β-barrel of BamA can exist in two distinct 
conformations. In the first, the barrel is open to the periplasm (and hence is 
presumably an acceptor state for OMPs), known as ‘inward open’, but with the 
membrane-facing gate of the BamA β-barrel laterally closed. In the second 
conformation the β1 and β16 strands of the BamA barrel are open, causing it to 
be laterally open to the membrane, and extracellular face. Thus far, ‘lateral open’ 
conformations had only been observed in BAM crystal structures which lack the 
42 kDa, β-propeller accessory protein, BamB207,208, raising the possibility that 
changes in the BamA β-barrel may represent a gating reaction driven by BamB 
binding and dissociation.  
In the cryo-EM structure, shown in Figure 3-8, BamA is in a distinctly ‘lateral open’ 
conformation, with a separation between β1 and β16. This is the first solution 
state structure of the BAM complex and has also allowed us to observe a novel 
conformation, of the ‘lateral-open’ form of the BamA β-barrel in the presence of 




Figure 3-8: Cryo-EM structure of the BAM complex. Views of the front and back 
face of the cryo-EM structure of the intact BAM complex at 4.9 Å resolution. BamA is 
coloured blue, BamB in green, BamC in yellow, BamD in orange and BamE in magenta 
and the approximate position of the outer membrane (OM) is marked. Density 
corresponding to the micelle of n-dodecyl--D-maltoside (DDM) in the structure is shown 
as a pale grey mesh. (b) Flexible fitting of a hybrid X-ray structure into the EM density. 
The views and coloring are identical, but density for the micelle has been masked, and 
the EM density made transparent, showing the fitted pseudo-atomic model within. The 
location of lateral opening and position of β-strand β1 are marked. Figure adapted from 
Iadanza et al.(2016)210. 
 
 
The cryo-EM structure generated at 4.9 Å resolution allows determination of a 
lateral open BamA structure in the full complex. In addition, the region of lateral 
gating, around 1 and 16 shows high mobility evidenced by low local resolution 





Figure 3-9: CryoEM structure coloured by estimated local resolution. Shown 
is a single front (β1/β16 seam)-facing view at high (a) and low (b) threshold values, so 
the detergent micelle is, or is not visible respectively. Resolution values are coloured 
according to the key. Poor local resolution is seen in more dynamic regions (eg. 
POTRA1, BamC N-terminal domain), the top of the β-barrel and in the detergent micelle. 
Figure adapted from Iadanza et al.(2016)210. 
 
A notable alteration between the cryo-EM structure and those already 
published207,208 was in the conformation of the POTRA domains. The N-terminal 
POTRA 1 domain appears the most mobile, but in fact this results from the 
conformational change propagated through the POTRA domains. Comparison of 
the different crystal and cryo-EM structures demonstrates the angle between 
POTRA domains 2 and 3 is most variable, consistent with previous suggestions 
that this region is capable of hinge-like motions203. This analysis showed that the 
angle between POTRA2 and POTRA3 is wide (~120 º) in the lateral closed crystal 
structures with BamB present and more acute (~104° to ~110°) in lateral open 
crystal structures (Figure 3-10). The cryo-EM structure displays a wide angle 
between the POTRA domains, indicating this may be correlated with presence of 
BamB, rather than the open/closed position of the lateral gate208,210. However, 
comparison of the structures demonstrates that extension of the POTRAs 
vertically away from the barrel appears to more closely link to the barrel 





Figure 3-10: Comparison of POTRA domains across BAM complex 
structures. a) Comparison of the cryo-EM and 5D0Q208 lateral open crystal structure 
demonstrates the obtuse angle between POTRA domains 2 and 3 appears to correlate 
with presence of BamB rather than lateral gate opening or closing. b) The extension of 
the POTRA domains away from BamA and the membrane is more closely related to 
lateral gate opening, noted by comparison of the cryo-EM structure to 5D0O208. Image 
reproduced from Iadanza et al.,(2016)210.  
 
The cryo-EM structure also permits us to look at the interactions with the 
detergent micelle, which is a mimic of the lipid membrane. The detergent micelle 
surrounds the BamA barrel and encapsulates the hydrophobic residues. 
Additional interactions are observed with the periplasmic regions of the BAM 
complex. Contacts with the micelle are observed for BamA from a loop in POTRA 
3 (residues 196-214) which contains a hydrophobic sequence (RDE-
VPWWNVVG-DRK) (Figure 3-11a). Additionally, the N-terminus of BamB and 
BamE and a conserved hydrophobic helix of BamD are observed buried in the 









Figure 3-11: Interactions between BAM and the detergent micelle. The 
detergent micelle is shown as grey mesh. a) The N-terminus of BamB (green) dips into 
the detergent micelle. This segment is unmodelled in X-ray structures of BAM207-209. 
BamA (blue) POTRA3 also possesses a hydrophobic loop buried in the micelle, with 
details of the hydrophobic residues inset. (b) A hydrophobic 310 helix in BamD (orange) 
inserts into the micelle, with hydrophobic residues buried in the hydrocarbon tail groups 
of the detergent (see inset) and polar residues flanking the helix placed to interact with 
the polar head groups of the detergent. (c) The N terminus of BamE (magenta), which is 
the site of the lipid anchor, also inserts into the micelle, well away from the body of the 
BamA β-barrel. Figure reproduced from Iadanza/Higgins et al., (2016)210. 
 
Comparisons of structures of the BAM complex, between this ‘lateral open’ cryo-
EM structure and ‘lateral open’ crystal structure 5D0Q208 demonstrates the 
dynamics possible in BamD. BamD here appears to be flexible in two halves, with 
the C-terminal halves aligning, and the N-terminal halves not (Figure 3-12). The 
structures appear to differ around a hinge point, at the location where BamD is 
noted to contact the detergent micelle (Figure 3-11). Therefore communication 






Figure 3-12: BamD conformational change between cryo-EM and crystal 
structures. Comparison of BamDE from cryo-EM (5LJO)210 and crystal (5DOQ)208 
structures. Crystal structure (5DOQ) is light green throughout, cryo-EM BamD is orange 
with BamE magenta. Structures were aligned on BamE, and the C-terminal portion of 
BamD (right-hand side) aligns correctly, while the N-terminal portion(left-hand) deviates 
significantly between structures (orange to green). Image adapted from Iadanza et al.210. 
 
In conclusion, following considerable optimisation, the BAM complex can now be 
obtained at high yield and purity. This preparation of the intact BAM complex, 
particularly the purity and stability of the complex in DDM, facilitated analysis by 
native mass spectrometry and cryo-EM. The cryo-EM structure of the complex is 
unique in showing the intact BAM complex possessing BamA in a lateral open 
conformation in the presence of BamB. It remains not only the sole cryo-EM 
structure of the complex, but also the only structure with this particular 
conformation. Comparison of the cryo-EM structure to existing crystal structures 
has allowed some of the dynamics of the complex to be revealed. The large 
conformational changes observed in the swinging of the POTRA domains can be 
distilled to two aspects: the angle between POTRA2 and 3, which is correlated to 
the presence of BamB and the movement of POTRAs away from the membrane 
which is linked to lateral gate position. In addition BamD is noticed to 
conformationally change at a hinge point in the protein. The relevance of all these 




3.4 BAM reconstitution in proteoliposomes 
On obtaining pure BAM, the next step was reconstitution in lipids for activity 
assays. Prior studies, using both the intact complex, and that purified as two 
subcomplexes utilise the same published protocol reported to function effectively 
for reconstitution of BAM in E.coli polar lipid extract proteoliposomes189,274. 
Briefly, the method involves the addition of purified BAM complex to solubilized 
E.coli polar lipids, a ~20 fold dilution in Tris buffer, incubation on ice, and 
ultracentrifugation to pellet the proteoliposomes (see Methods Section 2.10.1 for 
details). This method, (‘dilution’) did not appear to work effectively in my 
preparation. To determine yield, the amount of protein in the supernatant and 
resuspended pellet after ultracentrifugation were analysed by SDS-PAGE (Figure 
3-13). The results showed that despite having been reported to reconstitute the 
BAM complex into liposomes at high efficiency159,189,274, this was not the case in 
my preparation, and the majority of protein was found in the supernatant. This 
preparation was originally carried out with protein prepared in Triton X-100, for 







Figure 3-13: SDS-PAGE examining the efficiency of BAM complex 
reconstitution into proteoliposomes. Following creation of proteoliposomes by the 
dilution method, a sample of the protein (in detergent), the 200 l liposome sample (both 
at 1:10 dilution), and the 4 mL supernatant (undiluted), were analysed by SDS PAGE. 1 
and 2 designate protein from separate peaks of same prep; X designates empty 
liposomes. If the reconstitution has been effective, band intensity for BAM in the 
proteoliposome sample should nearly match that of protein, while very little protein is 
expected in the liposome supernatant sample. 
 
Following the generation of larger quantities of the BAM complex using DDM, it 
was decided to optimize reconstitution in proteoliposomes using alternative 
methods. The methods tested included use of Biobeads and a new method of 
extensive dialysis (referred to hereafter as ‘dialysis’), compared to the previous 
dilution method (Figure 3-14). The Biobeads method relies on the hydrophobic 
nature of Biobeads to bind and remove detergent, and was executed as 
described previously278,303 (Methods, Section 2.10.3). This was unsuccessful as 
all protein was lost in this preparation (Figure 3-14). The dialysis method was 
carried out as reported for the outer membrane protein FhuA257 and involved the 
incorporation of purified BAM complex with DDM-solubilized E.coli polar lipids 
and dialysis into detergent-free buffer over 7-days to permit the spontaneous 
formation of proteoliposomes (see Methods 2.10.2 for a detailed protocol). 
Following extensive dialysis, samples are briefly centrifuged, causing liposomes 
to pellet along with associated protein. This pellet is resuspended and analysed 
as the “Dialysis pellet” (Figure 3-14, lanes 5 & 6). These experiments showed 
106 
 
that the five proteins of the BAM complex are all associated with the liposomes 
and exhibit folded BamA. OMPs possess the property of heat modifiability, 
whereby they will remain folded in SDS-PAGE unless boiled307 and the folded 
and unfolded forms migrate differently. While isolated BamA requires low SDS 
conditions to exhibit this property, BamA within the BAM complex displays a clear 
bandshift on boiling in standard SDS-PAGE conditions. In Figure 3-14 (lanes 5 & 
6) the clear bandshift of BamA demonstrates that BamA is folded in the 
liposomes. Following this result, dialysis proteoliposomes were exclusively used 
for all the experiments described. 
 
Figure 3-14: SDS-PAGE comparison of different methods to generate 
proteoliposomes containing the BAM complex. SDS PAGE analysis shows the 
purified BAM complex in DDM (lanes 1&2) and Biobeads (3&4), Dialysis (5-8) and 
Dilution (9-11) methods to generate proteoliposomes containing the BAM complex, with 
boiled (+) samples displaying the expected bandshift on unfolded BamA. A* denotes 
folded BamA. The original BAM protein sample, in DDM was diluted 1:10, while the 
resuspended dialysis pellet and all samples from ultracentrifugation were diluted 1:2, for 
approximate protein concentration of 3-5 µM in the final sample analysed.  
 
 
3.4.1 Analysis of proteoliposomes using dynamic light scattering 
Dynamic light scattering (DLS) is a powerful tool to obtain information on particle 
sizing308. This method was used to examine wild-type BAM complex 
proteoliposomes, generated by either the dilution or dialysis methods. It was of 
interest to analyse the relative sizes of liposomes generated by different methods 
to compare to the 100 nm LUVs previously used for BamA work (see Chapter 4), 
especially given that lipid curvature is known to affect the folding of membrane 
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proteins72,309-311. In addition, the size of the liposome may have considerable 
effect on efficiency of protein folding, with proteins folding more rapidly into 
smaller vesicles72,79. The particle size calculated by DLS is the hydrodynamic 





    Equation 3-1 
Equation 3-1: Stokes-Einstein Equation for determining the hydrodynamic radius 
(Rh) of a particle using DLS. D = translational diffusion coefficient (cm2 s-1), k = 
Boltzmann’s constant, T= absolute temperature and η = viscosity (kg m-1 s-1). 
 
The hydrodynamic radius calculated is the radius of a sphere with the same 
translational diffusion coefficient. In addition one must recall that aspects of the 
surface will contribute to particle sizing, and the fact that E.coli polar lipids are 
composed of multiple lipid types, with inherent heterogeneity. Shown is the 
correlation function, which is calculated by  Equation 3-2, for the sample and the 
regularised hydrodynamic radius, for which the major peak is labelled. 
𝑔2(𝜏) =  
〈𝐼(𝑡)𝐼(𝑡+𝜏)〉
〈𝐼(𝑡)〉2
    Equation 3-2 
 Equation 3-2: Correlation Function where I is intensity of light, t is initial time, 
and 𝒕 + 𝝉 is elapsed time, and brackets indicate an average over all t values. 
 
The results of the DLS analysis of BAM proteoliposomes generated by dilution 
(Figure 3-15) indicate that there is predominantly a single population with a mean 
hydrodynamic radius of 91.53 ± 47 nm. The Polydispersity index is 0.278 for this 
sample. As samples are considered monodisperse with a PDI close to 0.1, and 
polydisperse with PDI > 0.6 therefore the sample is considered monodisperse312. 
The small peaks seen either side are probably contaminants and hence judged 






Figure 3-15: Correlation function and regularisation plot for BAM 
proteoliposomes generated by dilution and ultracentrifugation. 
Proteoliposome samples were diluted 1/120 to obtain a lipid concentration of ~50 µg/mL 
and 250 µL of the samples were then injected. See Methods Section 2.11 for details. 
 
The proteoliposomes generated by dialysis appear larger with a mean 
hydrodynamic radius of 200 ± 167 nm (Figure 3-16). In addition to the larger error 
on this peak, the samples appear more polydisperse with the polydispersity index 
of 0.74.  
 
 
Figure 3-16: Correlation function and regularisation plot for BAM 
proteoliposomes generated by extensive dialysis. Proteoliposome samples 
were diluted 1/60 to obtain a lipid concentration of ~50 µg/mL and 250 µL of the samples 
were then injected. See Methods Section 2.11 for details. 
 
The proteoliposomes generated by dialysis appear larger than those generated 
by dilution and ultracentrifugation and are more heterogeneous. In addition, the 
experiment was carried out only once for each sample, therefore replicate error 
is unclear. The mean hydrodynamic radius in both populations is in accordance 
with that reported in the literature for studies of E.coli polar lipid liposomes using 
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DLS (~200 nm diameter)313. The experiment was unfortunately not carried out 
with proteoliposomes containing other BAM variants or repeated with other 
preparations of wild-type proteoliposomes. However, it has now been repeated 
by my colleague Dr Bob Schiffrin, with his batch of dialysis proteoliposomes. The 
results showed more monodisperse peaks with mean hydrodynamic radii of 50-
60 nm for BAM proteoliposomes and ~58 nm for empty proteoliposomes (Dr Bob 






3.5 OmpT assay 
Reconstitution of BAM in proteoliposomes is necessary to assay its activity as an 
OMP folding catalyst. The enzymatic OmpT assay189,268 has been used widely as 
a measure of BAM complex activity. It was employed to great effect in this project. 
The fluorimetric assay, first published in 2000268, utilises OmpT’s protease 
properties, and a substrate Abz-Ala-Arg-Arg-Ala-Tyr(NO2)-NH2. When excited at 
325 nm the o-aminobenzoyl (Abz) moiety will emit fluorescence with a maximum 
at 430 nm. However, this is quenched by the nitrotyrosine, Tyr(NO2), of the intact 
substrate. OmpT will cleave between the arginines268,275, separating the 
fluorophore and quencher and producing a fluorescence readout. While 
possessing some limitations, particularly in that OMP folding is only indirectly 
measured using this assay, this section will discuss some of the optimisation and 
applications of this assay. BAM proteoliposomes were regularly prepared for use 
in this assay, and were used immediately or snap-frozen for storage at -80 ºC. 
The fluoropeptide was ordered from PeptideSynthetics and resuspended in 18 
mΩ H2O to a 10x stock concentration. OmpT was purified from inclusion bodies 
(see Methods 2.3.1) and preparations of SurA were carried out by myself, Julia 
Humes and Dr Bob Schiffrin and used interchangeably (Methods, Section 2.3.3). 
 
3.5.1 Optimization of the OmpT assay 
The OmpT enzymatic assay works when OmpT is delivered by SurA, folded by 
functional BAM in proteoliposomes and is then able to cleave the fluoropeptide 





Figure 3-17: Schematic of OmpT enzymatic assay with BAM 
proteoliposomes. The 10-stranded β-barrel OmpT, denatured in urea, is mixed with 
chaperone SurA. The fluoropeptide (ARRAY) is mixed with BAM complex in E.coli polar 
lipid proteoliposomes. When the two subreactions are mixed together and OmpT is 
folded it is capable of cleaving the fluoropeptide, producing a fluorescence output. 
 
While SurA can to a certain extent be replaced by urea at concentrations of 0.5-
2 M159 it appears principally to function to maintain OMP folding competence by 
preventing aggregation. In the absence of any of the active components, 
however, there is no fluorescence, and changing any of these parameters can 
alter the output of fluorescence intensity versus time. Controls, demonstrating the 
efficacy of this assay were carried out multiple times, with one representative 
example in optimised conditions shown below (Figure 3-18). The assay was 
controlled to only remove one active component in each sample and shows that 
BAM, OmpT, substrate and SurA are all required for a fluorescence output 




Figure 3-18: OmpT assay controls. The OmpT assay was set up with 0.25 M BAM 
proteoliposomes created by the dialysis method, 5 M OmpT, 35 M SurA, 1 mM 
fluorogenic peptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5.  
 
 
Initially, following creation of proteoliposomes by multiple methods, the activity of 
both “old” (dilution) and “new” (dialysis) proteoliposomes was assayed for the 
same apparent concentration of BAM (Figure 3-19). The results demonstrate the 
much higher activity of the dialysis method for production of BAM 
proteoliposomes with a fast kinetic trace and considerably shorter t50.  
 
Figure 3-19: Analysis of dilution and dialysis methods for the creation of 
BAM proteoliposomes. (a) activity in OmpT assay and (b) t50 extracted from assay. 
Samples contained 2.5 M BAM proteoliposomes, 10 M OmpT, 70 M SurA, 1mM 
fluoropeptide, 0.88 M urea in glycine-NaOH pH 9.5. The t50 utilises the average and 




It was following this striking result (Figure 3-19) that dialysis proteoliposomes 
were exclusively used moving forward. Next, the conditions for the activity assay 
were optimised. Although experiments had been started using 2.5 M BAM 
(Figure 3-19), this concentration led to a rapid apparent folding rate using the 
dialysis method of creation of BAM proteoliposomes. A slower initial rate was 
desirable to better quantify small differences in the apparent folding rate. 
Therefore the concentrations of different components were altered to optimise 
the assay. It was found that decreasing the OmpT and SurA concentration did 
not significantly slow the apparent folding rate. However, decreasing the BAM 
concentration had a marked effect, as expected (Figure 3-20).   
 
  
Figure 3-20: Optimisation of conditions for the OmpT activity assay with (a) 
changes in OmpT and SurA concentration and (b) changes in BAM and 
OmpT concentration. a) Initial assay conditions (Standard, orange) were 1.25 M 
BAM, 10 M OmpT, 70 M SurA, 1 mM fluoropeptide, 0.8 M urea in 50 mM glycine-
NaOH pH 9.5. This was modified by dilution to 5 M final OmpT (blue line) or 5 M 
OmpT, 35 M SurA (cyan line) with other conditions as standard. b) Initial conditions 
(standard, yellow) utilised 2.5 M BAM, 10 M OmpT, 70 M SurA, 1 mM fluoropeptide, 
0.8 M urea in 50 mM glycine-NaOH pH 9.5. This was modified by dilution to 0.25 M 
BAM (pink line) or 0.25 M BAM, 1 M OmpT (purple line) with other conditions as 
standard. Each experiment was carried out only once. 
 
Using the results of optimisation dilutions (Figure 3-20) the conditions used for 
further assays were 0.25 M BAM, 5 M OmpT, 35 M SurA, 1 mM fluoropeptide, 
0.8 M urea, 50 mM glycine-NaOH pH 9.5 with experiments measured at 25 ºC, 




3.5.2 Understanding the OmpT assay 
The OmpT activity assay has a number of applications, as discussed later 
(Sections 3.5.3, 3.5.4 and 5.5), but it was also desirable to understand how this 
indirect assay reports on OmpT folding, and perhaps to devise a kinetic model. 
To this effect, considerable work was performed varying the concentrations of all 
components to understand their contribution. Now working from the standard 
conditions (0.25 M BAM proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM 
peptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5), dilutions of BAM and OmpT 
were carried out. It is immediately clear that altering the concentration of the BAM 
complex has an effect on the measured activity in the assay as expected (Figure 
3-21a). However, increasing BAM concentration does not appear to lead to a 
linear increase in initial rate of folding, and measurement is complicated by the 
appearance of a lag phase. More subtle, however, is the effect of OmpT 
concentration, which surprisingly has only a small effect on the apparent folding 
rate, with perhaps even an increase in rate at decreased concentration (Figure 
3-21b). This is evidently paradoxical as correctly folded OmpT is necessary to 
cleave the fluoropeptide to produce a fluorescence signal. But as BAM is 
necessary to first fold OmpT (Figure 3-18) and it is present at a significantly lower 
(20-fold) concentration than its substrate OmpT, perhaps it is the effect of 
dropping OmpT to nearer the concentration of its catalytic enzyme. Additionally, 
the concentration of SurA was unchanged in this experiment, therefore at a lower 
concentration of OmpT there is a more significant excess of chaperone, perhaps 






Figure 3-21: Effect of variation of (a) BAM and (b) OmpT concentration on 
OmpT activity assay. The standard conditions, depicted as a red line in both cases 
utilised 0.25 M BAM proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM peptide, 0.8 M 
urea in 50 mM glycine-NaOH pH 9.5. The results of a & b were from the same assay, 
which are represented separately for clarity. In (a) BAM concentration was varied: 0.25 
M, 0.5 M, 0.06125 M and 0.025 M final BAM concentrations accordingly and all 
other concentrations remaining as standard. In (b) OmpT concentration was varied by 
dilution of the original stock in 8 M urea. A constant final urea concentration of 0.8 M was 
maintained. The final concentrations of OmpT were 5 M, 2.5 M, 0.5 M and 0.25 M 
with constant BAM concentration of 0.25 M. This experiment was carried out twice for 
which one representative example is shown. 
 
In addition to the direct effect of the concentration of the BAM complex, altering 
the concentration of BAM proteoliposomes has a confounding secondary effect, 
of altering the lipid: protein ratio (LPR). As dilutions of BAM are carried out by 
diluting the reconstituted proteoliposomes this is unavoidable when using the 
same set of proteoliposomes. However, to test not only the effect of the BAM 
complex, but also the effect of the LPR, proteoliposomes were generated with 
lower original concentrations of BAM. The dialysis protocol generates 
proteoliposomes with a low LPR (2:1 by weight, ~120:1 molar ratio) and it is 
possible that this crowded BAM causes the high activity observed, but may also 
limit the total substrate folding. Proteoliposomes were therefore created using 
1/10 and 1/100 dilutions of BAM in detergent, creating liposomes with 20:1 and 
200:1 LPR by weight. Reconstitution appeared successful. However, particularly 
for the 1/100 dilution of BAM, the protein concentration could not be accurately 
measured. For this sample therefore total concentration is assumed at 0.07 M, 
based on consistent reconstitution of BAM at ~7M in non-diluted samples. The 
first assay (Figure 3-22a) compares normal proteoliposomes (made at 2:1 LPR 
by weight) at final BAM concentrations standard (0.25 M), ½ (0.125 M), and ¼ 
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(0.0625 M) with those made with 1/10 (y) and 1/100 (z) less BAM in the 
proteoliposomes. The legend therefore refers to the final concentration of BAM in 
that sample, relative to the standard of 0.25 M with x, y, or z denoting the original 
LPR. Unsurprisingly, considering previous results, less BAM causes lower 
activity, and there does not appear to be a compensating effect by higher LPR (y 
and z). 
Experiments were also carried out with a lower concentration of OmpT to more 
accurately measure activity at low concentrations of BAM (Figure 3-22b). A 1/10 
BAM proteoliposome preparation produces very low activity (Figure 3-22a orange 
line). This becomes easier to compare if the concentration of OmpT is also 
reduced (Figure 3-22b). In addition, in this experiment, the same concentration 
of BAM was compared across different LPRs. This allows us to see, for example, 
that at the same concentration of BAM (0.005 μM, ‘1/50 BAM’) and liposomes 
made with a 2:1 (x,green) or 200:1(z,pink) LPR, the lower LPR results in a more 
active system.  The same trend is seen for BAM at 0.05 μM (‘1/5 BAM’) between 
proteoliposomes made with 2:1 LPR (x,sky blue) or 20:1 LPR (y,purple). 
Therefore, having more lipid around the BAM likely decreases, rather than 











Figure 3-22: Effect of LPR, BAM and OmpT concentration on the OmpT 
activity assay. The standard conditions, depicted as a red line in both cases utilises 
0.25 M BAM proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM peptide, 0.8 M urea in 
50 mM glycine-NaOH pH 9.5. In this figure (x) denotes proteoliposomes generated with 
the original 2:1 LPR, whereas (y) denotes a proteoliposomes with a 20:1 LPR and (z) a 
200:1 LPR. Therefore for panel (a), the last three traces, with (z) utilise the 
proteoliposomes containing 1/100 original concentration of BAM, creating 1/100 
(~0.0025 M final BAM), 1/200 (~0.00125 M final BAM), and 1/400 (~0.000625 M final 
BAM). In panel (b) the format is the same, comparing dilutions across proteoliposomes 
with different LPRs. The majority of assays for this experiment, were carried out with 
1/10 OmpT (0.5 M) retaining other conditions (35 M SurA, 1 mM peptide, 0.8 M urea 
in 50 mM glycine-NaOH pH 9.5) as standard. Each experiment was carried out twice, for 
which one replicate is shown. 
 
The results of altering BAM concentration and LPR are increasingly interesting 
when one considers the model of BamA oligomerisation211,212. This has been a 
pervasive hypothesis since original identification of the BamA protein211, but is 
strongly supported by studies demonstrating OMPs to co-localise216,283. These 
studies demonstrate that copies of BAM cluster to function. This would suggest 
that BAM proteoliposomes generated with a lower LPR would exhibit greater 
activity, as the copies of the BAM complex would be more clustered than for the 
same concentration of BAM proteoliposomes created with a high proportion of 
lipid. This is in fact exactly what is observed, with the lower LPR leading to 
increased activity in BAM folding OmpT, lending support from this experiment to 
oligomerisation and BAM islands. 
A final aspect of the OmpT assay which was of interest and a control for observed 
activity, was whether isolated BamA is capable of catalysing the folding of OmpT 
into liposomes formed of E.coli polar lipid extract. It has been shown previously 
that BamA can be assembled by BAM lipoproteins and this is more efficient than 
it can be assembled by itself272. However, BAM lipoproteins are not capable of 
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catalysing OmpA assembly272. In order to examine this, proteoliposomes of E.coli 
polar lipid extract were generated containing folded BamA (Methods, Section 
2.10.2). The reconstitution and correct folding was verified (Figure 3-23a) and 
these were then tested in the OmpT assay and compared against  
proteoliposomes containing the BAM complex. Proteoliposomes containing 
BamA were tested both at the same lipid (1) or protein (2) concentration used for 
the BAM complex proteoliposomes (Figure 3-23, see Methods 2.10.2 for details). 
The results show, remarkably, that BamA cannot fold OmpT under the conditions 
employed, whilst BAM is a highly efficient catalyst. 
 
Figure 3-23: BamA in liposomes formed from E.coli  polar lipids does not 
assist OmpT folding. (a) Semi-native PAGE with low SDS concentration (0.1 % (w/v)) 
to demonstrate bandshift of folded BamA. BamA was prefolded in TBS+0.05% (w/v) 
DDM and 3 M urea, to mimic the protocol to produce BAM-containing proteoliposomes, 
before following the proteoliposomes dialysis procedure. BamA has clearly associated 
with the liposomes (present in pellet) and is mostly folded. A * denotes folded BamA, 
which is unfolded when boiled (+). (b) An OmpT activity assay was carried out with BAM 
complex and BamA proteoliposomes. The conditions used for BAM are 0.25 M BAM 
proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM peptide, 0.8 M urea in 50 mM glycine-
NaOH pH 9.5. For BamA, proteoliposomes were created at the same weight LPR as 
BAM complex proteoliposomes, resulting in a different BamA: lipid molar ratio. The 
BamA proteoliposomes were either diluted for the same assumed concentration of lipid 
(1) as in the BAM proteoliposomes and a concentration of ~0.6 μM, or diluted to 






3.5.3 Assessing inhibitors in the OmpT assay 
The results presented above show that OmpT can be folded only when catalysed 
by BAM and delivered by the chaperone SurA (Figure 3-18). The assay was 
optimized for assessing how alterations to the BAM complex impact its catalytic 
ability, discussed in Chapter 5 (Section 5.5). However, an important application 
of the OmpT assay developed here is in screening potential inhibitors of OMP 
folding or BAM activity. Three different potential inhibitors have been of interest 
based on the literature, and were tested in this assay, the results of which are 
summarised below. 
The first two “inhibitors” (BamD and ‘Peptide2’) are based on the same concept 
and research. It is known that BamA and BamD are the only essential 
components of the BAM complex21,25,187,188. The “- signal” hypothesised to be 
present in OMPs and vital for substrate assembly was originally proposed to first 
bind BamD by in silico experiments demonstrating the ability to dock the peptide 
in the BamD TPR scaffold195. The proposed signal, containing a conserved 
Glycine residue and patterns of hydrophobic residues (i.e. GxxΦxΦ, where Φ 
denotes hydrophobic)174 is found in the 14 strand of BamA175.  Mutagenesis 
experiments have shown this signal to be both necessary and sufficient for 
binding of substrate BamA to BamD175. Furthermore, a 15 amino-acid stretch 
(NIRMSAGIALQWMSP, henceforth denoted as Peptide 2) containing the 
recognition signal is able to inhibit the folding of BamA by BAM, is toxic in vivo  
and may act as a general inhibitor of OMP assembly175. This peptide was 
therefore purchased and its effect on OmpT folding assayed. The effects of the 
peptide had not been characterised in in vitro activity assays such as ours. 
Additionally, this and other research suggested that BamD binds OMPs prior to 
their assembly in the membrane175,220. Therefore, the addition of soluble BamD 
to a folding reaction would be anticipated to slow OMP folding by sequestering 
substrate. Due to low solubility of purified BamD, these assays were carried out 
at reduced OmpT concentration. However no effect of BamD was seen at a 25- 
or 40- fold molar excess over OmpT (Figure 3-24a).  
In the majority of the inhibition assays the component was tested both by pre-
incubation in the OmpT-SurA subreaction or the BAM proteoliposome-peptide 
subreaction. It is indicated for each sample in which subreaction (BAM/OmpT+) 
preincubation occurred. The -signal mimic, Peptide 2, was anticipated to be 
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recognised by the BAM complex and thus may compete and slow folding of 
OmpT. It was thus anticipated that a specific effect would be seen for the peptide 
when pre-incubated with BAM proteoliposomes. However, any effect in this case 
was indistinguishable from the effect of the DMSO control (Figure 3-24b). The 
peptide only demonstrated an effect when pre-incubated with OmpT in low SurA 
conditions (Figure 3-24b, light blue&green). Due to the effect only in low SurA 
conditions, the peptide is possibly causing aggregation of OmpT, rather than 
acting as a specific inhibitor. 
 
Figure 3-24: Inhibition of OmpT folding by BAM by a) BamD and b) 15aa 
“Peptide2”. (a) Standard conditions, shown in orange utilise 0.25 M BAM 
proteoliposomes, 0.5 M OmpT, 35 M SurA, 1 mM fluoropeptide, 0.8 M urea in 50 mM 
glycine-NaOH pH 9.5. BamD in pre-incubation with BAM (green line) is at 20 M final 
concentration and with OmpT (cyan) is at 12.5 M. (b) Standard conditions, denoted by 
a red line, contain 0.25 M BAM proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM 
fluoropeptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5. Peptide 2 is made up in DMSO 
in 10x stocks, therefore an equal volume DMSO control is included. Conditions are as 
standard for thicker lines, but were also carried out with low SurA (10 μM final 
concentration), denoted by thinner lines. Each experiment was carried out twice for which 
one representative example is shown. 
 
The final inhibitor tested was a macrocyclic peptide (Figure 3-25). This peptide, 
JB-95, was of interest following research demonstrating it to possess 
antimicrobial activity, to increase OM permeability, and to downregulate 
expression of several OMPs47. An interesting possibility therefore was that this 
peptide affects BAM. A macrocylic peptide, L27-11 which was shown to be active 






Figure 3-25: Structures of Macrocyclic peptides. a)JB-95, image from Urfer et 
al., 201647. b) L27-11, image from Schmidt et al., 2013315. 
 
While the macrocyclic peptide does apparently show a titratable effect of 
inhibition, with 25 M of peptide ablating any observed folding, the reoccurring 
trend is that the control peptide (L27-11) demonstrates the same effects (Figure 
3-26). In addition to assaying these peptides by pre-incubation in BAM or OmpT 
subreactions (Figure 3-26a), they were also tested on OmpT prefolded in DUPC 
LUVs (Figure 3-26b), see Methods 2.12.3 for details. In the cases of OmpT 
prefolded in DUPC LUVs, inhibition by the peptides is less (Figure 3-26b, thin 
lines, pink to blue/green) than with OmpT folding in BAM (thick lines, brown to 
blue/green). However, the control peptide L27-11 demonstrates the same 
inhibition (Figure 3-24 thick blue/green). Therefore we cannot conclude JB-95 to 






 Figure 3-26: Inhibition of OmpT folding with macrocylic peptides. a) 
Macrocyclic peptides JB-95 and L27-11 are dissolved in glycine buffer and pre-incubated 
with BAM before commencing the assay. Each reaction contains 0.25 M BAM 
proteoliposomes, 5 M OmpT, 35 M SurA, 1 mM fluoropeptide, 0.8 M urea in 50 mM 
glycine-NaOH pH 9.5, with the described final concentrations of peptide. (b) Macrocyclic 
peptides were tested both with OmpT folded by BAM, by pre-incubation of peptide with 
the BAM subreaction, and OmpT in DUPC. OmpT DUPC samples were prefolded in 
DUPC overnight at 25 ºC and then mixed in plate with LPS, fluoropeptide and inhibitor. 
For ease of folding in DUPC, and for consistency OmpT concentration is 0.8 μM 
throughout and where SurA is used this is 5.6 μM, to be at the normal 7x excess, all 
other BAM-assay concentrations are as standard (0.25 M BAM proteoliposomes, 1 mM 
fluoropeptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5).  Peptides are used at 5 μM 
final concentration. DUPC samples contain 0.24 M urea, 1mg/ml LPS and 2.56 mM 
DUPC (molar LPR 3200:1). The experiments were carried out three times, for which one 
representative example is shown. 
 
There were confounding effects in this case as it was later noticed that the peptide 
of interest possesses sequential charged residues (Figure 3-25), which are the 
recognition site for cleavage by OmpT268,275. Therefore it may compete with 
fluoropeptide as a cleavage substrate, and slow apparent fluorescence by this 
means, rather than inhibition. It was attempted to untangle the effects of the 
macrocyclic peptides on BAM and OmpT utilising OmpT prefolded in DUPC LUVs 
as opposed to folded by BAM proteoliposomes. It would be expected in this case 
that if the peptide is specific against BAM, inhibition would not occur, but 
competition with the fluoropeptide would still be observed. As noted, the 
magnitude of inhibition by the peptides is less for OmpT prefolded in DUPC LUVs 
(Figure 3-26, thin lines) than folded by BAM proteoliposomes, therefore perhaps 
the competition effect is minimal. However, both JB-95 and the control peptide 
L27-11 consistently demonstrate the same effect. It is unlikely that specific BAM 
inhibition is being observed in this case. Furthermore, the peptides in question 
were designed resembling cationic antimicrobial peptides (CAMPs)316, and are 
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therefore short, possessing positively charged residues. These consequently 
resemble the sequences of cell-penetrating peptides (CPP)317. CPPs can be 
synthetic or natural, but are characterised by their ability to cross the membrane 
with minimal toxic effect317. One of the best examples of CPPs is the Tat peptide 
of Human Immunodeficiency Virus (HIV)318. One mechanism by which CPPs are 
proposed to enter cells is membrane disruption. Therefore it is likely that the 
peptide inhibitors in question play a non-specific role in membrane disruption, 
which would be obscuring any specific effect in inhibition of BAM. While the 
peptide L27-11 has been specifically characterised as functioning against the OM 
protein LptD319, in the context of these assays, critical controls on the function of 
each peptide on empty liposomes would be necessary before assessing 
inhibitory effects towards BAM function. 
 
3.5.4 The effect of different chaperones of BAM-mediated OmpT folding 
The OmpT enzymatic assay also provides an effective and rapid way to 
determine the effects of many different players in the OMP folding system. In 
addition to probing the effects of substrate, BAM and inhibitors, it is also possible 
to examine the role of SurA in delivering OMPs to the BAM complex. This work 
was performed in conjunction with Julia Humes (University of Leeds), who was 
examining the role of the different domains of SurA on OMP folding and delivery 
to BAM.  
SurA is a conserved periplasmic chaperone, vital to the assembly of OMPs. SurA 
possesses four domains: two parvulin-like peptide prolyl isomerase domains (P1 
and P2) and N- and C-terminal domains166.  The removal of one or both PPIase 
domains does not damage OM integrity or lead to an increase in the σE stress 
response or reduction of membrane integrity171,172. However, the PPIase domains 
have been suggested to regulate the chaperone activity of the vital N-Ct domains 
of the chaperone172. It was of interest to test how the different domains of SurA 
may contribute to, or regulate, SurA chaperone ability. Variants were constructed 
that lacked either the P2 domain (ΔP2) or both PPIase 1 and 2 domains, fusing 
the N- and C-terminal domains together (N-Ct), see Methods 2.3.3. Various 
assays were then carried out to determine the ability of these different variants to 
bind OMPs, prevent aggregation and deliver to BAM (Humes&Schiffrin, in 
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preparation). The SurA variants were additionally compared with other E.coli 
chaperones (Skp, Spy and SecB).  
The OmpT assay was then used to determine the effectiveness of the SurA 
variants and other chaperones to fold and deliver OmpT to BAM. This exploits 
the finding described above, that in the absence of SurA there is no fluorescence 
increase (Figure 3-18). Aggregation data from light-scattering has shown that 
OmpT is aggregation prone (Humes&Schiffrin, in preparation), and requires a 
100-fold excess of SurA to prevent aggregation when incubated in glycine buffer 
containing 0.24 M NaCl. In the no Nacl conditions used in the OmpT activity 
assay, OmpT aggregation is greatly decreased. However, it is likely that in the 
absence of any SurA, some OmpT will aggregate and not be delivered to BAM.  
The aggregation data has shown that neither SurA variant was able to prevent 
the aggregation of OmpT as effectively as WT(Humes&Schiffrin, in preparation). 
The OmpT activity assay reports the ability of SurA to chaperone OmpT and 
deliver the OMP to the BAM complex for folding. The OmpT activity assay data 
(Figure 3-27) clearly demonstrate that while the ΔP2 variant was able to aid 
OmpT folding nearly to the level of wild-type SurA, all other chaperones 
functioned at a considerably lower level. The N-Ct SurA variant demonstrates 
worse folding of OmpT than wild-type or ΔP2 SurA. Additionally, other E.coli 
chaperones were tested. SurA and Skp are periplasmic chaperones of OMPs, 
while Spy is periplasmic and known to bind soluble proteins, and SecB interacts 
with OMPs in the cytoplasm, therefore it would be anticipated that they would 
have different OMP-chaperoning abilities. SecB is apparently unable to deliver 
substrate, with nearly no fluorescence increase seen (Figure 3-27) whilst the 
periplasmic chaperones (Skp and Spy) demonstrate some ability to chaperone 
for OmpT folding, less than that of wild-type SurA. As the different chaperones 
demonstrate different behaviour not adequately reflected in the t50 values, the 
initial rate of the folding assays were also quantified and compared (Figure 
3-27c). This more accurately reflects the ability of SurA variants and Skp to 
partially aid folding in the OmpT assay, while SecB and Spy cannot. The results 
present an interesting contrast with aggregation data, in which other 
chaperones, particularly Skp, may function nearly to WT levels. These 
chaperones, however are not able to perform SurA’s specific role of delivery to 




Figure 3-27: SurA variants and other chaperones assist in OmpT assay but 
not to wild-type levels. (a) Example OmpT assay comparing different chaperones in 
the same conditions. The setup in these experiments was 0.25 μM BAM, 5 μM OmpT, 
35 μM chaperone, 1mM fluorogenic peptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5 
b) t50 with average and SEM across a minimum of 3 repeats, with the exception of Spy, 
which is 2. c) Initial rate, calculated as slope for normalised fluorescence increase over 
initial 500 seconds. Shown is the average and SEM across a minimum of 3 repeats, with 
the exception of Spy, which is 2. SecB shows a negligible negative rate due to a 
considerable lag-time.  
 
Based on these results it appeared likely that other chaperones and SurA variants 
were functioning, simply not as effectively as wild-type SurA. This was 
additionally tested with a reduced chaperone and OMP concentration relative to 
BAM (2 M OmpT, 20 M chaperone, 0.25 M BAM) and the same trend was 
observed across the chaperones. Additionally, whether the SurA variants could 
function as effectively as wild-type SurA if used at an increased chaperone: OMP 
ratio was explored. Particularly for the chaperone N-Ct, which is considerably 
smaller than WT SurA, it may simply not have sufficient surface area to bind 
substrate OMPs when used at an equivalent concentration. The typical 
concentrations in the OmpT assay are 35 M SurA, with 5 M OmpT. The setup 
of this assay already involves a seven-fold excess of chaperone over substrate. 
This was now tested for N-Ct at 2- and 4- fold greater chaperone:substrate ratio 
(effective ratio 14- and 28- fold excess) and with wild-type SurA at a 4-fold greater 
concentration for comparison. The comparison of t50 values for repeated assays 
across the conditions (Figure 3-28) demonstrates that increasing the amount of 
SurA does not alter folding t50. Assays containing N-Ct SurA consistently 
demonstrate a higher t50, indicating slower folding, than those with wild-type 
SurA. In this assay, the ability of wild-type SurA to chaperone OmpT cannot be 
matched even by a vast excess of N-Ct SurA. In conclusion, data from the OmpT 
assay has contributed to understanding the roles of SurA domains. This 
126 
 
additionally shows that OMP delivery, performed by SurA in the OmpT assay may 
differ from its role preventing aggregation.   
 
Figure 3-28: Comparison of t50 for WT and N-Ct SurA at increased 
SurA:OMP ratios. The average and SEM is shown across a minimum of three repeats. 
The standard in this case (1x) was 35 M SurA, with 5 M OmpT, 0.25 M BAM, 1 mM 
peptide, 0.8 M urea in 50 mM glycine-NaOH pH 9.5. All other conditions were kept 
constant and only the concentration of chaperone altered, see Methods, Section 2.12.3 
for details. Both wild-type SurA results are significantly different from all N-Ct sample 
results, but within wild-type and N-Ct subsets differences are not significant. Two sample 





3.6 Membrane mimetics 
In any discussion of membrane proteins one cannot ignore the effect of the 
membrane on protein function. The examples discussed in this thesis primarily 
involve proteoliposomes: either synthetic lipid 100 nm LUVs, or proteoliposomes 
of E.coli polar lipid extract, created by dialysis or dilution and structural studies in 
detergent. It was therefore also of interest to study the BAM complex utilising 
other membrane mimetics. 
Protein-supported nanodiscs involve the reconstitution of a membrane protein 
into phospholipids encircled by a helical protein320. In this case, the membrane 
protein of interest is solubilized in detergent and mixed with phospholipids and 
the “membrane scaffolding protein” (MSP). The detergent is removed and the 
phospholipid assembles into a bilayer, around the target protein. Two molecules 
of MSP wrap around the edges, in a belt-like fashion, with one covering each side 
of the hydrophobic alkyl chains of the leaflet (Figure 3-29c)306, a conformation 
confirmed by magic-angle spinning NMR321. Nanodiscs are attractive as the MSP 
belt maintains stability, and structural and functional studies of the membrane 
protein may be carried out on the same sample320. While there is as yet no crystal 
structure of membrane proteins in nanodiscs322, cryo-EM has been used, with the 
structure of a ryanodine receptor resolved to a 6.1 A resolution323. Obtaining a 
cryo-EM structure of BAM in a nanodisc would be the first insight into the structure 
of the complex in a lipid, with the added advantage that activity assays can be 
applied to the same sample.  
Preparation of nanodiscs containing the BAM complex resembles preparation of 
proteoliposomes. It first involves purification of BAM from the membrane using 
detergent. Although a non-ionic detergent such as DDM is considered ‘mild’, and 
less likely to denature or inactivate a protein324, it is clearly disruptive to the native 
environment. This is why the use of SMALPs is an attractive new possibility. The 
SMALP, or styrene-maleic acid (SMA) lipid particle, uses the amphiphathic 
synthetic copolymer SMA to extract proteins from their native membrane, in a pH-
dependent manner (Figure 3-29a&b)325. The protein can then be purified by 
affinity chromatography or size-exclusion chromatography, and remains 
encapsulated within its native lipid by a belt of the copolymer326. This is evidently 
similar to the use of amphipathic polymers, named amphipols327, but is now 
directly able to solubilise the biological membrane326. This technique has slowly 
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advanced since its advent in 2009305, where one of its first demonstrations was 
with the OMP PagP, and the enzyme was shown to be active. SMALPs have 
already lent themselves well to structural studies. One crystal structure, of 
Haloquadratum walsbyi bacteriorhodopsin was solved in lipidic cubic phase, 
reconstituted directly from SMALPS328. Cryo-EM has been used to solve the 
structure in SMALPs of the ABC transporter P-glycoprotein/ABCB1 by single 
particle cryo-EM329 and the multidrug efflux pump AcrB has been visualised by 
negative stain single particle EM330. 
Like nanodiscs, SMALPs make concurrent structural and functional studies of 
membrane proteins possible, and as yet there are no published examples of BAM 
reconstitution in SMALPs, therefore this was an exciting and novel project. 
 
 
Figure 3-29: SMALP and Nanodisc Reconstitution of Membrane Proteins. a) 
Schematic of solubilisation of membrane proteins by SMA. Lipids of the membrane are 
shown in orange, the SMA in purple, with multi-coloured membrane proteins 
encapsulated. Image adapted from Pollock et al., 2018 326. b) Structure of Styrene-Maleic 
acid. The most commonly used, and that used in this work is 2:1 styrene:maleic acid. c) 
Composition of MSP1 nanodisc with two membrane-scaffolding proteins (shown in gold 




3.6.1 Preparation of BAM in SMALPs 
In order to extract BAM with SMALPs, the same initial protocol was followed to 
grow and express BAM in E.coli and extract membranes by ultracentrifugation 
(Methods, Section 2.3.5). Following the first ultracentrifugation step, membranes 
were hand homogenised in resuspension buffer (50 mM Tris, 0.5 M NaCl, 1 mM 
DTT, pH 8). This was then mixed with SMA at 5% (w/v) in the same buffer and 
allowed to resuspend for ~3 hours. The insoluble fraction was pelleted, the 
supernatant filtered and applied to a HisTrap column. Following overnight binding 
to HisTrap, the sample was eluted and analysed by SDS-PAGE. The original 
protocol involved a second purification step by SEC. However, significant 
amounts of protein were lost in pre- and post-SEC concentrating and on the 
column, likely due to the low solubility of SMA. This is immediately evident in 
SDS-PAGE analysis of elution fractions from the nickel affinity and size exclusion 
chromatography columns (Figure 3-30).  
 
Figure 3-30: Analysis of BAM-SMALPs purification by nickel affinity and 
SEC by SDS-PAGE. Following solubilisation of BAM membranes with SMA the 
sample is centrifuged and a scraping of the insoluble pellet resuspended in SDS loading 
buffer (insoluble). The supernatant is filtered and applied to a 5 mL HisTrap column. 
Samples are analysed for the pre-Ni solution, flow-through (FT) and Wash (with 10 mM 
imidazole). Sample is eluted in twenty 1 mL fractions with buffer containing 500 mM 
imidazole. The elution fractions containing BAM are pooled, concentrated 10-fold (pre-
SEC sample shown in 1/10 dilution) and applied in 0.5mL injections to an analytical 
Superdex S200, whereupon 0.5 mL fractions are collected. No distinct peak was seen in 
SEC by monitoring of A280 and instead fractions were analysed across the typical volume 
where BAM is anticipated to elute. Shown are samples of the solution pre-SEC and 
representative fractions across the volume range analysed. 
 
At this point the protocol was repeated using a phosphate-based buffer with 
glycerol (50 mM phosphate pH 8, 500 mM NaCl, 10 % glycerol) instead of Tris-
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based throughout, following a published protocol304, see Methods (2.14) for 
details. This increased stability of the SMALP samples, but did not increase yield 
post-SEC. It was noted that following purification by nickel affinity 
chromatography the sample was reasonably pure; this was improved by carrying 
out additional washes of the Ni column pre- and post- binding of sample, at 
increasing low (20-100 mM) imidazole concentrations prior to elution. Following 
analysis by SDS-PAGE (Figure 3-31) it was concluded that the SEC step was 
unnecessary in this case, and therefore final yield could be significantly 
increased. 
 
Figure 3-31: Purification of BAM-SMALPs by nickel affinity. As before, 
samples were taken of the insoluble pellet, solution pre-HisTrap, flow-through and 2 
washes. Resuspension of membranes and subsequent steps were carried out with 50 
mM phosphate pH 8, 500 mM NaCl, 10 % (v/v) glycerol. Wash1 was carried out with 
buffer containing 20 mM imidazole and wash2 100 mM imidazole. Sample is eluted from 
the HisTrap in twenty 1 mL fractions with buffer containing 500 mM imidazole. Sample 
was diluted in non-imidazole buffer prior to concentrating the protein or dialysed following 
the concentrating step. 
 
BAM protein concentration was measured by the BCA assay (Methods, Section 





3.6.2 Preparation of BAM nanodiscs 
Unlike SMALPs which offer an alternative method of extraction from the 
membrane and conservation of native lipids, nanodiscs were created from 
membrane scaffold proteins (MSPs)  binding around detergent-solubilised pure 
BAM and E.coli polar lipid extract. In this way they more closely resemble 
proteoliposomes, but are an attractive alternative for structural studies. There is 
considerable precedent in cryo-EM studies of MSP-nanodiscs323,331,332. It would 
be highly desirable for our work to be able to carry out structural and functional 
studies of the same sample, for example with disulphide-locked BAM complex 
variants.   
The preparation of MSP-nanodiscs involves the preparation of the BAM complex 
in DDM as previously described (Methods 2.3.5) and preparation of membrane 
scaffold proteins. There are a number of different choices of membrane scaffold 
proteins, however based on the size and literature precedent, we utilized 
MSP1D1274. This protein was kindly expressed and purified by Dr Anton 
Calabrese (Methods, Section 2.3.8) and utilised in His-tagged or cleaved forms. 
Simply, creation of nanodiscs involves mixing of BAM, scaffold protein and lipid 
with multiple washes with Biobeads to remove detergent and promote formation 
of discs (for details see Methods Section 2.15.2). While SDS-PAGE 
demonstrated that all original components were present, it was desirable to purify 
the sample further, and to verify integrity of the disc.  
One method to demonstrate formation of the disc is native PAGE274,333. If the 
scaffold protein has bound and encapsulated the BAM complex then the nanodisc 
should migrate at a molecular weight higher than that of the BAM complex in 
DDM. Protein in DDM detergent, nanodisc and SMALP were analysed and 
compared by native PAGE (Methods, Section 2.6.4) (Figure 3-32). Detergent-
solubilised BAM consistently migrated as a double band by native PAGE. The 
reason for this is unclear, as it may denote two conformations of BAM, but has 
been consistently observed in our studies of the BAM complex. Interestingly, 
while SMALPS show the same migration pattern, with a double band, nanodiscs 
migrate as a single, higher molecular weight band. This verifies the formation of 
the nanodisc, with the presence of the membrane-scaffold proteins. The single 
band implies that the nanodisc is possibly constraining the movements of BAM 






Figure 3-32: Native PAGE of BAM in detergent, nanodiscs and SMALPs. 
Blue-Native PAGE was carried out to demonstrate presence of the BAM complex after 
its reconstitution into different environments. Precast Invitrogen NativePAGE 4-16 % Bis-
Tris gels were used according to the manufacturer’s instructions. Approximately 10 μg 
of each sample were loaded, as well as Native Mark Standard (LifeTechnologies). 
Electrophoresis is carried out at 150 V for 120 minutes at room temperature (see 
Methods, Section 2.6.4). 
 
One method for analysis and purification of the sample was SEC, in which the 
sample should elute as a single peak, containing all component proteins. SEC 
was attempted for multiple preparations of nanodiscs. However, while increasing 
purity, SEC caused a reduction in yield. Comparison of analysis by SDS-PAGE 
(Figure 3-33) of the preSEC and SEC fractions clearly shows a significant loss of 
protein following size-exclusion. The SEC trace, however, shows a single peak, 






Figure 3-33: Purification of BAM-containing nanodiscs using SEC. Example 
trace for analysis of BAM nanodiscs on analytical Superdex S200 column. (b) SDS-
PAGE analysis for fractions across the size-exclusion peak, indicated with black bars on 
(a). 
 
SEC and native PAGE provide proof of formation of nanodiscs, and while SEC 
additionally increases purity, similarly to with SMALPs there was significant loss 
of yield following SEC. While nanodiscs samples are less likely to be dropping 
below solubility limits during chromatography, recovery after SEC was low. 
Additionally, as the starting concentration of BAM in the nanodiscs is low (~6 μM) 
significant loss of protein renders the desired activity assays impossible. A 
suitable concentration and volume of protein is required to both accurately assay 
concentration and carry out activity assays. For these reasons it was decided to 
increase the scale of the original nanodisc preparation (from 300 μL to 1 mL), 
while maintaining the original start concentration of 6 μM BAM and carry out 
nickel affinity purification rather than SEC. In order to carry out nickel affinity 
purification of BAM-containing nanodiscs it is necessary to use MSP1D1 with the 
His-tag cleaved. The nickel beads bind the His-tag on BamE and unbound 
MSP1D1 is washed away. Additionally, the sample can be eluted in a smaller 
volume than start volume, thus increasing the concentration. 
Preparation and purification of nanodiscs was also carried out for different BAM 
complex variants. Shown below is the simultaneous purification carried out for 
MSP1D1 nanodiscs of wild-type (WT) and lid-lock (LL) variants (Figure 3-34). 
This demonstrates that while small amounts of protein are lost in every step, the 
final product is pure and at high concentration (elution sample diluted 1:10, all 
other samples undiluted). Empty nanodiscs were usually prepared in parallel and 
used as a control, typically with untagged MSP1D1, as with the BAM nanodiscs. 
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Where necessary, His-tagged MSP1D1 was used for Empty discs and further 
purification or concentration could be achieved with Nickel affinity 
chromatography. When not immediately used, samples of nanodiscs were snap-
frozen and stored at -80 ºC. 
 
Figure 3-34: Purification of BAM nanodiscs by Ni affinity. The BAM nanodisc 
preparation in a 1 mL sample (Pre Ni) was applied to 100 μL pre-washed nickel beads. 
Following 3 hours incubation, the beads were washed twice with buffer containing 50 
mM imidazole and sample eluted with buffer containing 500 mM imidazole. A small 
sample of beads was also boiled in SDS loading buffer demonstrating that some protein 
was still bound. All nanodiscs contain untagged MSP1D1, E= empty nanodiscs, BAM 
nanodiscs contain WT = wild-type or LL =  lid-lock BAM variants. 
 
3.6.3 Activity of BAM in membrane mimetics 
As previously discussed (0), the use of membrane mimetics is attractive as they 
not only would enable future structural studies such as cryo-EM in the native lipid, 
but functional studies could be carried out on the same preparation of protein. 
Following preparation of BAM in MSP1D1 nanodiscs and SMALPs, the OmpT 
activity assay was carried out. Shown is one representative example of the 
activity assay for BAM proteoliposomes, nanodiscs and SMALPs and empty 
proteoliposomes and nanodiscs. The t50 of BAM-containing samples was 
calculated and compared across a minimum of three repeats (Figure 3-35).   
It is evident that both BAM nanodiscs and SMALPs appear to show activity in 
folding OmpT while empty nanodiscs consistently show no activity. This is the 
first known reconstitution of BAM in SMALPs and only the second time that BAM 
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complex reconstitution in nanodiscs has been demonstrated and proved to form 
active complex274.  This result is significant and interesting, as the activity of BAM 
in nanodiscs is evidence against models of BAM acting in an oligomeric complex. 
The nature of the MSP-encapsulated BAM permits no room for multiple copies of 
the BAM complex. Activity in these nanodiscs means that folding of protein into 
must occur by one copy of BAM. BAM-containing SMALPs with more native-like 
lipid, show significant activity in folding OmpT, intermediate between nanodiscs 
and proteoliposomes, demonstrating once again the importance of the 
membrane environment. 
 
Figure 3-35: BAM-SMALPs and nanodiscs show activity in OmpT assay. (a) 
An example OmpT assay comparing WT BAM in proteoliposomes, nanodiscs and 
SMALPs and empty proteoliposomes and nanodiscs.  The assay was set up as 
previously, with 0.25 μM BAM, 5 μM OmpT, 35 μM SurA, 1mM fluorogenic peptide, 0.8 
M urea in 50 mM glycine-NaOH pH 9.5. All proteoliposomes, SMALPs and nanodiscs 
were assayed for accurate BAM concentration prior to use using the Pierce BCA Protein 
Assay, and diluted to an appropriate concentration. Empty samples were used to an 
equivalent amount of lipid (proteoliposomes) or concentration of MSP1D1. (b) Average 
t50 with SEM across a minimum of three replicates.   
 
The assay for analysis of tOmpA folding by BAM by SDS-PAGE was optimised 
around this time (see Chapter 5, Section 5.5) and one experiment was carried 
out with wild-type BAM nanodiscs. While BAM proteoliposomes show efficient 
folding of tOmpA in these conditions, with folding nearly complete after one hour, 
the BAM nanodiscs show no appearance of a tOmpA folded band (Figure 3-36). 
This is highly surprising when compared to OmpT data that consistently shows 
activity of BAM in nanodiscs. Further experiments will be needed to understand 
this difference in activity, for example by tOmpA folding and analysis by SDS-





Figure 3-36: tOmpA shows no folding by SDS-PAGE with WT nanodiscs. a) 
SDS-PAGE analysis of tOmpA folding demonstrates no appearance of the folded band 
over time. b) Comparison of folding of tOmpA by wild-type BAM in proteoliposomes at 1 
hour, which shows near completion of folding. The assay contains 2 μM tOmpA, 10 μM 
SurA, 1 μM wild-type BAM in nanodiscs, 0.8 M urea in 20 mM Tris-HCl pH 8, 150 mM 
NaCl. The reaction is maintained at 25 ºC, samples are taken at the indicated timepoints 
and quenched by addition to 6x SDS loading buffer. One sample is boiled for 10 minutes, 
the rest are electrophoresed without boiling. One control lane contains Empty nanodiscs 
at equivalent concentrations of MSP1D1, and other conditions identically, for which 





The work carried out in this chapter presents structural studies of the BAM 
complex and sets the scene for further work understanding BAM complex activity. 
The optimization of protein and proteoliposome preparation and of the OmpT 
assay permits the investigation into BAM complex catalysis presented in Chapter 
5.  
The optimization of expression and purification of the BAM complex in DDM 
micelles as discussed in this chapter permitted its analysis by cryo-EM, carried 
out by Dr Matthew Iadanza (University of Leeds). This remains the only EM 
structure of the complex and the structure is the sole representation of the full 
BamABCDE complex containing BamA in a lateral-open conformation. This 
refutes the hypothesis that the presence of BamB is linked to the lateral closed 
state of BamA32,207-210. Instead the change in POTRA domain conformation, 
linked to presence of BamB suggests a mechanism of communication across the 
complex. Additionally, the detergent micelle, visible in EM but not crystal 
structures, creates a membrane mimetic and highlights regions of the BAM 
complex for potential membrane interactions. This is particularly evident in BamD 
where the location for membrane interaction causes a hinge and conformational 
change within the protein (Figure 3-11 & Figure 3-12). 
This chapter also delves into understanding the assay widely used for BAM 
complex activity: the OmpT protease assay. BAM within the proteoliposomes 
generated by the ‘dialysis’ method developed here is  more active, as measured 
by this assay, than those produced by ‘dilution’ here or in the 
literature159,189,272,274. Optimisation of the OmpT protocol has produced a robust 
assay, consistent across proteoliposome batches, with measurable kinetics 
which can be used to tease out elements of BAM-OMP interaction. Whilst there 
are aspects which remain puzzling, the assay has proved useful, both in 
determining the effects of BAM dynamics, as will be discussed in Chapter 5, and 
in screening inhibitors and examining SurA mutations. The screening of potential 
inhibitors in two cases (Figure 3-24 BamD and Peptide2) has determined that 
these inhibitors are not significantly active in this assay, demonstrating little effect 
when at significant excess over the proposed substrate. In the third case, 
however (Figure 3-26, JB-95), it is evident that a different assay is required. The 
macrocyclic peptide JB-95 is of considerable interest as a potential inhibitor of 
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the BAM complex47, but due to possessing sequential charged residues, cannot 
be used in an assay containing OmpT. Further work using this peptide is clearly 
of interest and has been begun, by my colleague Dr Bob Schiffrin, using the 
tOmpA folding assay discussed in Chapter 5. The results of this assay have 
demonstrated that both Peptide 2 and JB-95 are effective inhibitors of BAM-
assisted tOmpA folding when utilised at 20- and 50- fold excess of BAM, 
respectively (Dr Bob Schiffrin, personal communication). As BAM concentration 
in this assay is only 1 μM this still represents inhibition at a low concentration. 
However, as discussed above, controls are necessary with JB-95 to ensure that 
the peptide is not functioning as a cell-penetrating peptide and disrupting the 
membrane in a non-specific manner. 
Examination of the SurA variants by substitution in the OmpT assay appears to 
show that while ΔP2 SurA is capable of fulfilling the function of WT SurA, N-Ct 
SurA and other chaperones (Figure 3-27) are not. The capability of wild-type SurA 
is not recovered at lower OmpT concentrations or increased chaperone:OmpT 
ratio (Figure 3-28). Additionally, while binding with nanomolar Kd was detected 
for WT SurA to the BAM complex in detergent, no binding could be accurately 
measured for the mutants, implying a much weaker interaction (Julia Humes, 
unpublished data). 
However, this does not currently agree with data using the SurA variants in the 
tOmpA folding assay (Humes & Schiffrin, in preparation), which show that the 
ΔP2 SurA is only partially active compared with WT, and more similar to N-Ct 
SurA. The results seen for OmpT are therefore unexpected, particularly as OmpT 
is a slightly larger substrate, and aggregation data suggest that the P2 domain of 
SurA is required to prevent aggregation of OmpT (Humes&Schiffrin, in 
preparation). This difference requires further study with folding of OmpT or other 
OMPs by the BAM complex as measured by SDS-PAGE to resolve the substrate 
specificity of the effects observed. 
Finally, two membrane mimetics were used for BAM complex studies: SMALPs 
and nanodiscs. For both of these purification of the sample was optimised and 
function of BAM in both environments demonstrated using the OmpT assay.  This 
is the first demonstration that BAM can be purified using SMALPs to create an 
active complex, and only the second demonstration of reconstitution in 
nanodiscs274. On-going work is now proceeding, using cryo-EM in both of these 
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alternative forms to obtain structural information, and to elucidate how the 
membrane surrounding BAM may impact its structure.  
A wide range of SMA-like polymers, of varying sizes and physical properties are 
being developed. Some of these, of longer size than the 2:1 styrene:maleic acid 
SMA used here325, may be more suitable and facilitate studies with a large 
complex such as BAM. 
The sample of BAM in nanodiscs, identical to that presented here, is currently 
being analysed by Dr Matt Iadanza by cryo-EM. This initial data is highly 
interesting, with a bigger variation in BAM structures than noticed in previous 
detergent datasets. This suggests that the complex is considerably more dynamic 
in the lipid bilayer present in the nanodisc than in a detergent micelle. This is in 
contrast to data showing that OmpA is more dynamic in a micelle than lipid 
bilayer334, but strongly supported by NMR data showing increased dynamics of 
OmpX in DMPC-nanodiscs compared to a detergent micelle335. This highlights 








4 Results Chapter 2: Investigating the lateral gating hypothesis 
and the role of the β-signal for BamA-assisted OMP folding 
4.1 Introduction 
The work described in this chapter addresses two aspects of existing models of 
BAM catalysis: lateral gating and targeting by the β-signal. These concepts are 
not mutually exclusive and are in fact complementary, although one may be 
correct without the other. The experiments and hypotheses behind both concepts 
have been introduced (1.10-4 and 1.11) as well as the alternative models existing 
in the case of lateral gating (1.10) and are introduced again only briefly here. 
4.1.1 Lateral gating in BamA 
The lateral opening in the BAM complex is the theory that BamA opens via a 
separation of the β1 and β16 strands and this is linked to its catalytic mechanism 
in folding OMPs. There is a long-existing “BamA hybrid barrel” model212 wherein 
the opening of the strands allows substrate OMP hairpins to template on and form 
a new, mixed OMP barrel before the substrate buds off into the membrane 
(Figure 4-1a). New models integrate aspects of BamA lateral opening while 
suggesting a hybrid barrel is energetically unfavourable and unlikely33 and it is 
possible templating occurs on one strand while the barrel does not close. 
Irregardless, the lateral opening of BamA has now been accepted to occur. This 
was originally hypothesised from molecular dynamics simulations, and supported 
by experiments demonstrating that introduction of cysteines on β1 and β16 to 
disulphide cross-link BamA in the lateral closed conformation caused synthetic 
lethality (Figure 4-1b)199.  Recent structures of the BAM complex207-210, however, 
show BamA in both the lateral open and closed conformation, proving that this 
dynamic change occurs (Figure 4-1c). The observed conformations sampled, and 
the in vivo lethality of disulphide cross-linking, however, do not explain how BamA 
lateral gating links to functional activity. It was a key aim of this thesis to examine 
the role of lateral gating, beginning in this chapter with its importance in in vitro 
catalytic activity of isolated BamA. The aim was to utilise the same cysteine pairs 
demonstrating lethality in vivo, introduce these in in vitro experiments on BamA-
catalysed folding and analyse their potential inhibition of BamA function. The data 
ultimately obtained, on BamA-assisted folding of tOmpA in DMPC LUVs (Section 
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4.2.5) is published in Schiffrin et al., 2017, “Effects of Periplasmic Chaperones 
and Membrane Thickness on BamA-Catalyzed Outer-Membrane Protein 
Folding”, Journal of Molecular Biology, 429, 3776-3792. For this, I carried out all 
experiments and data analysis on the BamA variants, and the manuscript was 
largely written by Dr Bob Schiffrin (University of Leeds) with input from all authors. 
 
Figure 4-1: Lateral opening of BamA. a) Hypothesised model of BamA hybrid 
barrel formation and substrate budding with substrate in red and BamA in blue. Adapted 
from Schiffrin et al., (2017)33. b) Cysteine pairs along β1 and β16 which are lethal in vivo. 
Green denotes disulfides which would point into the membrane surrounding BamA, 
whereas yellow denotes those which would point into the lumen. Figure adapted from 
Noinaj et al., (2014)199. c) BamA barrel (residues 424-806) seen in lateral-open 
conformation from the EM structure of the complex [5LJ0]210. 
 
4.1.2 The β-signal 
The concept of the β-signal is that a ‘signal sequence’ to direct OMPs to BAM is 
encoded within the sequence28,71,211,285. As previously discussed (Introduction 
1.11), this sequence is highly conserved, is characterised by alternating 
hydrophobic residues, and a vital C-terminal Phe285. The sequence is species-
specific211 and mutagenesis, while not necessarily detrimental to folding, usually 
affects BAM-catalysed folding71. 
Direct studies of the role of the β-signal remain scattered and minimal, with a 
mixture of in vivo and in vitro data. We wished to examine the hypothesis of 
species-specificity at the residue level, and the high conservation of the sequence 
by analysing OMP folding and its catalysis by BamA and the BAM complex. Two 
different approaches were taken, firstly for the species specificity and secondly 
examining a single conserved residue: the highly conserved Gly approximately 
143 
 
six residues from the C-terminus (Figure 4-2). It was hypothesised that both 
approaches would yield OMPs capable of folding but with altered recognition by 
BamA, and thus altered BamA- or BAM complex- catalysed folding.  
 
Figure 4-2: OMP β-signal comparisons. (a) The C-terminal 10 amino acids of a 
selection of OMPs from E.coli displays the high level of conservation in the β-signal. 
There is a pattern of alternating hydrophobic residues, highlighted in blue, a conserved 
terminal Phe, highlighted in yellow and a mostly conserved Gly, highlighted in green. (b) 
Comparison of the C-terminal 10 amino acids of E.coli OmpA with N.meningitidis PorA, 
numbered by alternate residues from the C-terminus (eg. +1). Residues of tOmpA 
mutated to those of PorA are highlighted in orange. Other colours are as in (a). 
 
In the first approach, a tOmpA variant was created that incorporated the 
penultimate three residues of N.meningitidis PorA, replacing the corresponding 
residues in tOmpA (Figure 4-2b). In vitro studies measuring channel opening of 
BamA by OMP sequences had suggested incompatability between β-signal 
sequences from Neisseria and Escherichia due to the charged residue found 
before the C-terminal Phe in Neisseria sequences (+2 position)211. Later 
bioinformatics analysis suggested incompatibility was more likely due to the 
Histidine found at the +3 position in Neisseria OMPs. Comparison of frequency 
plots for Escherichia and Neisseria C-terminal signal peptides (Figure 4-3) 
demonstrates that alternating hydrophobic residues and C-terminal Phe are 
conserved across both genera while the Histidine that is common at the +3 
position in Neisseria is absent in Escherichia286. As Escherichia coli tOmpA 
sequence possesses a positively charged +2 residue (Arg) but not the distinctive 
Histidine (Figure 4-2), this was a good candidate for testing how the substitution 




Figure 4-3: Comparison of C-terminal insertion signal for (a)Escherichia 
and (b)Neisseria strains. Frequency plots are constructed with C-terminal insertion 
signal peptides, with 188 unique peptides from 31 Escherchia strains and 50 unique 
peptides of 7 Neisseria strains. The +3 position is indicated with an arrow. None of the 
Escherichia C-terminal β-strands in the database used have His at the +3 position, 
whereas it is found in up to 57% of the peptides derived from β-Proteobacteria. Figure 
adapted from Paramasivam et al., (2012)286. 
 
The structure of tOmpA with the residues of interest to be mutated is shown 
(Figure 4-4). 
 
Figure 4-4: Structure of tOmpA highlighting mutagenesis. tOmpA [1BXW]153 is 
shown with residues SYR 168-170 highlighted in red b) Zoom centred on residues SYR 
168-170 with a stick representation. c) Same region as (b) displaying mutagenesis of 
residues: S168R, Y169H, R170K. Images were created in Pymol. 
 
The second aspect of investigating the role of the β-signal in BAM-catalysed OMP 
folding examines the highly conserved Gly approximately six residues from the 
C-terminus. This Gly is conserved across a variety of OMPs within E.coli (Figure 




Figure 4-5: Frequency plot of C-terminal β-strands from Proteobacteria. 
Figure from Paramasivam et al.286, demonstrates the frequency of the conserved Gly 
across Proteobacteria OMPs. Plots show (a) -Proteobacteria (b) β-Proteobacteria (c) 
γ-Proteobacteria  (d) δ-Proteobacteria (e) –Proteobacteria. For the +6 position, glycine 
is the amino acid most likely to occur, across all Proteobacteria. This residue 
conservation is only found for the +6 Gly and the terminal Phe residues. 
 
These studies initially utilised OmpT, with the intention of examining the effect of 
mutating the conserved Gly measuring catalysis of folding with the full BAM 
complex using the OmpT assay (Chapter 3, Section 3.5). Initially a mutant of 
OmpT, Gly306Pro, was designed, purified and characterised, and subsequently 
a further OmpT variant was made, with the conserved Gly mutated to Ala 
(G306A). Finally, to investigate the effect of substitution of the equivalent Gly in 
another OMP, tOmpA-G166A was generated and analysed. The structures of the 




Figure 4-6 Structural models of β-signal mutants a) OmpT [1I78]336 with G306 
highlighted in red. (b) Zoom centred on OmpT-G306  with a stick representation in red 
displaying predicted conformation of the mutant b) G306P and c) G306A. d) 
Transmembrane domain of OmpA (tOmpA) [1BXW]153 with G166 highlighted in red e) 
Zoom centred on tOmpA-G166, with a stick representation displaying mutagenesis of 
G166A.  
 
As previously discussed, little work has been performed previously on unravelling 
the role of the OMP β-signal in folding and insertion by detailed in vitro studies. 
In particular, studies are lacking examining how variation in the β-signal affects 
recognition by BAM. The aim of this work, therefore, was to investigate how 
BamA-mediated catalysis of folding is impacted by changes to the β-signal. This 
was performed measuring BamA- and the BAM complex-catalysed folding in 
vitro. Additionally how the folding of one mutant, tOmpA-RHK is catalysed by the 







4.2 Lateral gating in BamA 
The importance of lateral gating in BamA function has been supported by in vivo 
data showing that double cysteine mutants purported to close the BamA gate are 
lethal to E.coli199. These variants however, have not previously been examined 
in vitro. To address this question, the same mutagenesis approach as that used 
for the in vivo studies was employed. Firstly, a Cys-free BamA mutant 
(C690S/C700S) was created and then new double cysteine pairs to disulphide 
lock the BamA lateral gate were introduced. Although site-directed mutagenesis 
to create four of the disulphide pairs reported in the literature was initially 
attempted (G429C/T809C, I430C/K808C, G431C/G807C and G433C/N805C) 
(Figure 4-1)199, the I430C/K808C and G431C/G807C pairs were the first to be 
cloned successfully. These BamA mutants were created using Q5 site-directed 
mutagenesis (primers and protocol are detailed in Methods 2.1.5 and 2.2.3 
respectively). Consequently, these double cysteine pairs, the Cys-free pseudo 
wild-type, and wild-type BamA were those expressed and characterised as 
described in the sections below. 
 
4.2.1 Expression and purification of BamA and its variants 
Following successful generation of the mutants of BamA by site-directed 
mutagenesis, the variant proteins were expressed and purified as described in 
Methods Section 2.3.1. Briefly, each protein was expressed in E.coli BL21 (DE3) 
and purified by inclusion body isolation followed by size exclusion 
chromatography under denaturing conditions (see Methods Section 2.3.1 for 
details). The elution profile obtained by SEC for each BamA variant is shown in 
Figure 4-7. The protein composition of the elution peak was visualised by 
electrophoresis on SDS-PAGE (Figure 4-7), from which a clear band for BamA 
was observed. Fractions were then selected to be pooled and concentrated (see 
Section 2.1 for details). BamA wild-type (wt), Cys-free (C690S/C700S), 
BamA430/808 (C690S/C700S/I430C/K808C) and BamA431/807(C690S/C700S/ 
G431C/G807C) were thus all successfully produced, with yields of 141, 109, 159 





Figure 4-7: Purification of BamA. Shown is an example SEC trace of purification of 
BamA and fractions analysed by SDS-PAGE for a) wt; b) Cys-free ; c) BamA430/808 ; d) 
BamA431/807. SEC was carried out using a Sephacryl-S200 column with 25 mM Tris, 6M 
GuHCl pH 8 (see Methods 2.3.1 for details). Three fractions are shown by SDS-PAGE 
across the peak of protein elution, indicated on the elution trace with black bars. BamA 
has a molecular mass of 88 kDa and can be seen compared to the protein marker to the 
left of each gel image. Protein is shown buffer-exchanged from 25 mM Tris, 6M GuHCl 
pH 8 to 8 M urea, 50 mM glycine-NaOH pH 9.5 for a) and b), but not c) and d) thus the 
apparent smearing of protein bands. For c) and d) as elution fractions are not clear, a 
final (F) sample, of pooled, purified fractions is shown, demonstrating these proteins to 
be pure. 
 
4.2.2 Characterisation of BamA variants 
The need to assess BamA variants includes their characterisation in vitro followed 
by an assessment of their catalytic capabilities on OMP folding. While initial 
experiments showed that the disulphide variants are expressed in cells199 an 
assessment of their ability to be reconstituted into liposomes in vitro had not been 
carried out. 
This chapter focuses principally on folding assays in synthetic Large Unilamellar 
Vesicles (LUVs), and using BamA catalytic activity to unravel these intricacies. 
As discussed (Introduction Section 1.8), while the native lipid head groups in the 
outer membrane impose a kinetic barrier on OMP folding, this is relieved by 
BamA71. In studies of membrane protein folding, lipids with phosphatidylcholine 
head groups have been widely employed71,72 as these support fast folding. To 
allow reliable and measurable kinetics using tryptophan fluorescence 
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emission163,250,337; initial experiments in this chapter used 100 nm LUVs created 
from the 11-carbon chain diundecanoyl-sn-glycero-3-phosphatidylcholine 
(DUPC). For these lipid preparations, protein folding was carried out at 25 °C in 
50 mM glycine-NaOH, pH 9.5 (see Methods Sections 2.7 and 2.8 for details). 
4.2.2.1 Band-shift assays in DUPC liposomes 
BamA protein variants were folded into 100 nm DUPC liposomes and folding was 
verified by means of a band shift assay (Figure 4-8) using semi-native (cold) SDS-
PAGE in low (0.1 % (w/v)) SDS (Methods Section 2.6.2). This permits separation 
of bands of folded and unfolded BamA307. This heat modifiability is a common 
property of OMPs72,307 and can be used to monitor the progress and yield of OMP 
folding and insertion into lipid bilayers71,72,79,159,189. Samples are boiled (+) to 
cause unfolding, while those remaining unboiled (-), and thus folded, migrate 
faster in semi-native SDS-PAGE. For BamA it is necessary to use semi-native 
conditions and low SDS to maintain the stability of the BamA barrel, whereas for 
other OMP substrates, the same heat modifiability folding band-shift can be seen 
without the need for low temperatures and concentrations of SDS (Methods 
Section 2.6.2).  
The band-shift assay (Figure 4-8) demonstrated that all of the BamA variants 
created fold successfully into the DUPC liposomes. Analysis of the bandshift by 
densitometry indicated that although not matching the wild-type folding yield of 
90%, high (~70%) folding efficiency is seen for all BamA variants. A discrepancy 
is seen in this experiment between anticipated and observed concentrations of 
BamA variants due to mis-measurement of the stock concentration, this was 






Figure 4-8: Bandshift analysis of all BamA variants using semi-native SDS 
PAGE. BamA variants of wild-type, Cys-free, BamA430/808 and BamA431/807 proteins 
folded into DUPC liposomes, with no boiling (-) or unfolded after boiling (+). Samples 
contained 0.8 μM BamA, 1.28 mM DUPC (molar LPR 1600:1), and 0.24 M urea in 50 




4.2.2.2 Fluorescence Emission Spectroscopy  
To demonstrate successful folding of wild-type BamA and the variants created, 
fluorescence emission spectroscopy was next carried out for all BamA variants, 
folded into DUPC liposomes or unfolded in 8 M urea (see Methods Section 2.6.1).  
Due to the nature of the intrinsic tryptophan fluorescence250, a different emission 
spectrum will be observed for folded versus unfolded protein. For BamA, folded 
proteins show a blue shift in Trp fluorescence, with wavelength of maximum 
fluorescence intensity (λmax) occurring at a shorter wavelength, and with a higher 
fluorescence intensity relative to the unfolded state250. This was observed for 
wild-type BamA and all of the purified variants (Figure 4-9) and also by 
comparison of calculated λmax (Table 4-1). The results provide a clear indication 
that all variants of BamA are folded, and display the same characteristic 
tryptophan fluorescence emission spectra noted for BamA wild-type in folded and 
unfolded forms. This is further evidence that the BamA variants are folding 
correctly and act similarly to wild-type, although perhaps show lower folding 




Figure 4-9: Fluorescence emission spectra for folded and unfolded samples 
of all BamA variants. a) Wild-type BamA; b) Cys-free BamA; c) BamA430/808; d) 
BamA431/807. Samples contained 0.8 μM BamA, 1.28 mM DUPC, and 0.24 M urea in 50 
mM glycine buffer, pH 9.5 for folded samples, or 0.8 μM BamA in 8 M urea for unfolded 
samples. Samples were folded by incubation with LUVs at 25 °C for two hours prior to 
measurement. Each spectrum was recorded from 280 nm to 400 nm in 1 nm increments, 
using an excitation wavelength of 280 nm. An appropriate “blank” sample was subtracted 
from measurements, to remove light scattering by liposomes from the final spectra 
observed (see Methods Section 2.8.1 for details). 
 
 
 λmax (nm) 
 Wild-Type Cys-free BamA430/808 BamA431/807 
Folded 325 325 326 326 
Unfolded 348 346 348 348 
Table 4-1: Comparison of λmax values for BamA wild-type, Cys-free 
(C690S/C700S), and BamA430/808 and BamA431/807. The wavelength at which the 
fluorescence spectrum is at its maximum is shown, and is consistent across variants, 





4.2.2.3 Circular Dichroism (CD) spectroscopy of BamA and variants 
Circular dichroism was also utilised to determine whether the BamA variants 
adopt the expected β-barrel architecture when folded into different environments, 
and also to enable a comparison between the extent of folding of all the BamA 
variants.  Folding of each of the BamA variants into DUPC liposomes (Figure 
4-10a) resulted in far UV CD spectra typical of a -sheet protein, with a negative 
maximum at ~220 nm. This confirms that all proteins are capable of folding in this 
lipid type. In addition, all variants gave rise to CD spectra that differ substantially 
from the spectra of their unfolded states obtained in 8 M urea (Figure 4-10b).  
 
Figure 4-10: Comparison of far UV CD spectra of BamA wild-type and 
variants in a) DUPC LUVs and b) unfolded in 8 M urea. a) All BamA protein 
variants folded in DUPC liposomes contained 0.8 μM BamA, 1.28 mM DUPC LUVs, and 
0.24 M urea in 50 mM glycine buffer, pH 9.5.  All folded samples were incubated at 25 
°C for two hours prior to measurement. b) Unfolded BamA protein variants (0.8 μM 
BamA) in 8 M urea 50 mM glycine buffer, pH 9.5. An appropriate blank was subtracted 
for each sample. The Mean Residue Ellipticity (for derivation see Methods Section 2.8.2) 





4.2.3 Kinetics of BamA-assisted OMP folding 
BamA is of interest as this -barrel protein, even when isolated from the BAM 
complex, is capable of accelerating the folding of substrate OMPs into synthetic 
liposomes71,271. This effect is specific to BamA as prefolded OmpA in the LUVs 
does not exert the same catalytic effect241. This was hypothesised to be a useful 
means to assess the importance of BamA lateral gating in vitro as BamA variants 
with the β-barrel disulphide locked may provide little or no assistance to substrate 
OMP folding if gating is vital for function. Consequently, experimental conditions 
were set up in which the acceleration of OMP folding by BamA can be reliably 
measured utilising the natural tryptophan fluorescence of OMPs. The truncated 
-barrel of the small outer membrane protein OmpA (tOmpA, residues 1-171) 
was used as a substrate in these experiments. This was chosen because it is 
known that tOmpA will fold spontaneously into liposomes formed from the 
synthetic lipids DUPC, DUPC:DDPE, or later DMPC used here, on a measurable 
timescale and gives rise to a large change in fluorescence intensity288.  
As discussed above, initially DUPC LUVs were the synthetic liposomes of choice 
for observing the catalytic activity of BamA disulphide lock variants on tOmpA 
folding. This is because the liposomes formed and BamA-assisted folding into the 
liposomes had been well-characterised hitherto71,72,241,271. The experiments yield 
folding transients that can be fit to exponential functions, with reliable folding rate 
constants. In addition, folding occurs in presence or absence of BamA at 
measurable timescales and at room temperature (25 °C), which is not close to 
the sub-zero phase transition temperature for DUPC. The first kinetic experiments 
performed here focused on validating the experimental set-up by comparison to 
previous findings, and were used to establish that consistent data are obtained 
across varying liposome batches. In all experiments folding of tOmpA was 
monitored following the rapid dilution of denatured tOmpA (in 8 M urea, 50 mM 
glycine-NaOH pH 9.5) into 100 nm LUVs in 50 mM glycine-NaOH pH 9.5 
containing BamA (in the presence or absence of Skp as required) at 
predetermined concentrations. For all kinetic experiments, the traces were fitted 
globally to a single- or double- exponential function, as appropriate (Methods 
Section 2.9), and rate constants k1 and k2 are reported. Skp and tOmpA proteins 
were kindly provided by Bob Schiffrin (University of Leeds) and were purified as 
previously described288 (see Methods 2.3.1 and 2.3.3). 
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Firstly the folding of tOmpA in DUPC liposomes upon dilution 200-fold from 8 M 
urea was measured (Figure 4-11a). The results show that tOmpA folds with an 
observed rate constant of 21.8 ± 0.2 x 10-3 s-1. BamA-assisted folding of tOmpA 
in DUPC is exceptionally fast in these conditions, complete within ~200 
seconds241. This fast kinetic rate means any experimental errors in sample 
handling would cause a significant portion of the first kinetic phase to be missed, 
and small differences between BamA-accelerated sample folding would be nearly 
impossible to determine. The addition of chaperone, Skp was used to slow folding 
in order that small differences may be observed. The “holdase” activity of the 
chaperone Skp is known to prevent the folding of tOmpA, resulting in no 
fluorescence change in the absence of BamA163,271(Figure 4-11b). The presence 
of BamA, prefolded into liposomes allows the release of tOmpA from Skp, 
permitting folding271. In addition, this experimental setup permits examination of 
the potential importance of BamA lateral gating not only in catalysing OMP 
assembly, but also in the handover from chaperones.   
Upon pre-incubation of tOmpA with a 2-fold molar excess of Skp trimer without 
BamA, no fluorescence increase and thus no folding is observed (Figure 4-11b).  
This indicates that in the absence of BamA, Skp functions as a “holdase” 
sequestering the substrate tOmpA, consistent with previous results163,271. 
 
Figure 4-11: Kinetic traces for tOmpA folding into DUPC liposomes in the 
(a) absence or (b) presence of two-fold molar excess of Skp trimers 
monitored by intrinsic tryptophan fluorescence. Black lines in (a) represent the 
fits of the data to a single exponential function. Four replicate samples of each assay are 
shown. Samples contained 0.4 μM tOmpA, 1.28 mM DUPC LUVs, 0.8 μM Skp trimer for 




Having validated the set-up and use of DUPC liposomes for folding of tOmpA the 
next step was to examine the catalytic effect of BamA and the effect of barrel 
cross-linking on tOmpA folding by prefolding wild-type BamA or BamA430/808 into 
DUPC liposomes. It was hypothesised that the BamA double cysteine variant 
would form an intramolecular disulphide cross-link, preventing lateral gating199. If 
lateral gating was a prerequisite of its function, cross-linking the lateral gate would 
be expected to diminish the ability of BamA to facilitate tOmpA folding. To be sure 
of determining the effect in a barrel-locked state, measurements were also made 
with the addition of oxidizing agents (1 mM diamide or 100 µM CuSO4). 
The folding of tOmpA from Skp into DUPC liposomes containing prefolded wild-
type BamA (Figure 4-12a), at a rate constant of 7.4 ± 0.1 x 10-4 s-1 , is consistent 
with the rate constant of  1 x 10-3 s-1, determined previously following repeated 
experiments241. However, the folding of tOmpA with prefolded BamA430/808 
(Figure 4-12b), which was anticipated to be slower than with wild-type BamA, 
yielded a rate constant of 24.7 ± 0.5 x 10-4 s-1 and is therefore more than 3-fold 
faster than wild-type BamA. Furthermore, the addition of oxidizing agents (Figure 
4-12c & d), anticipated to slow the observed rate constant still further, caused 
high variability between kinetic transients, with the same or higher observed rate 




Figure 4-12: Folding of tOmpA into DUPC liposomes with BamA and Skp. 
Four replicate traces are shown for folding of tOmpA into liposomes containing 
prefolded a) wild-type BamA; b) BamA430/808; c) BamA430/808 + 100 µM CuSO4; and d) 
BamA430/808 + 1 mM diamide. Black lines represent the fits of the data to a single 
exponential function. Three or four replicate samples of each measurement are shown. 
Samples contained 0.4 μM tOmpA, 0.8 μM BamA, 0.8 μM Skp trimer, 1.28 mM DUPC 
LUVs, and 0.24 M urea in 50 mM glycine buffer, pH 9.5 and were measured at 25 °C. 
 
The results obtained with prefolded BamA in DUPC liposomes were highly 
variable, with inconsistent effects on the addition of different oxidizing agents. In 
addition, the data appeared noisy (Figure 4-12) rendering interpretation  of the 
results difficult. This appears partly attributable to the fast rate of folding, as slight 
inconsistencies in sample preparation, or dead time in beginning the experiment 
could lead to high variability in the observed rate constants of folding between 
experiments containing BamA variants. For these reasons it was decided to 
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repeat these experiments utilising lipids shown previously to result in a slower 
rate of tOmpA folding71. In addition, the slower intrinsic rate of folding of OMPs 
into longer chain, or more complex lipids would be expected to lead to a greater 
catalytic effect of BamA71,72.  
 
4.2.4 Kinetics of BamA assisted OMP folding in DUPC: DDPE 
It was decided next to use more native-like lipids and emulate the method of 
Gessman et al71 whereby phosphatidylethanolamine lipids (diC10:0PE DDPE) are 
doped in DUPC  to create a DUPC:DDPE lipid bilayer. 100 nm LUVs created from 
DUPC:DDPE (80:20 molar ratio) were thus used to investigate the efficiency of 
BamA-assisted folding of tOmpA.  DUPC is commonly used for OMP folding 
studies into liposomes, as it has been shown previously that OMPs fold efficiently 
into phosphatidylcholine LUVs with short (12 or less carbon) chain length71,72. 
Increasing the proportion of lipid with ‘native’ headgroups, such as 
phosphatidylethanolamine or phosphatidylglycerol slows the rate of OMP folding 
into liposomes, and more effectively mimics the lipid that may be present in the 
cell and increases the effect of pre-folded BamA71.  
Studies demonstrate that even a molar percentage of 20% DDPE in DPPC LUVs 
will slow the folding of all OMPs measured (tOmpA, OmpA, OmpX and OmpLA) 
compared to DPPC alone71. Prefolded BamA is capable of relieving the kinetic 
effect of the native lipid headgroups, accelerating folding to near that found in 
DPPC-alone LUVs71. Incorporation of DDPE creating DUPC:DDPE liposomes 
thus allows for more effective study of BamA-aided folding, as the addition of 
BamA may have a more substantial effect on substrate folding rates in lipid 
bilayers that do not support rapid, spontaneous OMP folding and insertion.   
Based on this rationale, a mixed liposome of DUPC:DDPE (80:20 molar ratio), 
similar to those used by Gessman et al 201471 (see Methods Section 2.7) was 
used to characterize BamA-assisted OMP folding. As OMPs fold less efficiently 
into this lipid mixture it is not necessary to use Skp as a holdase to determine 
whether BamA has an effect on the observed rate of folding. This simplifies the 
experiment as the chaperone handover to BamA is no longer a contributing factor 
to observed folding rate. 
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Firstly, a band shift assay (Figure 4-13) was carried out to determine whether 
effective folding occurs for all BamA variants in LUVs of this lipid composition. 
The band shift assay demonstrated that all of the BamA variants studied here are 
capable of folding into 100 nm DUPC:DDPE LUVs. Samples which are “folded” 
show an unfolded band of relatively higher intensity than observed previously 
(Figure 4-13), indicating that BamA folds with lower efficiency in this lipid type, as 
anticipated71. Nonetheless, the amount of folded BamA was sufficient to measure 
the effect of BamA on OMP folding into these liposomes. 
 
Figure 4-13: Band shift assay in DUPC:DDPE liposomes for all BamA 
variants. Wild-type, Cysteine-free and two double cysteine mutants in DUPC:DDPE 
LUVs. Samples contained 0.8 μM BamA, 1.28 mM DUPC or DUPC/DDPE LUVs, and 
0.24 M urea in 50 mM glycine buffer, pH 9.5 and were folded at 25 °C for 2 hours prior 
to analysis by electrophoresis.  Samples are with (+) or without (-) 30 minutes boiling at 
100 °C demonstrating heat modifiability of BamA with altered electrophoretic mobility in 
the folded sample. 
 
The results showed, as expected, that tOmpA folds spontaneously and efficiently 
into DUPC:DDPE lipids alone (Figure 4-14). The kinetics fit to a double 
exponential function, with rate constants (k1 = 16.2 ± 0.7 x 10-4 s-1 and k2 = 2.1 ± 
0.2 x 10-4 s-1), significantly slower than that obtained (k1 = 21.6± 0.2 x 10-3 s-1) for 
tOmpA alone in DUPC liposomes (Figure 4-11a). This slow spontaneous rate of 
folding shows that DUPC:DDPE liposomes are a good choice to investigate 
BamA-assisted folding of this protein. The fit to single- or double- exponential is 
poor, suggestive of a complex folding or insertion mechanism that was not 
investigated further here. Therefore, the t50 or half-time to maximum 
fluorescence, for each of the four transients was calculated by fitting a horizontal 
line to the end of the data, see Methods 2.9 for details. The average t50 calculated 




Figure 4-14: Kinetic traces for tOmpA folding in DUPC:DDPE liposomes 
monitored by intrinsic tryptophan fluorescence. Grey broken lines represent the 
attempted fits of the data to a double exponential function. This shows that the data does 
not fit a double exponential due to due to the lag time observed, but yielded smaller 
residuals than fit to the single-exponential. Four replicate samples are shown. Samples 
contained 0.4 μM tOmpA, 1.28 mM DUPC:DDPE LUVs, and 0.24 M urea in 50 mM 
glycine buffer, pH 9.5 and were measured at 25 °C.  
 
The presence of prefolded wild-type BamA in DUPC:DDPE LUVs leads to an 
increase in the observed rate constant of tOmpA folding (Figure 4-15) with rate 
constants k1 = 8.9 ± 0.9 x 10-3 s-1 and k2 = 0.2 ± 0.2 x 10-3 s-1. In these experiments 
the data fit well to a double exponential, and the folding times are in accordance 
with those noted in the literature for similar liposomes, monitored by gel assays72. 
For comparison with observed rates of tOmpA folding without BamA the t50 of 
each transient was also calculated. The average is 86.2 ± 14.1 s. This provides 
a second measure of the catalytic effect provided by BamA. However, for the 
majority of traces in DUPC:DDPE the final fluorescence is not flat, therefore an 









Figure 4-15: Kinetic traces for tOmpA folding in DUPC:DDPE LUVs 
containing prefolded BamA. Purple indicates each replicate, which were fit globally 
to a double exponential (indicated by black lines). For details see Methods Section 2.9. 
BamA was prefolded in 100 nm LUVs at a concentration of 0.8 μM by incubation at 25 
°C for two hours prior to measurement. Samples contained 0.4 μM tOmpA, 0.8 μM 
BamA, 1.28 mM DUPC:DDPE(80:20 molar ratio), and 0.24 M urea in 50 mM glycine 
buffer, pH 9.5 at 25 °C.  
 
The experiment was repeated with BamA430/808 and BamA431/807 (Figure 4-16). 
Initially both double cysteine variants of BamA appeared capable of accelerating 
tOmpA folding, as the rate constants of folding are many-fold higher than for 
tOmpA in isolation. However, variability is observed between the lateral-lock 
BamA variants, with fit to a single-exponential function optimal for folding 









Figure 4-16: Kinetic traces for tOmpA folding in DUPC:DDPE LUVs 
containing prefolded (a) BamA430/808 or (b) BamA431/807  fit to double, or 
single exponential functions, respectively. Experiments were carried out with 
final concentrations 0.4 μM tOmpA, 0.8 μM  BamA, 1.28 mM DUPC:DDPE (80:20 molar 
ratio) LUVs, and 0.24 M urea in 50 mM glycine buffer, pH 9.5. 
 
Despite the differences in fit to exponential function, the results from comparison 
of Figure 4-14 and Figure 4-16 demonstrate that both double-cysteine BamA 
variants accelerate tOmpA folding. However, folding of tOmpA with prefolded 
BamA431/807 fits to a single exponential, unlike the double-exponential seen with 
wild-type BamA and therefore these cannot be easily compared, although it 
appears the k1 extracted is lower for BamA431/807 than wild-type. Kinetic transients 
with prefolded  BamA430/808 fit well to a double-exponential and therefore can be 
compared to wild-type. In this case the first rate constant (k1) extracted is higher 
(18.3 ± 0.9 x 10-3 s-1) than for that of wild-type (8.92 ± 0.9 x 10-3 s-1). This is 
evidently the opposite effect than that anticipated. 
Folding of tOmpA with prefolded BamA430/808 was also tested in the presence of 
reducing and oxidizing agents to influence the extent of cross-linking, however 
both appeared to decrease the observed rate. The inconsistencies observed in 
the data and difficulty in quantification led us to move away from DUPC:DDPE 
LUVS. The majority of kinetic traces do not demonstrate flat final fitting of 
fluorescence values, precluding extraction of a t50, while the mixture of single- 
and double- exponential fitting to kinetic transients renders comparison across all 
conditions impossible. In addition, the kinetic trace for folding of tOmpA in the 
absence of BamA (Figure 4-14) demonstrates a sigmoidal-like curve, clearly 
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different from that in the presence of BamA(Figure 4-15). This implies a more 
complex mechanism of folding than was addressed here.  
 
4.2.5 Kinetics of BamA assisted tOmpA folding in DMPC liposomes 
As previously mentioned, in addition to complex effects of polar head group on 
the rate of OMP folding, the longer the fatty acid chain length, the slower the 
substrate OMP will fold71.  It has now been demonstrated in LUVs with 
phosphatidylcholine head groups that increasing the lipid chain length by single 
carbons incrementally (from 12 carbon DLPC to 14 carbon DMPC), thus 
incrementally increasing bilayer thickness269 will substantially increase the fold 
rate enhancement provided by BamA241. The 14-carbon chain 1,2-dimyristoyl-sn-
glycero-3-phosphatidylcholine (DMPC) lipids generated liposomes in which 
BamA increases the folding rate of tOmpA by 12-fold241. It was anticipated that 
as substrate OMP folding rates were lower72, but the catalytic effect of BamA in 
assisting folding was greater241 any effects of inhibiting BamA lateral gating by 
disulphide bond formation may be more clearly seen in this lipid type. 
For tOmpA folding into DMPC lipids, only BamA430/808 was taken forward as a 
cross-link example, henceforth referred to as BamA X-link, as this variant 
generated the most reproducible folding transients.  Experiments were initially 
attempted with DTT and CuSO4 as reducing and oxidizing agents, respectively. 
However, the addition of DTT to prefolded X-link BamA resulted in an unexpected 
fluorescence decrease upon folding (Figure 4-17b), and therefore the alternative 
reducing agent TCEP was used (Figure 4-20). In addition, as the phase transition 
temperature of DMPC is 24 °C279, close to the previous experimental temperature 
of 25 °C, unlike for previous lipid types used, both BamA pre-folding and 
measured tOmpA folding were carried out at 30°C to ensure that the lipid 
remained in liquid phase rather than gel phase. Furthermore, folding of BamA 
into DMPC liposomes was carried out overnight to increase folding yield prior to 




Figure 4-17: Kinetic traces for tOmpA folding in DMPC liposomes 
containing prefolded BamA X-link with a) TCEP and b) DTT. Experiments were 
performed as previously described with final concentrations of 0.4 μM tOmpA, 0.8 μM 
BamA, 1.28 mM DMPC LUVs, and 0.24 M urea in 50 mM glycine buffer, pH 9.5, with 10 
mM TCEP or 25 mM DTT where applicable. BamA was first allowed to fold in the 
liposomes, here by incubation overnight at 30 °C. Reducing agents were then added to 
the folded sample, mixed thoroughly and the reaction started on the addition of tOmpA 
diluted 200-fold from 8 M urea. Each replicate trace is indicated in (a) red or (b) purple, 
with the global fit to a single exponential indicated by black lines.  
 
It was first verified that wild-type, cysteine-free and X-link BamA variants are all 
able to fold into DMPC liposomes. It was anticipated that folding yield would be 
greatly reduced in these longer chain lipid LUVs72 but it was verified that folding 
yield between BamA variants was approximately equal (Figure 4-18). Bandshift 
assays were carried out as previously detailed (see Methods Section 2.6.2 for 
details), with three repeats in different liposome batches and the folding yield 








Figure 4-18: Bandshift of BamA variants in DMPC liposomes. Samples 
contained 0.8 μM BamA, 1.28 mM DMPC LUVs, and 0.24 M urea in 50 mM glycine 
buffer, pH 9.5 and were folded at 30 °C overnight prior to analysis by semi-native SDS-
PAGE. Samples are shown with (+) and without (-) boiling prior to analysis. U denotes 
unfolded, and F folded bands of BamA variants. 
 
 
BamA construct BamA folding yield (%) 
Wild-type 51.7 ± 1.7 
Cys-free 55.9 ± 17.4 
X-link 51.4 ± 11.9 
Table 4-2: Folding yield of BamA variants and wild-type BamA in DMPC 
liposomes, observed by bandshift assay, quantified by densitometry. Three 
repeats in different liposome batches were independently analysed by semi-native SDS-
PAGE. The data shown are mean ± standard deviation. 
 
For each liposome preparation, the folding of tOmpA in the absence of BamA 
was first measured as a control (Figure 4-19). The data do not fit well to a single 
exponential function, but demonstrate that the folding rate constant (k1 = 39.9 ± 





Figure 4-19: Kinetic traces for tOmpA folding in the absence of BamA in 
DMPC liposomes. Black lines represent the fits of the data to a single exponential 
function. Four replicate samples are shown. Samples contained 0.4 μM tOmpA, 1.28 mM 
DMPC LUVs, and 0.24 M urea in 50 mM glycine buffer, pH 9.5 and were measured at 
30 °C. 
 
BamA-catalysis of tOmpA folding in DMPC liposomes was then assessed. 
Following overnight folding of BamA into the LUVs, a 10x stock of TCEP 
(reducing), CuSO4 (oxidizing) or buffer, 50mM glycine-NaOH pH 9.5 was added 
to the sample and incubated for a minimum of 30 minutes at 30°C before addition 
of tOmpA. A set of four transients was obtained (Figure 4-20), and each 





Figure 4-20: Example folding transients for BamA-catalysed folding of 
tOmpA, with wild-type, Cys-free and X-link BamA with addition of buffer, 
CuSO4 or TCEP. Four replicate samples of each assay are shown. Samples contained 
0.4 μM tOmpA, 0.8 μM BamA, 1.28 mM DMPC LUVs, and 0.24 M urea in 50 mM glycine 
buffer, pH 9.5 and were measured at 30 °C. Experiments were performed with the 
addition of buffer (blue), 1 mM CuSO4 (orange) or 25 mM TCEP (green). 
 
A first order rate equation was globally fit to each set of four transients and the 
rate constant k1 reported for each example. However, due to the notable lag 
phase present in DMPC folding reactions in the absence of BamA (see Figure 
4-19), the t50 value, or time taken to reach 50% of the total fluorescence change 





Folding condition t50 (minutes) 
 +buffer +CuSO4 +TCEP 
-BamA 276 ± 6 - - 
+WT BamA 22.3 ± 1.5 15.7 ± 1.1 7.9 ± 0.7 
+BamA (Cys-free) 18.8 ± 0.6 18.6 ± 2.0 12.4 ± 1.0 
+BamA (X-link mutant) 17.3 ± 1.7 16.8 ± 1.3 8.55 ± 0.45 
Table 4-3: Average t50 values for tOmpA folding in each condition. t50 values 
were extracted to analyse the folding rate. Each transient was independently analysed 
with a horizontal line fit to the final section of data. Three repeats of each experiment (12 
transients in total) were used to calculate the average t50 for each condition and standard 
error of the mean. 
 
From comparison of the t50 values, one can observe that although the addition of 
TCEP lowers the t50 ~2-3 fold in the case of all BamA variants (Table 4-3) the 
general trend is near identical (Figure 4-21b). The difference between wild-type, 
Cys-free and X-link BamA catalysis of tOmpA folding in the same conditions is 
negligible. Overlay of a normalised transient for all conditions of Cys-free and X-
link BamA-catalysed folding (Figure 4-21a) shows that these rates are near 
identical. In addition, visual comparison of t50 values (Figure 4-21b) demonstrates 
the significant catalytic effect on tOmpA folding provided by all BamA variants 
and the substantial increase in rate relative to absence of BamA and the 
insignificant differences between variants and conditions. This considerable 
catalytic effect, with ~12-fold rate enhancement is specific to BamA, as prefolding 







Figure 4-21: Comparison of BamA-catalysed folding of tOmpA. a)  Overlay of 
single normalised transients comparing BamA-catalysis of tOmpA folding by Cys-free 
mutant and X-link mutant in all conditions. b) Comparison of t50, as a measure of folding 
rate for tOmpA folding alone, or with prefolded  wild-type, Cys-free, or X-link BamA in all 
reduced and oxidized conditions. Three repeats of each experiment (12 transients in 
total) were used to calculate the average t50 for each condition with error bars showing 
standard error of the mean. 
 
It has previously been noted that removal of the two natural cysteines of BamA 
has little effect on function, as measured in vitro or in vivo199,210,231 and this variant 
therefore forms an excellent pseudo wild-type control. Due to the proposed role 
of lateral gating it had been anticipated that the catalytic effect of the X-link variant 
would be different to that of the wild-type or Cys-free. However, as overlay of the 
normalised transients (Figure 4-21a) renders apparent, the X-link variant also has 
the same catalytic activity as the Cys-free BamA. The lack of significant difference 
between BamA X-link catalytic activity in reduced or oxidized conditions 




4.2.6 Redox gels for BamA X-link mutant 
As a final control for this section of the work, conditions were optimised to enable 
the reduced and oxidized states of BamA to be resolved by SDS-PAGE. The 
process for this is detailed for the BAM complex, in Section 5.6. Results were 
optimised with 5% Tris-glycine gels (Methods Section 2.6.3) (Figure 4-24). Two 
examples are shown, firstly with cysteine-free and X-link variants folded in DUPC 
(Figure 4-22) and in DMPC (Figure 4-23).  
 
Figure 4-22: Non-reducing SDS-PAGE of BamA Cys-free and X-link mutant. 
BamA protein samples folded into DUPC liposomes at 2µM, were incubated for 30 
minutes with TCEP or CuSO4 at final concentrations 25 mM or 1 mM, respectively. 
Samples were mixed with 6x loading buffer, containing 0.6 % (w/v) SDS in the absence 
of DTT and loaded on the 5% acrylamide, Tris-Glycine gel, see Methods Section 2.6.3.  
 
In both examples the X-link variant in both buffer and in the presence of oxidizing 
agent (CuSO4/diamide) shows a double band. This clearly resolves to a single 
band upon treatment with reducing agent (DTT/TCEP). This demonstrates that 
BamA is in a partially oxidized state that can be reduced, but not oxidized to 
completion. Wild-type or Cys-free BamA remains as a single band in all redox 






Figure 4-23: Non-reducing SDS-PAGE of BamA Wild-type and X-link variant. 
BamA protein samples folded into DMPC liposomes at 2µM, were incubated for 1hour 
with DTT or diamide at final concentrations 25mM or 100 µM, respectively. Samples 
were mixed with 6x loading buffer, containing 0.6 % (w/v) SDS and boiled for 30 minutes 
before being loaded on the 5% acrylamide, Tris-Glycine gel, see Methods Section 2.6.3. 
 
The extent of oxidation for BamA in DMPC was determined by densitometry. This 
revealed the fraction of total protein sample oxidized for X-link protein as 60% in 
buffer, and 65% with the addition of diamide.  
 
4.2.7 BamA Lateral Gating Conclusions 
This section begins examination of the role of BamA lateral gating in its in vitro 
catalysis of OMP folding. Following initial studies in DUPC and DUPC:DDPE 
LUVs, assays of BamA-assisted folding of tOmpA in DMPC are carried out for 
most reproducible results. Non-reducing SDS-PAGE was used to show that 
greater than ~60% of the BamA X-link protein will be in the oxidized form in the 
conditions used for tOmpA folding assays. The results demonstrate that the X-
link BamA variant is able to catalyse tOmpA folding, and this occurs to the same 
extent as with wild-type BamA (Figure 4-21). It therefore appears that at least for 
the BamA-catalysed folding of tOmpA in synthetic DMPC liposomes, the opening 
of the BamA lateral gate is not essential for its function. This supports alternative 
hypotheses over lateral gating, particularly that of membrane 
destabilization71,212,279. It appears highly likely, with this data in mind, that the 
presence of any BamA variant in the bilayer of these synthetic LUVs is sufficient 
to aid the folding of the substrate tOmpA, likely by inducing local membrane 
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disorder. As previously noted, controls, carried out by Dr Bob Schiffrin 
concurrently, have proved that this effect is specific to BamA: prefolding OmpA 
into LUVs before addition of tOmpA had no catalytic effect on tOmpA folding241. 
 
4.3 β-signal: tOmpA-RHK 
The tOmpA-RHK protein variant discussed previously (4.1.2, Figure 4-4) was 
designed for studies on the role of the β-signal in BAM-mediated OMP folding 
and was previously cloned, expressed and purified by Dr. Bob Schiffrin 
(University of Leeds) according to the method used for wild-type tOmpA (see 
Methods 2.3.1). Aliquots of the protein in 6M GuHCl 25 mM Tris pH 8 had been 
snap-frozen and stored at -80 ºC and were thawed and buffer exchanged into the 
correct urea buffer immediately prior to use. 
Initial experiments examined the intrinsic folding rate and recognition of the β-
signal variant by BamA using fluorescence kinetic studies. These were performed 
by analysing tOmpA folding alone and BamA-assisted folding of tOmpA wild-type 
and RHK variants in 12 carbon chain 1,2-dilauroyl-sn-glycero-3-
phosphatidylcholine  (DLPC) and 14 carbon chain 1,2-dimyristoyl-sn-glycero-3-
phosphatidylcholine  (DMPC) LUVs. As previously discussed, while synthetic 
liposomes are not a native-like system, DMPC liposomes provide the lipid bilayer 
thickness (~23 Å)269 most likely to mimic the E.coli outer membrane270. In 
addition, with increasing lipid length the fold rate enhancement provided by BamA 
increases incrementally241. Carrying out experiments in DMPC LUVs therefore 
allows us to better observe small differences in BamA catalysed rates of OMP 
folding while utilising two different lipid types enables a better understanding of 
how tOmpA-RHK folding depends on lipid type. This variant has not previously 
been characterised and therefore this work is seminal in understanding its folding 
capabilities. In addition to wild-type BamA, the BamA X-link variant (430/808) was 
also used to better understand how the models of lateral locking and β-signal 
targeting may complement one another. 
Kinetic folding experiments were carried out as described previously, for wild-
type tOmpA(4.2.5). Folding of tOmpA was monitored upon rapid dilution 200-fold 
from 8 M urea in the presence or absence of prefolded wild-type or X-link BamA 
in LUVs formed from DLPC (prepared and used at 25 °C) and DMPC (at 30 °C). 
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Example folding kinetic traces are shown for all conditions in DLPC (Figure 4-24) 
and DMPC (Figure 4-25) liposomes. For all kinetic experiments, the traces were 
fitted globally to a single exponential function (Methods Section 2.9), and the rate 
constant k1 is reported. 
Figure 4-24 Example folding kinetic transients for wild-type or RHK tOmpA 
in DLPC liposomes with no BamA, wild-type BamA or X-link BamA. Four 
replicate samples of each assay are shown. Samples contained 0.4 μM tOmpA, 0.8 μM 
BamA where applicable, 1.28 mM DLPC LUVs, and 0.24 M urea in 50 mM glycine buffer, 
pH 9.5 and were measured at 25 °C. Transients are globally fit to a single 





Figure 4-25 Example folding kinetic transients for wild-type or RHK tOmpA 
in DMPC liposomes with no BamA, wild-type BamA or X-link BamA. Four 
replicate samples of each assay are shown. Samples contained 0.4 μM tOmpA, 0.8 μM 
BamA where applicable, 1.28 mM DMPC LUVs, and 0.24 M urea in 50 mM glycine buffer, 
pH 9.5 and were measured at 30 °C. Transients are globally fit to a single exponential, 





As previously, traces are quantified and compared by extraction of the t50 (see 
Methods 2.9 for details). Comparison of the folding traces immediately 
demonstrates the altered folding of the tOmpA-RHK variant, which folds ~2-fold 
slower than wild-type tOmpA in both lipid types. In addition, a significant rate 
enhancement provided by prefolded wild-type BamA or X-link BamA is observed 
in both cases (Figure 4-26).  
 
 
Figure 4-26: Comparison of t50s for folding kinetics in a) DLPC and b) DMPC 
for tOmpA wild-type (blue) and tOmpA-RHK (red). The t50 is the time taken to 
reach the fluorescence halfway between the minimum and a horizontal line fitted to the 
final 10% of data. A minimum of three replicates with 4 transients each, each with an 
independently calculated t50 were used. Shown is the average, and error bars indicate 
SEM. 
 
The tOmpA-RHK variant (red) folds more slowly than wild-type tOmpA (blue) in 
all conditions (Figure 4-26). Comparison of fold change in t50 of wild-type tOmpA 
over tOmpA-RHK highlights the key differences (Figure 4-27). Firstly, while 
tOmpARHK folds ~1.6x slower than wild-type (in both lipid types) approximately 
the same fold difference is observed for the two proteins when folding is 
accelerated by wild-type BamA (Figure 4-27). Therefore wild-type BamA is 
exerting a catalytic effect on both tOmpA variants, but maintaining the fold 
difference between them. In considering the X-link BamA variant, however, the 
story changes. The fold difference between tOmpA-RHK and wild-type catalysed 
by X-link BamA is nearly twice that previously observed (~3x), in both DLPC and 
DMPC lipids. This indicates that X-link BamA is less effective at catalysing the 
folding of tOmpA-RHK than of wild-type tOmpA, in both lipid types. Thus, while 
the BamA X-link variant is capable of catalysing wild-type tOmpA folding, the 
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combination of the X-link BamA barrel and a mutated substrate β-signal 
sequence reduces the catalytic effect of BamA on tOmpA folding. This suggests 
a correlation between lateral gate opening of BamA and β-signal recognition, 
where both are required for maximum enhancement of substrate folding rate in 
vitro. 
 
Figure 4-27: Fold change in t50 values between tOmpA wild-type and RHK 
in all conditions and two lipid types. The t50 for tOmpA-RHK is slower (larger) than 
wild-type in all cases. Therefore the fold change is calculated by 
t50(tOmpARHK)/t50(tOmpAwt) for all conditions. Error bars show propagated SEM (for 





4.4 β-signal: Gly variants  
The second approach to studying the roles of the β-signal in BamA-catalysed 
folding involved mutagenesis of the conserved Gly, firstly to Pro using OmpT as 
substrate and subsequently to Ala in OmpT and tOmpA. Q5 site-directed 
mutagenesis was carried out for all variants (primers and protocol are detailed in 
Methods Table 2-5 and Section 2.2.3). 
Following successful generation of the variants OmpT-G306P, OmpT-G306A and 
tOmpA-G166A by site-directed mutagenesis, the proteins were expressed and 
purified as described in Methods Section 2.3.1. Briefly, each protein was 
expressed in E.coli BL21 (DE3) and purified by inclusion body isolation followed 
by size exclusion chromatography under denaturing conditions (see Methods 
Section 2.3.1 for details). The elution profile obtained by SEC and protein 
composition of the elution peak as analysed by electrophoresis on SDS-PAGE is 
shown (Figure 4-28). Fractions were then selected to be pooled and concentrated 





Figure 4-28: Purification of β-signal mutants. Shown is an example SEC trace of 
purification of each protein and fractions analysed by SDS-PAGE for HT-OmpT-G306P, 
HT- OmpT-G306A, tOmpA-G166A.  SEC was carried out using a Sup75 column with 25 
mM Tris, 6M GuHCl pH 8 (see Methods 2.3.1 for details). Three fractions are shown by 
SDS-PAGE across the peak of protein elution, indicated on the elution trace with black 
bars. Proteins have a molecular mass of 35 kDa (HT-OmpT -G306A & -G306P) and 18 
kDa (tOmpA) and are shown compared to a protein marker to the left of each gel image. 
Protein is shown buffer-exchanged from 25 mM Tris, 6M GuHCl pH 8 to 8 M urea, 50 





4.4.1 Characterisation of β-signal variants 
As these were novel protein variants, a full characterisation of the folding of these 
proteins in synthetic liposomes was carried out. Folding in DUPC liposomes was 
examined by a number of techniques, firstly heat modifiability. As previously 
mentioned, this allows us to distinguish between folded and unfolded populations 
of OMPs due to their SDS-resistant properties when folded and left 
unboiled248,307. Unlike with BamA, however, most OMP barrels are sufficiently 
heat and SDS-resistant once folded that experiments can be carried out at room 
temperature and with typical Tris-Tricine SDS-PAGE (Methods, Section 2.6). 
OmpT-G306P was the first variant created, and the first to be tested. It was 
immediately apparent that the folding of this protein differed substantially from 
wild-type as this variant displayed no folding in the initial electrophoresis 
experiment (Figure 4-29). 
 
Figure 4-29: Folding of OmpT wild-type and G306P variant in DUPC 
liposomes analysed by SDS-PAGE. Samples contained 5 μM protein either with 4 
mM (800:1 molar LPR) DUPC LUVs, 2 M urea in 50 mM glycine-NaOH pH 9.5 (DUPC 
samples) or kept unfolded at 5 μM in 8 M urea, 50 mM glycine-NaOH pH 9.5 (urea 
samples). Folding was carried out for 3 hours at 25 ºC prior to electrophoresis. A sample 
of folded protein is boiled (+) for 30 minutes prior to electrophoresis. HT-OmpT is 35 kDa 
and when unfolded migrates close to its calculated molecular mass, while folded HT-
OmpT migrates at ~29 kDa268. 
 
It is possible that this lack of folding was due to limited folding time (3 hours in 
the initial experiment), the protein concentration, or the lipid-protein ratio (LPR) 
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used. It was subsequently verified that the OmpT-G306P variant did not show 
SDS-resistant folding properties by bandshift with longer folding times (3-16 
hours) in a wide range of protein concentrations (0.4 – 5 μM) and LPR 
conditions(800-3200 :1 molar LPR) (Figure 4-30). 
 
 
Figure 4-30: Folding of OmpT wild-type (WT) and G306P (Pro) variant in 
DUPC liposomes by SDS-PAGE. From the left: samples contained 5 μM protein 
with 4 mM (800:1 LPR) DUPC LUVs, 2 M urea in 50 mM glycine-NaOH pH 9.5; other 
concentrations and LPRs are as indicated, all with 2 M urea and in 50 mM glycine-NaOH 
pH 9.5. All folding was carried out overnight at 25 ºC unless indicated otherwise. 
 
As all electrophoresis experiments for this protein utilised standard SDS-PAGE, 
and the OmpT-G306P variant appears sensitive to SDS the experiments were 
repeated utilising semi-native SDS-PAGE as used for bandshift assays of BamA 
(see Methods Section 2.6.2) (Figure 4-31). These gels contain no SDS in the gel 
and only 0.1% (w/v) SDS in the loading buffer, which is added to the samples 
immediately prior to gel loading. In addition, the gels are run at 4ºC and low (10-
20) mA to avoid any heat-denaturation of sample. These experiments 
conclusively demonstrate the OmpTG306P variant is not able to adopt an SDS-
resistant folding conformation under any of the conditions explored, by contrast 




Figure 4-31: Folding of HT-OmpT wild-type (WT) and OmpT-G306P (Pro) 
variant in DUPC liposomes by semi-native SDS-PAGE Samples contained the 
indicated protein concentration and LPR with 2 M urea in 50 mM glycine-NaOH pH 9.5. 
All folding was carried out overnight at 25 ºC unless otherwise indicated. Samples were 
mixed with low-SDS loading buffer without boiling (-) or prior to 30 minutes boiling (+).   
 
Bandshift electrophoresis experiments were next attempted with all β-signal 
variants including the tOmpA-RHK variant for comparison (Figure 4-32). As it was 
known that folding may be kinetically slower or occur with lower yield than for the 
wild-type proteins all experiments were carried out with proteins folded in DUPC 
liposomes overnight at 25 °C. In these conditions wild-type tOmpA folding goes 
to completion. Complete (~100%) folding was observed for all tOmpA variants, 
however while wild-type OmpT folds nearly to completion (~74%), no folding is 
observed for OmpT- G306P or -G306A variants.   
 
Figure 4-32: Folding of all OmpT and tOmpA mutants in DUPC analysed by 
SDS PAGE. Samples contained 5 μM protein with 4 mM (800:1 LPR) DUPC LUVs, 2 
M urea in 50 mM Glycine-NaOH pH 9.5 Folding was carried out overnight at 25 ºC prior 
to electrophoresis. Samples were mixed with low-SDS loading buffer without boiling (-) 




Further characterisation of the proteins was next carried out in DUPC LUVs using 
fluorescence emission spectra (Figure 4-33). As with BamA discussed previously 
(4.2.2.2), folded OMPs display a blue shift, with wavelength of maximum 
fluorescence intensity (λmax) occurring at a shorter wavelength, and with a higher 
fluorescence intensity relative to the unfolded state. This is observed for all 
variants analysed here for both proteins. The results for OmpT can be misleading, 
as OmpT has been shown previously to display a folded fluorescence emission 
spectrum when collapsed in buffer163, due to folding of the extracellular β-strands. 
However, it should be noted that the spectra of the variants still do not differ 
significantly from those of wild-type protein. 
 
 
Figure 4-33: Fluorescence emission spectra for a) OmpT and b) tOmpA 
protein variants. Shown are spectra of variants both folded in DUPC LUVs and 
unfolded in 8 M urea. Protein was folded in DUPC LUVs at 0.4 μM OmpT/tOmpA, 1.28 
mM DUPC LUVs (3200 LPR), and 2 M urea in 50 mM glycine buffer, pH 9.5.  All folded 
samples were incubated at 25 °C overnight prior to measurement. Unfolded protein 
variants contain 0.4 μM OmpT/tOmpA in 8 M urea 50 mM glycine buffer, pH 9.5. Each 
spectrum was recorded from 280 nm to 400 nm in 1 nm increments, using an excitation 
wavelength of 280 nm. An appropriate “blank” sample was subtracted from 
measurements, to remove light scattering by liposomes from the final spectra observed 
(see Methods Section 2.8.1 for details). 
 
 
4.4.2 Analysis of Gly variants using Far UV CD 
Far UV CD was also utilised to determine whether the variants adopt the 
expected β-barrel architecture. Folding of each of the OmpT/tOmpA variants 
into DUPC liposomes resulted in far UV CD spectra typical of a -sheet protein ( 
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Figure 4-34) with a negative maximum at 220 nm, confirming that all proteins are 
capable of forming β-sheet structure in this lipid.  In addition, all variants gave rise 
to far UV CD spectra that differ substantially from the spectra of their unfolded 




Figure 4-34: Comparison of CD spectra for OmpT (a & b) and tOmpA (c & d) 
variants in folded (a & c) and unfolded (b & d) forms. Protein was folded in 
DUPC LUVs at 5 μM OmpT/tOmpA, 4 mM DUPC LUVs (800:1 molar LPR), and 2 M urea 
in 50 mM glycine buffer, pH 9.5.  All folded samples were incubated at 25 °C overnight 
prior to measurement. Unfolded protein variants are 5 μM OmpT/tOmpA in 8 M urea 50 
mM glycine buffer, pH 9.5. An appropriate blank was subtracted for each sample. The 
Mean Residue Ellipticity (MRE) is plotted against wavelength, for how MRE is derived 
see Methods Section 2.8.2. 
 
As the OmpT variants were demonstrating β-sheet structure but no SDS 
resistance in any condition, CD spectra over a temperature ramp from 20 – 90 ºC 
were also obtained to determine the variants’ relative stability (Figure 4-35). Even 
at the highest temperature of 90 ºC all proteins show unperturbed β-sheet 
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structure. The results obtained here indicate that the OmpT Gly variants fold to a 
stable β-barrel structure, that surprisingly is not SDS-resistant. 
 
Figure 4-35: Temperature Ramp of OmpT (a) wild-type (b) G306A (c) G306P. 
The protein was folded in DUPC LUVs at 5 μM OmpT, 4 mM DUPC LUVs (800:1 molar 
LPR), and 2 M urea in 50 mM glycine buffer, pH 9.5.  All folded samples were incubated 
at 25 °C overnight prior to measurement. An appropriate blank was subtracted for each 
sample. The spectra was measured from 20- 90 ºC with a 1 ºC step and 120 seconds 




4.4.3 BAM-mediated folding of the β-signal Gly variants 
As previously discussed, the original experimental directive behind the 
mutagenesis was to understand the relevance of the β-signal to OMP folding by 
BAM. This had partially been begun by analysing catalysis of tOmpA-RHK folding 
by BamA (Figure 4-24-Figure 4-27), and the aim moving to OmpT was to utilise 
the OmpT assay and thus the BAM complex. It had been assumed that single 
point mutations would not be highly detrimental to the OMP’s intrinsic folding 
ability, but may inhibit its’ ability to be catalysed by BAM. It is immediately 
apparent with the OmpT Gly variants that this is not the case, and the single 
amino acid mutation significantly impairs the protein’s ability to adopt a stable 
SDS-resistant structure, however we proceeded to determine how interaction 
with BAM is affected by substitution of the conserved Gly in the β –signal. 
Fortunately, for OmpT, folding can be measured by the catalytic activity of native 
OmpT to cleave a fluorogenic peptide substrate189,268. This indirect assay is 
complex as it reports on whether the OmpT variants are capable of folding, if 
these structures are active and how they might interact with BAM.  Samples were 
set up as described previously (3.5.1 and Methods 2.12) to examine OmpT 
folding as catalysed by BAM. In parallel the catalysis of OmpT and its variants 
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prefolded in DUPC LUVs, at the same concentration and LPR as the fluorescence 
and CD experiments (molar LPR 800:1). The results are surprising, with OmpT 
activity resulting in all cases, but with very different rates (Figure 4-36). 
Due to the setup of the reaction, the DUPC and +BAM samples cannot be fairly 
compared. Not only is there a slight concentration difference of OmpT between 
them, but DUPC samples involve prefolded OmpT, whereas in +BAM samples 
the OmpT is being folded simultaneously to the peptide cleavage that is 
monitored. However this makes the magnitude of the catalytic effect of BAM upon 
the folding of OmpT even more apparent. The +BAM rates for wild-type OmpT 
and OmpT-G306A are considerably faster than those same proteins folded in 
DUPC (Figure 4-36) despite none of the OmpT being folded in its functional form 
at the start of the reaction. 
 
 
Figure 4-36: OmpT protease assay for OmpT wild-type and variants folded 
in DUPC or BAM complex proteoliposomes. The OmpT assay was carried out as 
previously described for +BAM samples. These contained 5 μM OmpT, 35 μM SurA, 
1mM fluorogenic peptide, 0.4 M urea, 0.25 µM BAM, E.coli polar lipid proteoliposomes, 
50mM glycine-NaOH pH 9.5. DUPC samples used OmpT variants prefolded into DUPC 
(overnight, 25 ºC) at 5 μM protein, 4 mM DUPC. This subreaction was then mixed with 
LPS and fluoropeptide in the assay plate, with final concentrations 4 μM OmpT, 1 mM 
fluoropeptide, 1mg/ml LPS, 1.8 M urea, 50 mM Glycine-NaOH pH 9.5.  The reaction was 




Many traces do not reach completion over the time-course measured, therefore 
an accurate t50 cannot be extracted in these cases. Thus while only qualitative 
comparison of the rates of folding can be drawn, the results show that wild-type 
and OmpT-G306A in the presence of BAM show near indistinguishable and rapid 
reaction rates. This implies efficient folding by BAM, and full protease activity as 
expected for the wild-type OmpT sample. Interestingly, however, the OmpT-
G306P under the same conditions displays a significantly slower trace. This has 
several possible conclusions: that the OmpT-G306P variant has lower protease 
activity than the other variants, that catalysis by BAM is slower or to a lower yield. 
The presence of any activity in the OmpT variant samples, the high activity seen 
for OmpT-G306A in the presence of BAM, but particularly the activity observed 
for OmpT-DUPC samples is surprising as from the SDS-PAGE analysis of the 
same samples (prior to addition of LPS and fluoropeptide) no folded band is 
observed for OmpT-G306P or OmpT-G306A (Figure 4-32). The protease activity 
only occurs when OmpT is correctly folded, confirming that variants are folded 
both in synthetic DUPC LUVs and in liposomes created from E.coli polar lipid 
extract, but do not adopt an SDS-resistant structure in DUPC. 
 
In addition to the OmpT assay, a second assay for determining BAM folding of 
OMPs utilising SDS-PAGE was developed (see Methods 2.13 and Chapter 5, 
Section 5.7). This relies on the heat modifiability property of OMPs and the ability 
to distinguish folded and unfolded populations of protein by SDS-PAGE. It can 
therefore be applied to a wide range of SDS-resistant OMP sequences. This 
assay can be used with the full BAM complex in the presence of the chaperone, 
SurA, and is ideal for monitoring the folding of tOmpA as both the folded and 
unfolded bands can be clearly seen (Figure 4-38), but less so for OmpT where 
the unfolded protein band overlaps with the BamB and C subunits on SDS-PAGE. 
This assay was predominantly used to monitor BAM-mediated folding of tOmpA. 
The setup of the assay will be discussed further (Section 5.7) however controls 
demonstrate that only very low folding of tOmpA occurs in empty proteoliposomes 




As previously stated, the setup is better suited for tOmpA as the unfolded and 
folded protein populations can be easily distinguished. In addition to allowing us 
to better observe folding, this enables us to show that no protein is lost or in an 
“elusive state” 230 as near constant protein intensity is observed by summing the 
intensity of folded and unfolded populations. The experiment was carried out with 
comparison of all β-signal mutants, in OmpT and tOmpA (Figure 4-37). Folding 
with BAM proteoliposomes was carried out with time-points taken after 1 and 3 
hours.  
One can observe that wild-type tOmpA is nearly completely folded following 1 
hour, and 100% after 3 hours, while the tOmpA-G166A(Ala) variant retains a 
small population in the unfolded state after 3 hours (Figure 4-37). The tOmpA-
RHK mutant is considerably slower still, with less than 50% of protein obtaining 
the folded state after 3 hours. All are better, however, than any OmpT variants, 
including wild-type which appear to demonstrate very low folding yield.  
 
Figure 4-37: SDS-PAGE demonstrating folding of tOmpA/OmpT β-signal 
variants in BAM proteoliposomes. Samples contain 2µM tOmpA/OmpT, 10µM 
SurA, 1µM BAM, E.coli polar lipid proteoliposomes, TBS pH8. Folding is carried out at 
25 ºC with time-points taken after 1 or 3 hours, and mixed 1:4 with 6x SDS loading buffer 






The assay can be used to measure multiple time-points over the course of the 
folding reaction, analyse fraction folded/total and obtain a kinetic readout of 
folding time. The time-course has been optimised for folding of wild-type tOmpA 
in BAM E.coli polar lipid proteoliposomes, as will be discussed in Chapter 5, and 
involves ten time-points from 2- 120 minutes. This enables us to obtain a 
reasonable kinetic trace to which a first order exponential can then be fit. 
One preliminary experiment was carried out to compare the two tOmpA variants 
to wild-type using this assay. For all three tOmpA variants in this particular assay 
the SDS-PAGE showed extra protein bands, not typically seen. Thus, although 
results were fully analysed, these may not be accurate. A representative gel, of 
wild-type tOmpA folding in this experiment is shown (Figure 4-38).  
Figure 4-38: Analysis of folding of wild-type tOmpA by BAM 
proteoliposomes by SDS-PAGE. Samples contain 2µM tOmpA, 10µM SurA, 1µM 
BAM, E.coli polar lipid proteoliposomes, TBS pH8. Folding is carried out at 25 ºC with 
time-points taken at 2, 5, 10, 15, 20, 30, 45, 60, 90 and 120 minutes, and mixed 1:4 with 
6x SDS loading buffer prior to electrophoresis. No samples are boiled to retain the correct 
folded and unfolded populations. 
 
Identical experiments were carried out in parallel for tOmpA-G166A and tOmpA-
RHK variants. The results were analysed by gel densitometry, folding yield 
calculated, plotted and fitted to a single exponential (see Methods Section 2.13). 
The folding of each variant is shown (Figure 4-39a) and rate constant k1 for folding 
transients are compared (Figure 4-39b). Comparison of rate constants can clearly 
be seen to be problematic, as from the graph both tOmpA wild-type and tOmpA-
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G166A variants start with near-identical initial traces but the tOmpA-G166A 
variant does not reach the same folding yield. Consequently the rate constant 
appears higher for this variant, and this does not accurately reflect the lower 
folding achieved. In addition the tOmpA-RHK variant clearly does not fit to a 
single exponential. The fraction folded at 1 hour is therefore also tabulated, as 




Figure 4-39: Kinetic plot of folding of tOmpA variants (a) and table of 
analysis (b). Fraction folded at each time-point is plotted and a single exponential fit 
using the Igor Graphing programme (a). The subsequent rate constant of the fit and the 









This chapter discusses progress towards investigating the role of lateral gating in 
BamA-mediated OMP folding and insertion, and the role of the OMP -signal in 
BAM-mediated folding. The lateral-gating aspect of the project began with the 
hypothesis from in vivo work, that disulphide-locking BamA in its lateral closed 
conformation will negatively impact its catalytic ability199. Utilising the same cross-
link mutant pairs shown to be lethal in vivo199 two X-link mutant proteins 
(I430C/K808C and G431C/G807C) were expressed, purified and characterised, 
in addition to the Cys-free BamA variant. The proteins were shown to be folded 
using synthetic Large Unilamellar Vesicles (LUVs), and cold SDS bandshift. CD 
spectroscopy and tryptophan fluorescence were employed to demonstrate that 
these BamA variants have no substantial differences to wild-type in folding 
capability in vitro. Next, the activity of BamA variants in catalysing substrate 
folding was determined utilising tryptophan fluorescence emission spectroscopy. 
Systematically moving from LUVs composed of the 11-carbon lipid DUPC, to 
those containing a proportion of native-like phosphatidylethanolamine 
(DUPC:DDPE 80:20 molar ratio), to the 14-carbon chain phosphatidylcholine 
DMPC the ability of BamA variants to catalyse folding relative to wild-type was 
examined. 
The OMP substrate used in these experiments was the β-barrel (residues 1-171) 
of the 8-stranded β-barrel OmpA (tOmpA). While able to fold in each lipid type 
used, a significant folding rate enhancement was observed in the presence of 
BamA, which increases with increasing acyl chain length241. It was observed that 
all BamA variants, including X-link variants were able to accelerate folding in 
every lipid type used (Figure 4-12, Figure 4-16, Figure 4-20). As any difference 
in BamA variant catalytic rate enhancement would be small, and therefore best 
observed in longer chain lipids where folding is slow 72,241 this body of work was 
concluded by thorough studies of BamA-assisted folding in DMPC lipids. 
Experiments were conducted in the 14-carbon chain LUVs as previously, and it 
was observed that wild-type, Cys-free and X-link BamA variants were all able to 
accelerate tOmpA folding to the same extent (Figure 4-21). In addition, studies 
were carried out in the presence of reducing agent (TCEP) and oxidizing agent 
(CuSO4) with no significant effect on folding rate. The BamA X-link variant was 
demonstrated to be in a mostly oxidized state, which could be reduced by TCEP 
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as visualized by non-reducing SDS-PAGE (Figure 4-24). Therefore it was 
concluded that the X-link BamA variant, regardless of oxidation state, was 
capable of accelerating substrate OMP folding. The data demonstrate that at 
least for BamA-assisted folding of tOmpA in synthetic LUVs, the lateral gating of 
the BamA β-barrel is not required. 
While this project has been in progress this work has been validated by the 
findings of another research group, who utilised the BamA-assisted folding of 
substrate OmpX into DDPC:DDPE (80:20 molar ratio) LUVs231. The work utilised 
three sets of disulphide pairs (Figure 4-40b), located along the β1 : β16 seam, 
with one pair (G431C/G807C)  identical to that used in this chapter. The BamA-
assisted folding of OmpX, as measured by heat-modifiability, was first shown for 
the Cys-free variant of BamA (C690S/C700S) (Figure 4-40a). It was next shown 
that all disulphide-pair variants, in both reduced and oxidized form, are equally 
capable of accelerating OmpX folding. Thus, they reach the same conclusion as 
found here, that regardless of oxidation state, barrel-locked BamA is capable of 
accelerating substrate folding 231 at least into LUVs in vitro. 
 
Figure 4-40: Barrel locked BamA assists folding of OmpX231. a) Fraction OmpX 
folded, as measured by heat modifiability, with no BamA (grey lines) and in the presence 
of Cys-free BamA in reducing (Red) and oxidizing (Ox) conditions b) Representation of 
the location of disulphide pairs on the BamA β1 and β16 strand seam c) Folding of OmpX 
in the presence of BamA double-cysteine mutants in reducing (Red) and oxidizing (Ox) 
conditions. Figure adapted from Doerner et al., 2017 231. 
 
The second section of work in this chapter focussed on the -signal and its 
importance for folding catalysed by BamA or the BAM complex. Systematic 
folding studies were carried out comparing wild-type tOmpA and tOmpA-RHK in 
which three residues on the terminal strand are mutated to more closely resemble 
that of neisserial OMPs. These studies, in DLPC and DMPC LUVs demonstrated 
that while tOmpA-RHK shows slower intrinsic folding rates than wild-type, the rate 
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of folding is equally accelerated by wild-type BamA, but not by BamA X-link 
(Figure 4-26; Figure 4-27). These novel findings are interesting on three counts. 
Firstly, like the neisserial signal (RHK), the tOmpA residues replaced (SYR) 
possess a positively charged residue in the +2 position (R170) (Figure 4-2). 
Contrary to a previous hypothesis that the charged residue may cause 
incompatibility between E.coli and Neisseria β-signals211 it is likely that the 
distinctive Histidine, found only in neisserial OMPs is responsible for any altered 
folding286. Secondly, while tOmpA-RHK folds more slowly than tOmpA wild-type, 
the fold-change between them (~1.6x) remains the same in wild-type BamA-
catalysed folding (Figure 4-26, Figure 4-27). This implies that while BamA is not 
able to compensate for the slower folding of tOmpA-RHK, the catalytic rate 
enhancement is equal. Lastly, it is interesting that the X-link variant does not 
equally accelerate wild-type and RHK tOmpA folding. The X-link BamA variant 
shows the same catalytic activity as wild-type BamA when folding wild-type 
tOmpA in DMPC (Figure 4-21), supporting the hypothesis that BamA acts as a 
membrane disruptase, rather than a specific recognition partner in this setup. 
However, the differential activity of X-link BamA with respect to tOmpA-RHK 
implies that while X-link BamA is a sufficient catalyst in the case of wild-type 
tOmpA, acting perhaps as a membrane disruptase, it is insufficient for the 
impaired tOmpA-RHK. This suggests that for BamA-mediated folding of tOmpA 
in the absence of an appropriate β-signal, such as in the tOmpA-RHK variant, 
perhaps BamA catalysis must play a more active role. An increased importance 
for BamA dynamics in this case would explain the slower folding of tOmpA-RHK 
by X-link BamA compared to wild-type BamA. Further experiments remain to be 
done to unravel these interconnected models of Bam-assisted substrate folding. 
Current results cannot support or refute the hypothesis of species-specificity as 
in these conditions BamA appears to show no specific recognition of substrate, 
acting primarily as a membrane disruptase. Perhaps by further study using the 
BAM complex, where substrate folding is more specifically catalysed, one can 
more thoroughly probe recognition by E.coli BamA of a hybrid tOmpA substrate.  
Other experiments on the OMP -signal involved mutation of the conserved Gly 
in the β-signal of OmpT and tOmpA. These results were surprising, as in OmpT 
the effects were drastic. These experiments demonstrated that the mutation of 
glycine 166 to alanine in tOmpA (G166A) resulted in a protein largely 
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indistinguishable from wild-type, with similar folding in DUPC liposomes as 
characterised by bandshift, fluorescence emission spectra and CD. From 
preliminary experiments, however, the tOmpA-G166A variant demonstrated 
impaired folding by the BAM complex (Figure 4-38, Figure 4-39). In addition to 
confirming this slower rate, other studies remain to be done with this variant. 
Firstly, it would be informative to examine tOmpA-G166A folding in DMPC 
liposomes and determine, as with tOmpA-RHK, whether slower folding was seen, 
and how this was accelerated by both wild-type and X-link BamA. Secondly, a 
more thorough study would involve sequential mutations along the -signal. This 
would help deconstruct the role of the -signal in intrinsic and BamA-catalysed 
folding. 
In OmpT, the results of mutating the conserved Gly were striking. While folding 
of the two variants (OmpT-G306A and OmpT-G306P) into DUPC LUVs is 
comparable to wild-type OmpT as assessed by fluorescence emission spectra 
and far UV CD (Figure 4-33, Figure 4-34), SDS-resistant band shift of OmpT 
variants was not observed in any folding conditions for DUPC LUVs (Figure 4-32). 
BAM complex catalysed folding demonstrates a small amount of folding of both 
variants by SDS PAGE (Figure 4-37) and activity of the OmpT-G306A variant in 
the protease assay resembles that of wild-type (Figure 4-36). It had been 
anticipated that mutation of this highly conserved Gly may impact recognition by 
BamA, but the drastic change, particularly in the inability to form an SDS-resistant 
folded structure in DUPC, is unprecedented. It appears, from this limited study, 
that it is OmpT-specific and even the mild mutagenesis of Gly306Ala significantly 
impacts the folding landscape. As discussed, this Gly is conserved across 
Proteobacteria. It is the amino acid occurring with the highest frequency in that 
position, for all studied -signals, across all classes of Proteobacteria (Figure 
4-5)286. 
There is one precedent in OMP literature of studies of this Gly residue. In studies 
of the folding of BamA, mutation of the conserved Gly (G771A), on the strand 14 
-signal did not impact ability to bind BamD (in a prerequisite to folding) but 
caused no folding detectable by SDS-PAGE175. This was attributed in that case 
to Gly being integral to the structure, in a manner unique to BamA due to internal 
stabilizing interactions175. While not evident in the structure of OmpT: the inability 
of OmpT-G306A and OmpT-G306P to form SDS-resistant structures suggests 
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the conserved Gly likely plays an important structural role. However, as these 
variants form -sheet structure, as analysed by far UV CD and fluorescence 
emission spectra, they are perhaps trapped in a folding intermediate while the 
conserved Glycine is crucial to formation of the final folded barrel. Further studies 
on this would again preferably include alanine scanning of the entire terminal 
strand of OmpT, a more thorough investigation into the altered folding and SDS-
resistance properties and on how the variants are catalysed by BAM.  
Altogether the results presented in this chapter shed light on the hypotheses of 
lateral gating and OMP -signal but demonstrate that while BamA-assisted 
substrate folding can elucidate a great deal on the interactions between protein, 
lipid and substrate these may not represent the same interactions seen in vivo. 
For BamA lateral gating for example, while the X-link examined is lethal in vivo 
and impairs activity in the BAM complex, it shows no alteration to catalysis of 
wild-type tOmpA folding in DMPC. In the following chapter, studies will move 
away from isolated BamA to examining the effect of lateral gating and other 
aspects of BamA dynamics on BAM complex activity in vitro utilising two 
complementary activity assays. 
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5 Results Chapter 3: Dynamics of the BAM complex 
5.1 Introduction 
As previously discussed, a key aim throughout the project was to determine the 
extent to which the lateral opening of BamA and the dynamics of its β-barrel are 
essential for its catalytic function. Having shown that lateral opening was not 
necessary for BamA catalysis of tOmpA folding into DMPC liposomes (4.2.5), it 
was desirable to move to the full complex and more native-like lipids. Following 
successful purification of the wild-type BAM complex (3.2.1), this could now be 
undertaken. Despite the demonstration that cysteine cross-links constraining the 
BamA barrel lateral gate or lid are lethal in vivo199, their effect on BAM activity 
has never been examined in vitro. Here I use two assays and two substrates to 
begin to unravel this fundamental question. 
In order to examine the role of BamA dynamics, a series of variants were created 
(Figure 5-1). Initially, the same Lateral-lock variant used in BamA alone 
(I430C/K808C) and the cysteine-free control were generated and studied in the 
context of the full BAM complex. It was also desirable to study a different aspect 
of the dynamics of BamA: the mobile loop 6 thought to be important for capping 
the BamA pore. Loop 6, at the top of the BamA barrel, is highly conserved, is 
thought to be important for the folding of BamA and of substrate proteins338,339 
and has been detected in differing conformations277. Most significantly, however, 
this long extracellular loop closes BamA on the extracellular side11 and a cysteine 
pair that would disulphide-lock the loop to the top of strand 1, over the pore 
(E435C/S665C) has also been shown to be lethal in vivo199. This same “Lid-lock” 
variant was therefore created for these studies. Subsequently, it was of interest 
to further constrain the dynamics of BamA and mutations were made to engineer 
the Lateral-lock (I430C/K808C) and Lid-lock (E435C/S665C) cysteine pairs into 
the same protein. This was named “Double-lock”. A final Lateral-lock variant was 
also added (‘Lateral-lock2’: G433C/N805C). This was attempted as an alternative 
to Lateral-lock1 as in the case of Lateral-lock2 the disulphide formed would 
theoretically be in the lumen of the BamA barrel, unlike in Lateral-lock1 where it 
may point into the membrane surrounding BamA199(Figure 5-1a,b). This, as with 
all the other disulphide pairs, had been shown to be lethal in vivo199 and the 





Figure 5-1: Depiction of four disulphide-lock variants in BamA. Positions  of  
all  the disulphide-lock  pair  variants  created  on  the  BamA  barrel, together with a 
schematic for each.  The two wild-type cysteines mutated to serine are indicated in blue 
sticks (C690/C700).  Lateral-lock mutations are indicated by yellow spheres.  Cross-
linking  across  the  proposed  exit  pore  of  the  BamA  barrel  creates  the Lid-lock 
variant  (c),  with  mutated  residues  indicated  in  green.  The Double-lock variant  (d)  
is  created  by  the  double-cysteine  pairs  of  both  Lateral-lock1  and  Lid-lock.  Images  
are  created  in  Pymol  with  structure  4N75340  used  for  (a)  and  (d)  and  5AYW209  
for  (b)  and  (c). 
 
5.2 Purification of BAM complex variants 
BAM complex variants were created using the wild-type pTrc99a BAM complex 
plasmid with site-directed mutagenesis to remove the two wild-type cysteines of 
BamA (C690S/C700S) and sequential mutagenesis to introduce each new 
cysteine. Details of the primers used and properties of proteins created can be 
found in Methods (Table 2-1 and Table 2-3). The optimized protocol for BAM 
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preparation using the detergent DDM was then applied to preparation of all the 
protein variants (Figure 5-2). A good yield and pure complex was obtained for all 
variants; the nomenclature given to each protein and yield following successful 
purification in DDM is given below (Table 5-1).  
 
 
Figure 5-2: Size-exclusion chromatography and SDS-PAGE for purification 
of all BAM complex variants. Shown is an example trace for elution from Superdex 
S200, 10/300 GL column for each variant and SDS-PAGE analysis of a central fraction 






Name Position and identity of substitutions Yield (mg/L grow) 
Wild-type - 2.1* 
Cys-free C690S/C700S 1.9 
Lateral-lock1 C690S/C700S/I430C/K808C 1.8* 
Lateral-lock2 C690S/C700S/G433C/N805C 1.8 
Lid-lock C690S/C700S/E435C/S665C 1.9 
Double mutant C690S/C700S/I430C/E435C/S665C/K808C 1.4 
Table 5-1: Nomenclature, mutagenesis and final yield of BAM complex 
proteins. The yield is calculated as total pure protein per litre of bacterial culture. An 
asterisk (*) denotes proteins for which preparation was carried out more than once, and 
the average yield is given. The mutagenesis to introduce disulphide pairs is indicated in 
bold. 
 
5.3 Reconstitution of BAM variants 
Following optimisation of the protocols for the purification of the wild-type BAM 
complex (3.2.1) and for reconstitution in proteoliposomes (3.4), the other BAM 
complex variants were reconstituted using the same method. Following each 
round of 7-day dialysis, SDS-PAGE was carried out for each BAM variant to verify 
successful reconstitution and presence of all five proteins (BamABCDE). 
Additionally a Pierce BCA assay was carried out to determine an accurate 
concentration of the BAM complex in each proteoliposome batch. Shown is one 
example of reconstitution in proteoliposomes for each variant (Figure 5-3). The 
pelleted proteoliposomes display a clear bandshift of BamA upon boiling, utilising 





Figure 5-3: BAM variants are intact and fully reconstituted in E.coli polar 
lipid proteoliposomes as verified by SDS PAGE. Proteins in TBS +0.05% (w/v)  
DDM (at 50-70μM) were reconstituted in proteoliposomes (to ~7 μM) by extensive 
dialysis. Following this, the samples were centrifuged, the pellet resuspended and 
analysed by electrophoresis with (+) or without (-) boiling. In addition to verifying the 
presence of the full complex, at 1:1:1:1:1 stoichiometry, this shows the bandshift of BamA 
upon boiling, demonstrating successful folding into liposomes.  
 
 
5.4 In vivo lethality of disulphide-lock variants 
It was in vivo assays that initially suggested the importance of the dynamics of 
BamA, demonstrating lethality when disulphide-lock variants were substituted for 
wild-type199. It was decided to repeat this in vivo work to ensure we could 
reproduce this seminal data and to test the effect of other novel mutations. This 
utilises JCM166 cells and a pZS21 plasmid, both kind gifts from Professor Tom 
Silhavy, Princeton University. The pZS21 plasmid has a kanamycin resistance 
gene and contains HT-BamA under control of an arabinose-inducible pBAD 
promoter. The JCM166 cells are carbenicillin resistant, and will naturally express 
wild-type BamA but this is suppressed in the presence of glucose. Growth on 
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glucose-containing medium is only possible if the BamA on the pZS21 plasmid is 
functional25,199. Plasmids used are summarised in Methods Table 2-1. 
Mutagenesis for each disulphide pair had to be done in the pZS21 plasmid by Q5 
site-directed mutagenesis; primers used are detailed in Methods Table 2-4. 
Plasmids were transformed into JCM166 cells, with a pRSFDuet-1 plasmid used 
as an empty vector control. Outgrowth of cells was carried out in arabinose-
containing medium and the transformation mixture was streaked on an 
arabinose/kanamycin/carbenicillin plate.  All transformants are anticipated to 
grow in these conditions, supplemented by arabinose, and this was the case 
(Figure 5-4). Colonies were subsequently picked, grown further in LB+arabinose, 
then pelleted, washed and resuspended to equivalent OD600 (see Methods, 
Section 2.16 for details). Cells of different BamA transformants could then be 
streaked on an LB agar plate containing glucose and incubated at 37 °C overnight 
(Figure 5-5). 
 
Figure 5-4: All BAM complex variants in JCM166 cells are able to grow when 
supplemented by arabinose. The plates show clear growth on LB agar + 100 µg/ml 
carbenicillin + 50 µg/ml kanamycin + 0.2% (w/v) arabinose for all conditions. The plates 
are: 1) Empty pRSF-Duet1 vector, 2-6 pZS21 plasmid with the noted BamA: 2) Wild-type 
BamA; 3) Lateral-lock1 (430C/808C), 4) Lid-lock (435C/665C), 5) Double-lock, 6) 
Lateral-lock2 (433C/805C). Note, all disulphide pairs were introduced into a cysteine-
free (C690S/C700S) pseudo wild-type. Plasmid containing the cysteine-free is not shown 




All plasmids, including empty vector, demonstrate good growth in the presence 
of arabinose (Figure 5-4), while the disulphide-lock variants are not capable of 
growth in the presence of glucose (Figure 5-5). Four of the lateral-lock cysteine 
pairs used in the literature were validated here, although only two, Lateral-lock1 
(430C/808C) and Lateral-lock2 (433C/805C), were used in these studies. Our 
findings were consistent with the literature199, with growth observed for cells 
transformed with plasmids containing wild-type or cysteine-free BamA and with 
none of the disulphide-lock pairs or empty vector (Figure 5-5). Literature studies 
had shown that this effect was specific to formation of the disulphides: single 
cysteine mutations were non-lethal and the viability of cysteine pair mutants was 
rescued by the presence of TCEP199. These controls were not repeated in this 
study. As anticipated, the double-lock variant was shown to be lethal; this had not 




Figure 5-5: Disulphide-lock variants in JCM166 cells are not able to grow in 
glucose conditions. The plates show growth on LB agar + 100 µg/ml carbenicillin + 
50 µg/ml kanamycin + 0.2% (w/v) glucose. In both (a) and (b) condition 1 is empty vector, 
the rest contain BamA on pZS21 as follows:  a) 2) Wild-type 3) 429C/809C 4) Lateral-
lock2: 433C/805C 5) Lateral-lock1: 430C/808C 6) 431C/807C. b) 2) Wild-type 3) 
Cysteine-free 4) Lid-lock 5) Double-lock 6) 435C. All cysteine mutations are carried out 





5.5 Assessing activity of BAM complex variants with the OmpT 
assay 
Having purified and reconstituted the BAM complex variants it was possible to 
assess their activity in OMP folding. This was initially carried out using the OmpT 
activity assay by comparing wild-type and cysteine-free to Lateral-lock1 and 
subsequently the Lid-lock variant. The other two protein variants were not 
generated until later in the project and subsequently not tested in this assay. As 
previously discussed (Chapter 3, 3.5) the OmpT assay is indirect, but provides a 
robust and reproducible means to observe BAM complex activity in folding this 
substrate.  
Testing activity was the crux of the creation of the BAM variants. These 
disulphide-lock variants are all lethal in vivo199 (Figure 5-5). While the lateral-lock 
mutations in the context of BamA-alone catalysis had no effect on tOmpA folding 
(Chapter 4, Figure 4-21), the effect in the BAM complex was anticipated to be 
different. It was unknown whether the disulphide-lock variants would demonstrate 
any activity at all, or perhaps only slightly altered activity compared to wild-type 
BAM complex. This was the purpose behind the optimisation of the OmpT assay, 
as discussed in Chapter 3. It was necessary to find conditions in which changes 
in BAM activity could be easily observed, while minor alterations in 
proteoliposomes or technical handling would not hinder the ability to draw 
conclusions. The conditions optimised in Chapter 3 could now be applied to 
assaying differences between the BAM complex variants. 
It was first demonstrated that wild-type and cysteine-free BAM complex 
proteoliposomes show nearly identical, fast folding activity in all redox conditions 
(Figure 5-6a). The Lateral-lock1 variant, however, demonstrated decreased 
activity relative to cysteine-free and wild-type but this was partially rescued on 
addition of reducing agent (DTT) to break the disulphide bond (Figure 5-6b). 
Example traces are shown, and these data were quantified by the t50, for which 
the average of four replicates is shown (Figure 5-7b). This demonstrates the 






Figure 5-6: OmpT assay shows decreased activity of the Lateral-lock 
variant. Example kinetic traces of OmpT folding by BAM proteoliposomes comparing: 
a) wild-type versus cysteine-free, where all traces overlay and b) wild-type and Lateral-
lock1 variant in all conditions. All experiments were performed with final concentrations 
of 0.25 μM BAM proteoliposomes, 5 μM OmpT, 1 mM fluorogenic peptide, 35 μM SurA, 
with the addition of DTT (50 mM) or CuSO4 (1mM). All experiments were performed in 
50 mM glycine-NaOH pH 9.5, 25 °C. 
 
Following this, the activity of the Lid-lock BAM complex variant was assayed. The 
result was even more striking, with activity more significantly decreased (Figure 
5-7a). Reduction of the Lid-lock disulphide bond by DTT also caused an apparent 
rescue, such that OmpT activity generated is even slightly faster than by wild-
type folding. The dramatically slower folding in buffer and oxidizing conditions 
was consistently observed, and is clearly not only significantly slower than wild-
type and cysteine-free BAM protein, but also slower than the Lateral-lock1 variant 
activity (Figure 5-7b). Altering concentrations of reducing and oxidizing agents 







Figure 5-7: Lid-lock variant shows lower activity by the OmpT assay. a) 
Example kinetic traces of OmpT folding by BAM proteoliposomes, comparing wild-type 
and Lid-lock variant in all conditions. All experiments were performed with final 
concentrations of 0.25 μM BAM proteoliposomes, 5 μM OmpT, 1 mM fluorogenic peptide, 
35 μM SurA, with the addition of DTT (50 mM) or CuSO4 (1mM). All experiments were 
performed in 50 mM glycine-NaOH pH 9.5, 25 °C. b) Bar chart for the average half-time 
of folding reactions with error bars showing standard error of the mean across a minimum 
of four repeats. 
 
 
5.6 Investigating the redox status of disulphide cross-links 
In order to interpret these results it is necessary to ascertain the redox states of 
the proteins. As all the cross-linked variants displayed some activity, as opposed 
to no activity anticipated from their lethality (Figure 5-5)199 it is unclear whether 
this is due to partial disulphide formation or a partial decrease in activity upon full 
cross-link formation.  To answer this question it was intended to resolve and view 
the oxidized and reduced populations of protein by SDS-PAGE.  This would also 
allow quantification of the extent of oxidation. This, however, was not 
straightforward. 
Optimization of the method was carried out on Lateral-lock1, initially using DTT 
and CuSO4 as used in the OmpT activity assays. BioRad 4-20% acrylamide (w/v) 
gradient gels, as had been used in publications showing the redox state of BamA 
in DMPC231 were first used. In addition, another larger gradient gel (4-20% (w/v) 
Novex gel) was also tested. Neither demonstrated noticeably different migration 
of BamA in reduced or oxidized conditions (Appendix1, Figure A1-1-2). The next 
gel type assayed was a homemade Tris-Glycine 5% (w/v) acrylamide gel, 
previously used to show the formation of the same disulphides studied here in 
the in vivo experiments199 (see Methods 2.6.3 for details). Separation of reduced 
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and oxidized forms of BamA was possible, revealing that Lateral-lock1 BAM 
appeared incapable of complete oxidation (Figure 5-8). 
 
Figure 5-8: SDS-PAGE for redox state of wild-type and Lateral-lock1 BAM 
complex. Proteoliposomes at 2 μM in TBS pH 8 were incubated with TBS (-), DTT (25 
mM) or CuSO4 (1 mM) for 1 hour at room temperature. Samples were mixed with 6x SDS 
loading buffer and boiled for 30 minutes. The samples were run on a 5% (w/v) acrylamide 
Tris-Glycine gel with MOPS buffer at 30 mA, 180 minutes, 4ºC.   
 
In an attempt to drive oxidation to completion multiple different oxidizing agents 
were tested, at varying concentrations, in both protein solution (in TBS+ 0.05% 
(w/v) DDM) and reconstituted proteoliposomes, for longer incubations and at 
higher temperatures (Appendix 1, Figure A1-3-Figure A1-4). None of these 
alterations appeared to impact the relative populations of reduced and oxidized 
Lateral-lock1 BamA observed. The oxidizing agent was switched from CuSO4 to 
diamide at this point, as this is commonly used in experiments requiring cell 
membrane permeation341,342. It appeared that a lower concentration was showing 
the same oxidative potential. It was also easily soluble in the TBS pH 8 buffer 
used and did not significantly alter pH.  It was noted that the Lid-lock variant 
showed a fully oxidized population in the presence of oxidizing agent (Appendix1, 
Figure A1-3). It was hypothesised that full oxidation could not be achieved for 
Lateral-Lock1 due to the position of the disulphide bond, facing into the 
membrane surrounding the barrel (Figure 5-1)199. Previous in vivo work 
demonstrated a greater extent of oxidation for all disulphides than seen here, and 
notably marginally higher for those directed towards the lumen of BamA relative 
to those facing the membrane199. Consequently a Lateral-lock2 variant (433/805) 
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was generated, where the disulphide would point into the lumen of the barrel and 
perhaps be easier to oxidize.  The Lid-lock variant is clearly capable of full 
reduction and oxidation, migrating as a single band reproducibly, with distinct 
mobility under oxidizing and reducing conditions (Figure 5-9). However Lateral-
lock2 was not capable of full oxidation (Figure 5-9). The Double-lock variant 
shows a more confusing pattern. While capable of full reduction, to a single band, 
the buffer and +diamide conditions appear to display a mixed population, but with 
consistent smearing between the bands (Figure 5-9).  This suggests formation of 
one or both of the potential disulphides. 
 
 
Figure 5-9: Redox SDS-PAGE for all BAM complex variants. BAM  
proteoliposomes  in TBS pH 8 were  diluted  to  2  μM  with  the  addition  of  buffer  (-),  
25  mM  DTT  or  100  μM  diamide.  5%  (w/v) acrylamide Tris-Glycine gels  were  used,  
run  with  MOPS  buffer  at  4°C,  3  hours,  30  mA  per  gel and stained with Instant 
Blue.   
 
These results inform our understanding of the OmpT assay results. While the 
activity of the Lateral-lock1 variant may be due to the population of protein that is 
not fully oxidized, this cannot be true for the Lid-lock BAM variant which is 
completely oxidized. Additionally, in both cases, reduction with DTT resolves 
protein to a single, reduced BamA band (Figure 5-9). However in the OmpT 
assay, the Lid-lock BAM proteoliposomes in reducing conditions demonstrate 
better than wild-type activity, while the Lateral-lock activity does not appear to 
fully recover (Figure 5-7b). One potential explanation is that the mutations 
introduced in the Lid-lock variant intrinsically improve activity while those of the 
Lateral-lock variant decrease it. 
One further assay was carried out to determine whether the protein was 
recalcitrant to oxidation and to obviate the possibility that one or both of the 
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sulfhydryls were already oxidized (by forming a disulphide bond with a small 
molecule for example). Firstly, as it is evident that both lateral-lock variants can 
be fully reduced (by the appearance of a single higher MW band) it appeared that 
perhaps by first reducing, then re-oxidizing the protein, it might be possible to 
reach full oxidation of the protein.  
This was attempted using the protein in detergent, fully reducing it and then 
binding to nickel beads and washing to remove reducing agent, then incubating 
with oxidizing agent (see Methods 2.6.3.1 for details). Samples pre-experiment 
(P), following DTT treatment (Reduced:R) and final (F) were mixed with SDS 
loading buffer and analysed by gel electrophoresis (Figure 5-10). The experiment 
demonstrates that while the proteins are fully reduced, with a single higher 
apparent molecular weight band for R sample in all variants, the final sample is 
once again a mixed population. This is particularly evident for Lateral-lock2, for 




Figure 5-10: SDS-PAGE analysis of “Reduce then Oxidize” for disulphide 
variants. Protein in TBS+DDM diluted to 4 μM was treated with DTT, incubated with 
nickel beads and washed and then treated with diamide. Samples are shown for Pre 
DTT (P), Reduced (R), first Wash (W), and Final (F). Samples were mixed with 6x loading 
buffer, boiled for 15 minutes and analysed on a 5%  (w/v) acrylamide Tris-Glycine gel 




The samples were also submitted for mass spectrometry analysis. It was 
hypothesised that a modification on the free cysteine that would impede formation 
of a disulphide, would be detectable as a secondary population by mass 
spectrometry. On the contrary, deconvolution of the mass spectrometry of both 
Lateral-lock proteins in detergent (where a mixed population is observed by gel) 
showed a single peak for the membrane protein region. It was determined that 
both lateral-lock BAM complex variants could not be fully oxidized and would 
remain in a mixed population. The extent of oxidation was consistent across 
proteoliposome preparations, and could be quantified (Figure 5-11). Analysis  of  
the average  fraction  oxidized  determines  that  this  does  not  differ  greatly  
between  the  two  lateral-lock  variants,  or  with  the  addition  of  (oxidizing  
agent) diamide.  
 
Figure 5-11: Fraction Oxidized for BAM proteoliposomes containing 
Lateral-lock1 and Lateral-lock2 variants. Analysis is  carried out  by  densitometry  
using  ImageJ.  Fraction oxidized is calculated as the ratio between intensity of the 
oxidized band and the sum of the oxidized and reduced band intensities.  Analysis  was  
carried  out across  5%  (w/v) acrylamide redox gels  (minimum  3  for  every  condition)  
with  average  and  standard deviation  shown. The significance of variation between 
conditions was assessed with two-sample t-tests. * indicates a significant difference with 





5.7 Assessing activity of BAM complex variants with a novel 
tOmpA assay 
The OmpT enzymatic assay is the most widely used method to assess BAM 
complex activity in vitro159,189,272,274. Yet this is an indirect assay, is not without 
considerable limitations, some of which are discussed (Section 3.5). Orthogonal 
assays used in the literature include assessing substrate protein folding by SDS-
PAGE followed by autoradiography159,189 or western blot272,274. These both exploit 
the heat modifiability property of OMPs that they will separate according to their 
folded and unfolded populations on SDS-PAGE. These assays are both indirect, 
assuming that folded and unfolded populations will be detected equally. While a 
fair assumption for autoradiography, this is not always the case for western blot, 
as has been shown for OmpG which exhibits lower detection of the folded form273. 
Detection by an antibody will depend on the peptides to which the antibody has 
been raised. Controls are necessary to ensure that the region of protein is equally 
exposed in both folded and unfolded protein conformations, that these migrate 
into the blotting membrane equally and are detected proportionately by antibody.  
Observing the folding of proteins directly by SDS-PAGE, while widely-used for 
monitoring spontaneous or BamA-assisted OMP folding in liposomes71,72,241 has 
not been performed for BAM-assisted OMP folding, likely due to the large number 
of proteins on the resulting gel and the low concentrations of OMP substrate 
typically used. Many substrate proteins are unsuitable for such an analysis, 
overlapping with one or other of the BAM subunits (unfolded OmpT 35 kDa with 
BamC 37 kDa; OmpA 37 kDa, between BamB 42 kDa and BamC 37 kDa). 
However, a deletion variant of the widely used substrate protein OmpA that is 
comprised of just the transmembrane domain (tOmpA) is 18 kDa, folds identically 
to full-length OmpA273 and migrates between BamD and BamE in both folded 
(~15 kDa) and unfolded (~18 kDa) forms. In order to be easily detectable and 
quantifiable by SDS-PAGE, the concentration of substrate OMP had to be 
suitably high. After some optimization, Dr Bob Schiffrin (University of Leeds) 
found that a 2 μM concentration of tOmpA and a 1 μM concentration of BAM 
provided conditions in which all proteins could be visualized by SDS-PAGE and 
the relative abundance of tOmpA folded and unfolded populations could be easily 
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quantified. The concentration of SurA, used to maintain high solubility of tOmpA, 
was less important, but was maintained at 10 μM, providing a 5-fold excess over 
substrate. Under these conditions the folding of tOmpA by the BAM complex 
could be reliably, consistently and quickly monitored. Folding of tOmpA by wild-
type BAM complex was complete after ~1 hour, enabling a time course of folding 
to be constructed by a discontinuous assay. Folding was initiated by mixing the 
protein components with proteoliposomes and then quenched after each 
timepoint by addition to SDS loading buffer (see Methods, Section 2.13).  
Analysis over longer folding times show that while folding by wild-type or cysteine-
free BAM proteoliposomes is complete after ~2 hours, little folding (0-2%) of 
tOmpA occurs in an equal volume of empty liposomes, in the absence of the BAM 
complex (Figure 5-12). Additionally, removal of SurA diminishes folding (Figure 
5-12).  
 
Figure 5-12:  Minimal folding is observed in empty liposomes and in the 
absence of SurA. The assay involves 1 µM BAM proteoliposomes, 2 µM tOmpA, 10 
µM SurA, 0.8 M urea, TBS pH 8, 25°C. Experiments were carried out at 25°C and, at the 
indicated time point, an aliquot of 15 µL was quenched by addition to 5 µL of 6x SDS 
loading buffer. Controls involved incubation for 2 and 4 hours and overnight (O/N) ~20 
hours. Example control SDS-polyacrylamide gels are shown with (a) and without (b) 
SurA. In (c) average and standard deviation of at least two replicates is shown. No folded 
tOmpA band is seen for empty liposomes in the absence of SurA. 
 
This assay therefore is robust and was next used to determine changes in 
catalytic activity for variants of the BAM complex. Two sub-reactions were set up: 
BAM proteoliposomes were diluted to 4 μM (2x final concentration) in TBS pH 8 
containing redox agents where necessary (also at 2x final concentration). The 
second subreaction comprised of SurA and tOmpA at 2x final concentration. The 
folding reaction was initiated by addition of equal volume of the SurA-tOmpA mix 
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to the BAM proteoliposomes (see Methods Section 2.13 for details). Following 
initiation of the folding reaction, the sample was maintained at 25 °C and folding 
of the samples was quenched at the appropriate time-points by addition of 15 μL 
sample to 5 μL 6x SDS-loading buffer. Samples were maintained at 25 ºC until 
all time-points had been taken and were immediately loaded on 15% (w/v) 
acrylamide Tris-Tricine buffered SDS-PAGE at room temperature, without 
boiling. An example SDS-PAGE of the folding reaction is shown (Figure 5-13). 
Ten time points were taken, between 2 minutes and 2 hours. 
 
Figure 5-13: BAM-catalysed folding of substrate can be measured by SDS-
PAGE. Example SDS-polyacrylamide gel demonstrating the analysis of the folding of 
OMP substrate tOmpA by BAM proteoliposomes in the presence of SurA. The assay 
involves 1 µM BAM proteoliposomes, 2 µM tOmpA, 10 µM SurA, 0.8 M urea, 20 mM Tris 
pH 8 150 mM NaCl, 25°C. Experiments were carried out at 25°C and at the indicated 
time point an aliquot of 15 µL was quenched by addition to 5 µL of 6x SDS loading buffer. 
 
The assay was carried out for wild-type, cysteine-free and all four disulphide-lock 
BAM complex variants in buffer, oxidizing and reduced conditions, see Appendix 
2 for an example gel in each condition. Folding was quantified by densitometry 
using ImageJ, of every lane within a gel using: 





It has been observed previously that tOmpA populates intermediate ‘elusive’ 
states during folding230. By contrast, we observed that the total band intensity 
(folded +unfolded) remained relatively constant across the folding time course 
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ruling out population of such species under the conditions employed here. 
Increase in folded band intensity was observed with a corresponding decrease in 
unfolded band intensity. This justifies quantitation of fraction folded using 
Equation 5-1. 
The result of the experiment comparing buffer conditions for the proteoliposome 
variants is immediately striking. While wild-type and cysteine-free BAM complex 
show relatively fast and similar folding rates of tOmpA, all four disulphide-lock 
variants show similar inhibited activity (Figure 5-14). 
 
Figure 5-14: All disulphide-locked BAM variants show similarly impaired 
activity. Average kinetic traces for all BAM variants folding tOmpA with fraction folded 
over time. Fraction folded for tOmpA is quantified by densitometry using ImageJ, of every 
lane within a gel using Equation 5-1. SDS-PAGE experiments were repeated a minimum 
of three times with the average and standard deviation shown and fit to a single 
exponential function. 
 
It is striking that the variants are able to catalyse folding tOmpA where in vivo 
lethality might predict an absence of activity. It is also notable that all variants 
show near identical traces in buffer conditions, indicating a consistent residual 
level of folding in the presence of the BAM complex. Comparison of the rates of 
BAM-catalysed tOmpA folding in buffer, reduced and oxidized conditions for each 
variant (Figure 5-15), demonstrates that in all disulphide-lock variants with the 
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exception of Lateral-lock1, folding is rescued to equal or greater than wild-type 
levels on addition of DTT. Shown are the average traces for folding by each 
variant, with wild-type shown in each for consistency and clarity (Figure 5-15). 
 
Figure 5-15: Average tOmpA folding by each BAM complex 
proteoliposomes in all redox conditions. Averaged kinetic traces for the folding 
of tOmpA catalysed by each BAM variant in buffer, reduced and oxidized conditions. 
SDS-PAGE experiments were repeated a minimum of three times, and quantified by 
Equation 5-1 with the average and standard deviation shown. Lid-lock+Diamide is only 
2 repeats. Experiments  were  performed  with  the  addition  of  25  mM  DTT  or  100  





In every case the average trace is fit to a single exponential from which a rate 
constant may be extracted. It is possible to compare across the wide range of 
variants and conditions by comparison of the exponential rate constants, extent 
of folding at a single time-point (eg. 1 hour) or t50. The 1 hour time-point is used 
as at this point wild-type and cysteine-free BAM complex variants show nearly 
complete (>84%) folding of substrate, whereas all disulphide-lock variants show 
~50% folding in buffer conditions. The comparison shows that in wild-type and 
cysteine-free BAM proteoliposomes the addition of redox agents does not alter 
activity. In all disulphide-lock variants the addition of reducing agent increases 
the extent of folding observed (Figure 5-16). This indicates a strong trend for 
rescue of the variants upon reducing agent breaking the disulphide bond. In the 
case of Lateral-lock2, Lid-lock and Double-lock the variants are fully active, to 
greater than wild-type levels, when reduced (Figure 5-16). This is not the case 
for Lateral-lock1, which shows only partial increase in activity. This is unexpected 
considering the more significant rescue of this variant seen in OmpT folding 
assays (Figure 5-6b & Figure 5-7b), but also surprising as the Double-lock 
variant, which shows full rescue, contains the cysteine pair of Lateral-lock1. The 
evident difference between Lateral-lock1 and Lateral-lock2 may also be affected 
by the positions of the cysteines, which in Lateral-lock1, pointing into the 
membrane (Figure 5-1a) may diminish activity. It is significant, however, that for 





Figure 5-16: All  disulphide-lock  variants  show  impaired  activity,  rescued  
in the majority of cases by  addition  of  DTT.  Comparison  of  all  conditions  
using  the  average  fraction  folded  at  1  hour  time-point.  Shown are the averages and 
standard deviation of three replicates, with the exception of Lid-lock+diamide which is 
only 2 repeats. 
 
It was also of interest to quantify folding over longer timescales to determine 
whether the disulphide-lock variants were capable of folding tOmpA to 
completion. Folding assays were therefore performed as described previously. 
The reactions were set to fold, but time-points were taken at 2 and 4 hours and 
overnight (~20 hours) and analysed on SDS-PAGE with comparison to other 
variants at long time-points. Example SDS-PAGE are shown in Figure 5-17 and 
Figure 5-18. This demonstrated that given sufficient time, the variants are able to 
fold tOmpA to completion (Figure 5-19). This is in contrast to the controls 
previously shown (Figure 5-12) demonstrating that in empty proteoliposomes 





Figure 5-17: Example of SDS-PAGE for longer time-points of folding by 
wild-type, Lateral-lock1 and Lateral-lock2 BAM proteoliposomes. The  same  
experiment  was  carried  out  as  previously  with  time-points  taken  after  2 and 4 hours 
and  overnight (O/N, ~20  hours).  Most samples are shown without boiling (-), but 
overnight samples are also shown boiled (+) where BamA and tOmpA migrate according 
to their expected molecular weight. 
 
Figure 5-18: Example of SDS-PAGE for longer time-points of folding by Lid-
lock and Double-lock BAM proteoliposomes and empty liposomes. The  
same  experiment  was  carried  out  as  previously  with  time-points  taken  after  2 and  
4  hours and overnight (O/N, ~20  hours).  Most samples are shown without boiling (-), 
but overnight BAM-folded samples are also shown boiled (+) where BamA and tOmpA 






Figure 5-19: Folding with  all  BAM  complex  variants  eventually  reaches  
completion. The  same  experiment  was  carried  out  as  previously  with  time-points  
taken  after  2,  4  or  ~16  hours and quantified according to Equation 5-1.  Shown are 





5.8 Concentration titration of BAM proteoliposomes 
In both lateral-lock samples the oxidized population in proteoliposomes is, on 
average ~50% of the protein sample (Figure 5-11). In addition, both variants show 
approximately 50% of the activity of wild-type BAM proteoliposomes for folding 
tOmpA in the same conditions (Figure 5-16). One might therefore deduce that the 
reduced fraction of the sample (~50%) is contributing to this observed activity 
(~50%) while the oxidized portion is non-functional. 
It was decided to test this hypothesis by carrying out the tOmpA folding assay 
with a titration of Lateral-lock2 at decreasing concentrations in the presence of 
DTT. The tOmpA folding reaction was therefore initiated with different 
concentrations of BAM and the fraction tOmpA folded at the 1 hour time-point 
was compared. Controls included Lateral-lock2 in the absence of DTT and 
titration of the concentration of wild-type BAM.  
Should the oxidized protein be inactive, then the activity of the 100% 
concentration of Lateral-lock2 without DTT (Figure 5-20, green bar) would be 
approximately matched by the 50% concentration of Lateral-lock2+DTT. This 
folding yield is indicated in Figure 5-20 with a dotted line. Instead, the 50% 
concentration of Lateral-lock2+ DTT (0.5 µM, indicated with an asterisk) 
demonstrated a higher fraction folded of tOmpA. Low concentrations of Lateral-
lock2 +DTT exhibit greater activity than the Lateral-lock2 without DTT (Figure 
5-20, green bar, dotted line). This indicates that the reduced portion of Lateral-









Figure 5-20: Decreased concentration of Lateral-lock2 BAM 
proteoliposomes in the presence of DTT demonstrates higher than 
anticipated activity. The assay typically involves 1 µM BAM proteoliposomes, 2 µM 
tOmpA, 10 µM SurA, 0.8 M urea, TBS pH 8, 25°C. BAM proteoliposomes were diluted 
in TBS pH 8 to final experimental concentrations of 0.1- 1.0 μM and pre-incubated with 
DTT (to final concentration 25 mM) where appropriate. Experiments were carried out at 
25 °C. Folding was quenched after one hour by addition to 6x SDS loading buffer. 
Samples were analysed by SDS-PAGE with all samples from one variant on the same 
gel. 
 
The data appear to suggest that the oxidized form of Lateral-lock2 diminishes the 
otherwise high activity of the reduced form in folding tOmpA. One potential 
explanation is that the oxidized form creates a non-productive interaction: able to 
recognise and bind tOmpA but unable to catalyse folding. This would create a 
tOmpA “sink” such that the tOmpA folding yield of Lateral-lock2 (without DTT) 
would be lower than that seen for folding by a 50% concentration of reduced 
Lateral-lock2 alone, where the non-productive interaction does not occur. This 
explanation fits, however it is difficult to presently draw conclusions as at the 
concentrations and time-points measured here, folding of substrate is nearly 
complete in the majority of samples. The relationship between fraction folded and 
BAM concentration is clearly not linear for wild-type or Lateral-lock2+DTT in the 
conditions used. One cannot be certain of the effect of the Lateral-lock2 oxidized 
populations, as it is evident that halving the concentration of BAM (eg. 
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comparison of 1 µM and 0.5 µM) is not halving the subsequent tOmpA folding 
yield for either wild-type or Lateral-lock2. Rather than an endpoint assay, as in 
these data, to examine BAM as an enzyme I wish to extract initial rates of 
substrate folding, which should increase linearly with respect to BAM 
concentration. In order to do this in the future, the substrate concentration will be 
decreased, such that enzyme (BAM) excess can be assumed. Initial rates will be 
measured by increasing the number of early time-points measured in the folding 
of tOmpA. The behaviour of BAM as an enzyme will be verified by demonstrating 
that an increasing concentration of wild-type BAM yields a corresponding 
increase in initial rate. Finally, the initial rate of oxidized and reduced Lateral-
lock2 proteoliposomes will be determined.  For Lateral-lock2 BAM without 
reducing agent, containing a mixed population, three clear outcomes are 
possible, with different explanations. If the oxidized population is inactive, then 
initial rate of Lateral-lock2 would be at 50% that of Lateral-lock2+DTT. If the 
oxidized population is detrimental to overall activity, the resulting initial rate would 
be lower than fully reduced protein and if the oxidized population is contributing 
to activity then initial rate would be higher. Theoretically these comparisons will 
allow us to determine the extent to which BAM, locked across the β-barrel can 
contribute to catalytic activity. These simple experiments should help to 
determine the nature of the lateral-lock in the BAM complex in addition to 
examining the enzymatic properties of BAM complex catalysis.  
 
5.9 Discussion 
This chapter applies the optimisation of purification and reconstitution of the BAM 
complex described in Chapter 3 to studies of the importance of BamA dynamics. 
I generated four BAM complex variants with cysteine pairs to produce disulphide 
cross-links, and also a cysteine-free pseudo wild-type control. These complexes 
were purified (Figure 5-2) and reconstituted in proteoliposomes (Figure 5-3). I 
demonstrated that all of the disulphide-locking variants are lethal in vivo (Figure 
5-5), replicating literature findings199 with a novel finding in the case of the 
Double-lock variant. Utilising the OmpT activity assay in the conditions optimised 
previously (Section 3.5.1) I assessed the catalytic activity of lethal disulphide 
cross-linking of the BAM complex for the first time.  
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It is now widely understood that BamA visits both lateral-open and –closed 
conformations by structural studies showing the BAM complex in both states207-
210. While it is known that disulphide lateral-locking or Lid-locking of BamA is lethal 
to cells199, presumably as it is detrimental to BamA function, studies by myself, 
and another group231 have demonstrated that this effect does not translate to the 
catalytic activity of BamA in LUVs. In these BamA is equally functional in its lateral 
locked form. The effect of these disulphide locks, constraining BamA dynamics, 
on the catalytic activity of the full BAM complex have never previously been 
studied in vitro. 
I have demonstrated that both the Lid-lock and the Lateral-lock1 variants have 
diminished activity as assessed by the OmpT assay, which is rescued by the 
addition of reducing agent (Figure 5-7). All of the BAM complex disulphide 
variants display near identical decreased activity in the folding of tOmpA which is 
rescuable in the cases of Lateral-lock1, Lid-lock and Double-lock by addition of 
reducing agent (Figure 5-16). The consistent diminished activity appears to imply 
a base level of folding on constraining the dynamics of the BAM complex. This 
level of folding is not seen in empty proteoliposomes (Figure 5-12), and with 
sufficient time all BAM variants are capable of folding substrate to completion 
(Figure 5-19).  This suggests that the presence of the BAM complex, even 
constrained, catalyses folding. This may support a mixed model of BAM complex 
function: both by lateral opening dynamics, and by membrane destabilization.  
This chapter discusses a novel assay quantifying the folding of substrate by BAM 
complex proteoliposomes directly using SDS-PAGE. In contrast to previous 
reports of a tOmpA ‘elusive state’ in folding230, with an apparent disappearance 
of protein intensity, the sum of folded and unfolded band intensities remains 
relatively constant. The assay is robust, reliable and consistent, with reproducible 
kinetics of tOmpA folding by wild-type BAM proteoliposomes across different 
preparations of BAM and SurA and carried out by multiple members of the lab. In 
addition the assay has proved sensitive to alterations in the BAM complex and to 
altered concentrations of BAM. This assay is now being used further to examine 
the folding of other substrates by the BAM complex (eg. OmpX), to look at the 
role of SurA (as mentioned in Chapter 3, 0) and will be used to characterise the 
tOmpA variants previously mentioned (Sections 4.3 and 4.4). 
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The concentration titration carried out (Figure 5-20) is fascinating on two counts. 
Not only does it contradict the assumption that the oxidized population of the 
Lateral-lock protein is inactive and instead suggests it is detrimental to BAM 
catalytic activity, but a titration of the BAM complex such as this has not been 
carried out in studies of substrate folding. Previous studies have postulated a 
catalytic mechanism for BamA function by experiments on titration of substrate, 
demonstrating BamA can fold substrate to a higher concentration than the 
concentration of folded BamA. These studies on BamA245 and the BAM 
complex159 both suggest  a catalytic turnover of ~1.6 OMPs per BAM. The 
sigmoidal curve seen for titration of wild-type BAM complex (Figure 5-20) 
demonstrates sensitivity in this assay to low concentrations of BAM complex, but 
also demonstrates better than anticipated activity of the complex at these 
concentrations.  
The yield of tOmpA folding in this assay appears to exceed expected turnover, 
with BAM complex at 1 µM readily capable of folding 2 µM tOmpA quickly. The 
high fraction of tOmpA folded by low concentrations of wild-type and better still 
by Lateral-lock2 BAM within an hour (Figure 5-20) suggest that catalytic turnover 
is accelerated in the conditions used in this assay. For example, 0.4 µM Lateral-
lock2 +DTT folds nearly 80% of 2 µM tOmpA, suggesting a folding yield of 1.6 
µM, which is approximately four times the concentration of BAM complex. The 
basal rate of folding, in the presence of SurA would need to be more accurately 
measured to quantify the extent to which this is due to BAM. Once again, further 
studies will be required to untangle this catalytic rate, but this supports previous 
findings that BamA works by a catalytic mechanism159,245 and suggests that the 
catalytic turnover has been underestimated.  
In addition, experiments here demonstrate that disulphide variants, when 
reduced, may be more active than wild-type BAM, particularly in the cases of 
Lateral-lock2 and Lid-lock variants. This suggests that mutagenesis introducing 
cysteines to constrain the BamA barrel, creates a more active BAM complex. For 
the Lid-lock variant, this is dramatically seen in the OmpT assay (Figure 5-7). For 
Lateral-lock2 the titration data demonstrates consistently higher catalysis relative 
to wild-type BAM (Figure 5-20). In studying constraints of the BAM complex we 
have developed an enzyme that is in fact more active. Further work is needed to 
understand why this is the case. 
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Conclusions can most easily be drawn from the Lid-lock variant which exhibits 
disulphides in a fully oxidised state in the presence of buffer and diamide, but is 
fully reduced in the presence of DTT (Figure 5-9). This is in contrast with the other 
disulphide variants in which a totally oxidized population can never be obtained 
(Figure 5-9). The Lid-lock variant is lethal in vivo, in our assays (Figure 5-5) and 
in the literature199,208. Yet the Lid-lock variant clearly demonstrates that BAM 
retains activity, even with a fully oxidized cysteine cross-link (Figure 5-15e) and 
this is restored to wild-type levels of activity on reduction of the disulphide. 
Furthermore, folding of tOmpA by the Lid-lock variant in the absence of DTT 
(where the disulphide is fully oxidized), will eventually reach completion (Figure 
5-19). This demonstrates that the cross-link imposes a purely kinetic constraint 
on Lid-lock catalysis of substrate folding, which translates to lethality in vivo. 
Some explanation may be posited utilising the recent demonstration that the 
accumulation of unfolded OMPs in the periplasm is lethal to cells343. These recent 
studies, on an inhibitor of the chaperone RseP, demonstrate that reduction in cell 
viability due to this inhibitor can be overcome by overexpression of DegP, to 
remove levels of unfolded OMPs343. Similarly, deletion of the genes for abundant 
OMPs OmpA and OmpC confers resistance to the inhibitor, whereas cells 
possessing a defective BAM complex display increased sensitivity343. In the case 
of the BAM Lid-lock variant therefore, the slower activity of folding observed in 
vitro may be sufficient to cause a toxic level of unfolded OMPs. Therefore we 
begin to piece together a model where constraining the dynamics of the BamA β-
barrel slows the catalytic activity of BAM, likely causing accumulation of unfolded 





6.1 Overall Conclusion of Results 
This thesis has endeavoured to investigate BAM-assisted OMP folding, 
particularly the role of BamA dynamics, with a plethora of biochemical and 
biophysical techniques. From an initial launching point of examining in vitro how 
BamA lateral gating may influence BamA catalytic activity, the project has 
expanded to examine the BAM complex, membrane mimetics and the β-signal 
hypothesis.  
The data presented in Chapter 3 summarise the optimisation of the BAM complex 
preparation and the standard assay for its activity, the OmpT protease assay. The 
optimised purification protocol led to the sole published cryo-EM structure of the 
complex, which displayed BamA in a lateral-open structure in the presence of the 
full complex, and remains the only structure of the intact complex in this 
conformation207-209. 
Two approaches were taken to unpick the mechanism of BAM-assisted OMP 
folding and the role of BamA dynamics in OMP dynamics. Firstly, the work in 
Chapter 4 described the catalytic activity of isolated BamA in DMPC lipids in 
folding the substrate tOmpA. This system has been well characterised163,241,288 
and could easily be applied to investigating the effects of different variants of 
BamA. The results demonstrated no difference in BamA catalytic activity between 
the wild-type and lateral-lock forms of BamA. This implies that in DMPC LUVs, 
for folding of tOmpA, the lateral opening of BamA is not essential. 
The second approach investigating the role of BamA dynamics utilised the intact 
BAM complex, following its successful purification and reconstitution discussed 
in Chapter 3. A wider range of BamA variants were tested in the BAM complex: 
two examples of cysteine pairs across the lateral gate, a variant to lock the 
substrate exit pore (‘Lid-lock’) and a Double-lock variant. Two assays were 
employed, the OmpT enzymatic assay on Lateral-lock1 and Lid-lock variants, and 
tOmpA folding by SDS-PAGE using all BAM variants. 
The results demonstrated that cysteine pairs to lock the conformation of the 
BamA barrel only impair, but do not abolish BAM-catalysed OMP folding, of 
OmpT and tOmpA in E.coli polar lipid proteoliposomes. I further demonstrated 
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that folding of tOmpA by any of the BAM complex variants in proteoliposomes will 
eventually reach completion (Figure 5-19). Interestingly, all of the cysteine pairs 
are lethal in vivo199. The diminished folding kinetics of the variants render them 
inadequate in the context of the cell. Perhaps this is due simply to the fast 
turnover necessary in the cell, with both nascent protein production and 
minimisation of potential toxic intermediates, or perhaps the BamA cysteine-lock 
variants are incapable of folding larger substrates.  
One must consider the possibility that if the formation of the disulphide in the BAM 
variants does not reach completion, it is in fact the non-oxidized population of the 
protein that is providing all activity. In the case of BAM complex variants, activity 
is partially diminished and rescued on addition of reducing agent, therefore 
alterations in redox state have a clear effect. However, for BamA catalysis in 
DMPC no changes in activity are observed with addition of reducing or oxidizing 
agent (Figure 4-21).  Non-reducing PAGE confirmed that the majority of the 
protein is in the oxidized state in buffer and under oxidizing conditions, but is 
entirely reduced in the presence of reducing agent. The lack of change in 
observed BamA activity with changes in redox state leads us to conclude that the 
lateral lock (and therefore the redox state of it) makes no difference to the ability 
of BamA to catalyse tOmpA folding in vitro. 
For the lateral-lock and Double-lock variants of the BAM complex, BamA remains 
in a mixed population, therefore it has not yet been ascertained what proportion 
of the activity can be ascribed to the reduced or oxidized populations. A titration 
experiment was carried out to determine the compensating effect of the mixed 
population: at what fraction of Lateral-lock2 BAM in reduced state is the resultant 
activity equal to the partially oxidized population. However the results 
demonstrate that activity in the reduced state is likely worsened by the presence 
of protein in the oxidized state (Figure 5-20) and further experiments on the 
kinetics of each BAM variant are necessary to unpick these data. The finding that 
folding of tOmpA by the BAM complex variants will reach completion, and 
differences are primarily kinetic, is particularly insightful for the Lid-lock variant, 
in which BamA is fully oxidized, as confirmed by non-reducing PAGE. The results 
conclusively demonstrate that the fully oxidized, and therefore constrained Lid-
lock BAM shows partial function in catalysing tOmpA folding. 
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Additionally, I have used a cumulative perspective of the assays discussed in this 
thesis to examine two aspects of the OMP β-signal hypotheses. I have examined 
firstly the hypothesis of species-specificity: that E.coli BamA will not recognise 
signal sequences from a different organism211 using a hybrid tOmpA mutant 
containing residues from the signal sequence of N.meningitidis PorA with 
otherwise E.coli tOmpA sequence. The results provide further evidence that 
BamA in DMPC liposomes acts primarily according to the membrane disruptase 
model of function (Introduction 1.10). Folding of tOmpA-RHK is catalysed by wild-
type BamA with the same fold change as for wild-type tOmpA, implying no 
impaired recognition of the protein. Conversely, however, folding of tOmpA-RHK 
catalysed by Lateral-lock1 BamA is considerably slower. This suggests that 
impairing the dynamics of the BamA barrel diminishes its catalytic effect of folding 
an unfamiliar substrate. It remains possible that other components of the BAM 
complex increase the specificity of substrate recognition, therefore continuation 
of this project would focus on BAM-catalysed folding. This work has also included 
investigation into the conserved Gly of the β-signal which appears to exhibit a 
structural role in OmpT but not in tOmpA. In OmpT, mutation of Gly306, even to 
Ala, produces a protein incapable of spontaneous folding to an SDS-resistant 
structure. Mutation of the conserved Gly both in OmpT (G306A and G306P) and 
tOmpA (G166A) slows BAM-catalysed folding in E.coli liposomes (Figure 4-36 - 
Figure 4-39). This implies that little variation on this highly conserved residue can 
be tolerated. 
 
6.2 Evidence towards the models of BAM function 
The outer membrane proteins (OMPs) of Gram-negative bacteria must be 
transported to, and assemble in, the OM in an environment devoid of chemical 
energy, and far from their site of synthesis. The final step in this pathway is 
folding, catalysed by the BAM complex. Despite being essential21, 
conserved21,24,57 and with available structural models207-209 the mechanism of 
function of the BAM complex is not yet clear. There are several proposed models, 
summarised as threading, oligomerisation, membrane destabilisation and lateral 
opening, addressed in detail in Introduction, Section 1.10. The work in this thesis 
was driven particularly towards understanding the model of BamA lateral opening 
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and the extent to which this is important in BamA-catalysed OMP folding. The 
results have provided evidence relevant to several of the models: not only lateral 
opening, but membrane destabilisation and oligomerisation.  
The absence of a role for lateral opening in the case of BamA-catalysed tOmpA 
folding in DMPC LUVs lends support to the hypothesis that BamA destabilises 
membranes. In accord with this idea, parallel work by Dr Bob Schiffrin (University 
of Leeds) demonstrated the increased catalytic effect of BamA in longer chain 
lipid bilayers241, evidencing its role in reducing the energetic penalty of folding 
into these bilayers.  
In the context of the BAM complex, however, the results presented in Chapter 5 
demonstrate that any constraint on the dynamics of the BamA barrel does indeed 
reduce, but does not abolish, its ability to catalyse OMP folding. The clear role for 
lateral opening in the scenario of BAM-catalysed folding into E.coli lipid bilayers 
implies a strong lipid dependence for this mechanism. In addition, the mechanism 
may be substrate-dependent with an increased importance for lateral opening in 
larger or multimeric OMPs that may be more difficult to fold spontaneously. 
In contrast to the BamA-budding model originally proposed for the role of lateral 
opening, where the substrate interacts with both β1 and β16 in a lateral open 
BamA, results now favour a barrel elongation model (Figure 6-1)33. This suggests 
β-strand augmentation occurs on β1, but formation of a hybrid barrel and the 
repeated associated making and breaking of H-bonds does not occur. This model 
allows for the role of lateral gating, and accommodates previous observations 
suggesting that OMPs fold by sequential insertion of β-hairpins into the 
membrane237,238,257. In addition, the proposed interaction between BAM and 
substrate protein would then predominantly occur in the periplasm, with the 
periplasmic domains of BamA or the lipoproteins, such as BamD. This is 
consistent with the essential nature of BamD25,187, cross-linking of an LptDE 
complex to BamA and BamD in a stalled intermediate interaction220, and 




Figure 6-1: Models for OMP assembly by the BAM complex. In all models 
BamA is depicted in blue and the substrate protein in red. The lipoproteins BamB-E and 
the chaperone SurA are omitted for clarity. a) BamA-assisted: BamA acts as a 
“membrane disruptase” to catalyse folding. b) BamA-budding: BamA opens by a 
separation of β1 and β16, the substrate β-strands sequentially insert and interact before 
budding off into the membrane. c) Barrel-elongation: similar to the previous model BamA 
opens via the lateral gate, but the substrate OMP interacts only with β1 of BamA and 
periplasmic components of the complex. Formation of the barrel and insertion into the 
membrane completes folding. Figure reproduced from Schiffrin et al.,(2017)33. 
 
While the barrel elongation model leaves an unpaired β16 at the C-terminus of 
BamA with unsatisfied H-bond interactions, it may also explain the short length 
of β16 and propensity to form an inward kink (Figure 6-2a)11,209. Recent 
experiments on BamA folded in LDAO have demonstrated the ability of the β1 
strand to form H-bonds in addition to those with β16, and shown that this may 
increase the stability of the complex254. These experiments utilised extension of 
the β16 of BamA with 9 residues from the C-terminus of OmpX to extend the 
connection between β1 and β16 (Figure 6-2c). This provides strong evidence in 
support of the barrel elongation model as it proposes β1 as the site for OMP 
interaction and demonstrates the stability of interaction with a longer β-strand. 
These studies have also demonstrated the unusual dynamics of the BamA 
structure that samples register sliding of the β1 and β16. Studies were carried out 
for BamA in LDAO254 and had previously been shown in DDPC:DDPE LUVs231. 
In both cases it has been shown that disulphides may form across the lateral 
228 
 
gate, not only in the anticipated pairing, but to residues out of register: up to two 
higher or lower on the opposite β strand (Figure 6-2b).  
 
Figure 6-2: E.coli BamA transmembrane domain showing (a) inward kink of 
β16. (b) non-register cross-linking of β1 and β16. (c) Extension of β16 
creates a stable structure. (a) BamA from BAM complex structure [5EKQ]207 with β1 
and β16 highlighted in blue. The lateral open structure shows the latter β-strands tilted 
inwards to the barrel. (b) Cysteine residues engineered on G433 and T809 (magenta 
spheres) are able to form a disulfide despite being two steps out of register. This 
particular pair was shown for BamA both folded in LDAO254 and DDPC:DDPE LUVs231. 
β1 and β16 are highlighted in blue. Image created from BAM E.coli model227. (c) 
Extension of β16 with 9 residues of OmpX (blue) stabilizes the structure. Image adapted 
from Hartmann et al., (2018)254. 
 
 
A further proposed model of BAM function includes oligomerisation. As originally 
proposed, the model involves OMP threading through the pore at the centre of a 
BAM tetramer211,212. The structures of the BAM complex demonstrate this to be 
unlikely due to the anticipated steric clash between components of the 
complex207-210. However, there is increasing evidence that copies of the BAM 
complex interact, with theories that productive BAM complexes are tightly 
clustered together in “OMP islands” or “precincts”216,283. Activity of the BAM 
complex in protein-supported nanodiscs274 (Figure 3-35) was taken as evidence 
against an oligomerisation model, or suggestive that this is not the obligate form 
for functional BAM, as an isolated copy of the complex is active. However, 
reconsideration of the data permits alternative hypotheses. BAM in nanodiscs 
exhibits lower activity in the OmpT assay than proteoliposomes at the same 
concentration of BAM (Figure 3-35). One hypothesis as to why this may occur is 
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that the encapsulation of individual copies of the BAM complex in nanodiscs 
abolishes the productive interactions of copies of the BAM complex. BAM in 
proteoliposomes, demonstrating a higher level of activity, may be located close 
together or oligomerise, permitting the optimal functional form. However, no 
oligomers of BAM were observed in these studies by native PAGE of the complex 
in detergent, SMALPs or proteoliposomes.  In addition, while this was not 
examined in depth, experiments with altered LPR demonstrated that greater LPR 
decreased activity for the same concentration of BAM (Figure 3-22). Increased 
LPR would likely reduce the number of BAM clusters or their size. While these 
experiments are difficult to control, due to the necessity of making liposomes of 
different LPRs, and uncertainty about how exactly the BAM complex is clustering, 
this is further evidence supporting clustering of the BAM complex as increasing 
its activity. 
Furthermore, the results of the dilution series of BAM Lateral-lock2 are intriguing 
when considered in the context of OMP islands. In this work, the BAM complexes 
are principally considered separate, disparate enzymatic units. Approximately 
50% of the population of BAM complex Lateral-lock2 protein is in the oxidized 
conformation and 50% in the reduced conformation. However, the results 
demonstrate that an equal concentration of the reduced protein (50% of typical 
total concentration) exhibits greater activity than the mixed population. While 
these results may suggest that the oxidized population has a direct negative 
effect on the overall activity, by creating a non-productive interaction, it is also 
possible that the oxidized BAM impacts the activity of the reduced BAM units. 
This makes sense only in consideration of OMP islands where the proteins are 
tightly packed together. An oxidized BAM may clearly impact the dynamics and 
thus activity of its neighbouring BAM. Further studies remain to be done to 
comprehend how the clustering of BAM may impact activity and whether one 






6.3 The next studies to be done 
A great deal of work remains to be done to fully unravel the mechanism of BAM-
assisted OMP folding, of which a few experiments present themselves as obvious 
following the results of this thesis. One of the principal questions persists of 
whether BAM would function differently for OMPs of varying size. The examples 
discussed throughout this thesis have focussed predominantly on smaller OMPs, 
those of 8-10 β-strand size, as these are the more tractable: easier for protein 
expression, folding in different lipids and monitoring protein folding. The field now 
requires a thorough investigation into BAM-assisted folding of the larger OMPs. 
This has been partially begun with studies on 12-stranded autotransporter 
EspP273,274,344, 26-stranded LptD220 and BamA itself272. 
However, the library of unstudied OMPs remains large, and particularly the 
folding of multimeric OMPs is unexplored. Furthermore, the application of the 
BAM complex variants generated in this thesis to the folding of larger OMPs 
remains of interest. The roles of lateral opening, and BamA dynamics in general 
may be highly substrate-specific, with an increased importance in larger OMPs. 
This would partially explain the in vivo lethality of disulphide variants, which only 
cause a partial reduction in in vitro catalysis of folding. 
Secondly, it has only been briefly addressed how the role of the lipid is integral in 
BAM-assisted OMP folding. We are able to observe this clearly in BamA assisted 
folding of tOmpA, with LUVs formed of longer chain PC lipids causing retarded 
folding but a greater catalytic effect of BamA-assisted folding241. Preliminary 
results have been generated in this thesis examining the effect of different lipids 
(Figure 4-27), LPR (Figure 3-22) and membrane mimetics (Section 3.6). 
However, not only do all these aspects require further attention, but the questions 
of membrane curvature, vesicle size (in use of LUVs) and asymmetry to resemble 
the native bilayer, have of necessity been ignored.  
In unilamellar vesicles generated of synthetic phospholipids in the absence of 
BAM it has been demonstrated that vesicle size and membrane curvature 
impacts the intrinsic folding rate of OMPs. Smaller and thinner vesicles in this 
case accelerate folding72. However, studies remain to be done on how this alters 
when BamA or the BAM complex is present in the lipid of interest. Is the purported 
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role of BamA in membrane destabilisation equal to that of generating a vesicle 
with increased curvature? 
Secondly studies on the lipid:protein ratio (LPR) are of key interest in in vitro 
experiments. Not only could studies on LPR shed light on the theories of OMP 
islands or precincts, with increasing LPR reducing the propensity of such features 
in proteoliposomes, but they may elucidate the role of BAM oligomerisation in 
accelerating OMP assembly. A combination of detailed folding assays in vitro with 
studies on OMP localisation in vivo would allow us to unravel how the BAM 
“precincts” may contribute to its function. 
The data presented in this thesis raises many more questions in the field of BAM-
assisted OMP folding and presented here are simply some of the most evident 
questions to be examined moving forward. 
 
6.4 Towards a new antibacterial 
A key driver to a great deal of the research on Gram-negative bacteria, 
particularly on essential, conserved systems such as BAM21,24,81, is the pressing 
human need for ways to target and eradicate pathogenic Gram-negative bacteria. 
Gram-negative bacteria include widespread human pathogens, and with limited 
development of antibacterials and increasing antibiotic resistance the threat they 
pose can only grow7. The work in our laboratory takes one of many approaches 
towards advancing this field, by increasing our fundamental understanding of 
Gram-negative bacteria and how they function. BamA is vital in Gram-negative 
bacteria and therefore represents an obvious target for antimicrobials, rendered 
more attractive as its membrane location would potentially render cell penetration 
unnecessary. Despite understanding of the critical nature of BamA for decades21, 
and studies in its mutagenesis demonstrating that inhibiting the complex is 
lethal21,24,187,199,201 the understanding of BAM mechanism remains poor.  Due in 
part to its intractability as a membrane protein complex, the structure of the 
complex has not been solved until recently207-210, and many of the details of its 
mechanism remain unclear. How can it be that a complex that is so fundamental, 
so omnipresent, can be so little understood? 
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The field advances apace with injection of recombinant BamA providing a 
potential vaccination against Acinetobacter baumannii tested in a mouse 
model345. Meanwhile studies by the pharmaceutical company Genentech have 
developed antibodies that bind to and inhibit BamA in E.coli49,346. While the 
antibodies originally published are not useful clinically as binding requires 
truncated LPS49, this fuels further study in this area. It has been discussed briefly 
in this thesis how inhibitors assumed to work against BAM47,175 show minimal 
function, or differential function according to substrate in in vitro assays. Whilst in 
vitro assays can be useful in screening inhibitors and determining mode of action, 
an improved panel of in vitro and in vivo assays are necessary to investigate 
potential inhibitors of BAM. The macrocyclic peptides, discussed in the context of 
the potential inhibitor JB-95, are designed as synthetic peptidomimetic 
antibiotics47,314, taking inspiration from cationic antimicrobial peptides found as 
part of the innate immune system316. The peptide used as a control in 
experiments in this thesis, L27-11, was demonstrated to be specifically inhibiting 
LptD in Pseudomonas aeruginosa314,319. This led to the development of the 
closely related peptide Murepavadin, currently in phase III trials as an antibiotic 
towards Pseudomonas aeruginosa316,347, proving the exceptional potential of this 
research. 
The lateral opening of BamA was proved to be vital in E.coli by disulphide-locking 
of the BamA β-barrel causing lethality in bacteria199. Evidently one cannot 
introduce a lock into BamA opening in live bacteria, however, if one can 
understand the details of the mechanism perhaps it is possible to design 
inhibitors. This has been a key real-world goal to studies throughout my thesis. 
In examination of BamA and the BAM complex, however, caution must be 
exercised regarding the potential of inhibitory peptides or chemicals, as these 
may affect not only the mutualistic bacteria of the human intestinal microbiome, 
but also the Omp85 proteins of mitochondria and chloroplasts22,26. These proteins 
are highly similar, with recent studies on mitochondrial Sam50 proving the 
mechanism hypothesised for the lateral opening and β-signal recognition in 
BamA287. While substrate proteins do not necessarily show sequence similarity, 
β-barrel bacterial proteins are efficiently folded in the mitochondrial outer 
membrane dependent on the C-terminal β-signal28.  
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While these caveats remain, and there is still much to do to understand BAM 
mechanism of action, the examples discussed here show the progress and 
potential of new inhibitors towards BamA. BamA is essential in Gram-negative 
bacteria and our advancement of fundamental understanding of its mechanism 
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Appendix 1: Optimisation of SDS-PAGE conditions for 
resolution of intramolecular cross-links in the BAM 
complex 
Throughout, unless otherwise indicated, samples are incubated with redox 
agents for 1 hour at room temperature, following which 5 μL of 6x SDS loading 
buffer is added to a 15 μL sample. Samples are boiled for 30 minutes unless 
otherwise indicated and 15 μL of sample is loaded per well. Varying 
concentrations of oxidizing agents are denoted by the following scale: 1 (4 μM), 
2 (10 μM) 3 (40 μM), 4 (100 μM), 5 (1 mM), 6 (10 mM). Two precast gradient gel 
types were first assessed, before moving to homemade Tris-Glycine gels with 
low acrylamide concentration. 
 
Figure A1-1: Wild-type and Lateral-lock1 proteoliposomes on 4-20% (w/v) 
gradient gel. BAM proteoliposomes at 1 μM in TBS pH 8 were incubated with TBS 
alone (-), 1 mM (5) or 10 mM (6) CuSO4 or 25 mM DTT. Samples were incubated with 
redox agents for 1 hour at room temperature, then boiled for 30 minutes with addition of 
6x SDS loading buffer. Electrophoresis was carried out on a BioRad 4-20% (w/v) gel with 





Figure A1-2: Proteoliposomes on 4-20% (w/v) polyacrylamide Novex 
gradient gel. BAM proteoliposomes at 1 μM in TBS pH 8 were incubated with 1 mM 
CuSO4 (C), or 10 mM DTT (D), or TBS alone (-). Samples were incubated with redox 
agents for 2 hours at room temperature, then boiled for 30 minutes where indicated, with 
addition of 6x SDS loading buffer. The samples were analysed using a Novex 4-20% 
(w/v) polyacrylamide gel with Novex Tris-Glycine buffer at 125V for 4 hours. 
 
In addition to the change to a low acrylamide Tris-Glycine (TGS) gel, several 
different oxidizing agents were tested (Figure A1-3). 4,4’-dypyridyl-disulphide (4-
DPS), iodine and diamide were all hypothesised to be more membrane-
permeable than CuSO4 and it was concluded these might be better oxidizing 
agents in the case of Lateral-lock1. These were tested at increasing 
concentrations and in combination (Figure A1-3, 5,5: 1 mM diamide + 1 mM 
iodine). Intriguingly, iodine at 1 or 10 mM final concentrations (Figure A1-3, iodine 
5,6) appeared unable to migrate into the gel. No alterations of oxidizing agent or 








Figure A1-3: Lateral-lock1 proteoliposomes in the presence of oxidizing 
agents. Oxidation of Lateral-lock1 proteoliposomes was tested with a variety of 
oxidizing agents. The left-hand lane shows Lid-lock protein (in TBS+DDM) in the 
presence of 1 mM CuSO4 exhibits a single band. With the exception of the left-most lane, 
all samples are 2 μM Lateral-lock1 proteoliposomes. Diamide, iodine and 4’ DPS were 
added to final concentrations as indicated by the scale 1 (4 μM), 2 (10 μM) 3 (40 μM), 4 
(100 μM), 5 (1 mM), 6 (10 mM). In addition, a final concentration of 1 mM diamide + 1 
mM iodine was also tested (indicated as 5,5). Other final concentrations were CuSO4 (1 
mM), DTT (25 mM). As iodine is dissolved in DMSO and 4’ DPS in EtOH, equivalent 
volumes of solvent were used as a control. All other agents were made up to 10x stock 
concentration in TBS pH8.  Samples were incubated with redox agents for 1 hour at room 
temperature, then boiled for 30 minutes with addition of 6x SDS loading buffer. The 
samples were run on a 5% (w/v) acrylamide Tris-Glycine gel with MOPS buffer at 30 mA, 
180 minutes, 4ºC.  
 
The Lateral-lock1 proteoliposomes proved impossible to fully oxidize, showing a 
mixed population with all oxidizing agents, but it was hypothesised perhaps 
protein (in detergent) would be more amenable or accessible. The study was 
carried out on protein with varying concentrations of diamide and CuSO4 (Figure 
A1-4). It was determined that no increased oxidation was seen, but longer 
incubation and higher temperature were subsequently tested for both protein (P) 






Figure A1-4: Oxidation of Lateral-lock1 protein. The oxidation of Lateral-lock1 
protein as opposed to proteoliposomes was tested. Protein was diluted to 2 μM in TBS 
+ 0.05%  (w/v) DDM. Samples were incubated with redox agents for 1 hour at room 
temperature, then boiled for 30 minutes with addition of 6x SDS loading buffer. Final 
concentrations of diamide and CuSO4 were 1 (4 μM), 4 (100 μM) and 5 (1 mM), while 
the final concentration of DTT was 25 mM. The samples were run on a 5% (w/v) 
acrylamide Tris-Glycine gel with MOPS buffer at 30 mA, 180 minutes, 4ºC. 
 
Figure A1-5: Heat and long incubation times do not increase the oxidation 
of Lateral-lock1 proteoliposomes (PL) or protein (P). The effect of longer 
incubation and higher temperatures on the reduced:oxidized ratio was tested. Samples 
of Lateral-lock1 protein (P) in TBS+DDM, and proteoliposomes (PL) in TBS were diluted 
to 2 μM with (+) or without (-) diamide to a final concentration of 100 μM. Samples were 
incubated at the indicated temperature for ~ 72 hours. Following this samples were boiled 
for 30 minutes with addition of 6x SDS loading buffer. The samples were run on a 5% 
(w/v) acrylamide Tris-Glycine gel with MOPS buffer at 30 mA, 180 minutes, 4ºC. 
The Lateral-lock2 variant, with sulphydryl groups facing the lumen (Figure 5-1) 
also showed a mixed population when tested in protein (Figure A1-6), or 





Figure A1-6: Lateral-lock2 cannot be fully oxidized. Following generation of the 
new, Lateral-lock2 (433/805) protein variant, the oxidation state was tested on protein (in 
TBS + 0.05% (w/v) DDM) with a variety of redox agents. Protein at 2 μM is incubated 
with redox agents overnight (~16 hours) at 25 ºC then boiled for 30 minutes with addition 
of 6x SDS loading buffer. Final concentrations of diamide and 4’DPS are 2 (10 μM), 4 
(100 μM) and 5 (1 mM), while final concentration of DTT is 25 mM and CuSO4 1 mM. 
The samples are run on a 5% (w/v) acrylamide Tris-Glycine gel with MOPS buffer at 30 











Appendix2: Examples of the SDS-PAGE tOmpA folding assay for each BAM complex variant in buffer, 




Examples of the SDS-PAGE tOmpA folding assay for each BAM complex variant in buffer, +DTT and +diamide conditions 
(Part II) 
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